Modeling anthracycline-induced cardiotoxicity with patient-specific iPSCs by Haupt, Luis Peter
Modeling anthracycline-induced cardiotoxicity 
with patient-specific iPSCs
Dissertation
for the award of the degree
“Doctor rerum naturalium” (Dr. rer. nat.)
of the Georg-August-Universität Göttingen
within the doctoral program Biology
of the Georg-August University School of Science (GAUSS)
 
submitted by
Luis Peter Haupt
from Braunschweig
Göttingen, 2018
Thesis Committee
Prof.  Dr.  rer.  nat.  Sigrid  Hoyer-Fender,  Department  of  Developmental  Biology,  Johann-
Friedrich-Blumenbach Institute of Zoology and Anthropology Göttingen
Prof. Dr. rer. nat. Susanne Lutz, Institute of Pharmacology and Toxicology, University Medical 
Center Göttingen
Dr. rer. nat. Katrin Streckfuß-Bömeke, Department of Cardiology and Pneumology, University 
Medical Center Göttingen
Members of the Examination Board:
Reviewer:  Prof.  Dr.  rer.  nat.  Sigrid  Hoyer-Fender,  Department of  Developmental  Biology, 
Johann-Friedrich-Blumenbach Institute of Zoology and Anthropology Göttingen
Second Reviewer: Prof. Dr. rer. nat. Susanne Lutz, Institute of Pharmacology and Toxicology, 
University Medical Center Göttingen
Further members of the Examination Board:
Dr. rer. nat. Katrin Streckfuß-Bömeke, Department of Cardiology and Pneumology, University 
Medical Center Göttingen
Prof.  Dr.  med.  Dörthe  Katschinski,  Department  of  Cardiovascular  Physiology,  University 
Medical Center Göttingen
Prof. Dr. rer. nat. Ernst A. Wimmer, Department of Developmental Biology, Johann-Friedrich-
Blumenbach Institute of Zoology and Anthropology Göttingen
Prof.  Dr.  rer.  nat.  Rüdiger  Behr,  German  Primate  Center,  Leibniz  Institute  for  Primate 
Research
Date of the oral examination: February 20th, 2018
 Table of contents
Table of contents
    Abbreviations                                                                                                                           ..........................................................................................................................v  
    Summary                                                                                                                                ...............................................................................................................................xii  
1     Introduction                                                                                                                     ...................................................................................................................1  
1.1     Anthracycline-induced cardiotoxicity                                                                        ......................................................................1  
1.1.1     Pathomechanisms of ACT                                                                                  ................................................................................3  
1.1.1.1     Increased ROS production                                                                         .......................................................................3  
1.1.1.2     Topoisomerase II poisoning                                                                       .....................................................................7  
1.1.1.3     Disturbance of Calcium signaling                                                              ............................................................7  
1.1.1.4     Disarray of sarcomeric cytoskeleton, NRG1/ErbB2 signaling and the 
influence of non-CMs                                                                                                ..............................................................................................9  
1.1.2     Treatment and prophylactic therapy of ACT                                                   .................................................10  
1.1.3     Pharmacogenetics of ACT                                                                               .............................................................................11  
1.2     Induced pluripotent stem cells in cardiovascular medicine                                     ...................................13  
1.2.1     Characteristics of pluripotent stem cells                                                          ........................................................13  
1.2.2     Induced pluripotency                                                                                       .....................................................................................14  
1.2.3     Cardiac differentiation of hiPSCs                                                                    ..................................................................17  
1.2.4     Cardiac applications of hiPSCs                                                                        ......................................................................19  
1.2.4.1     Regenerative medicine                                                                             ...........................................................................20  
1.2.4.2     Disease modeling and drug screening                                                      ....................................................20  
1.3     Modeling ACT using PSC-CMs                                                                              ............................................................................22  
1.4     Aims of this thesis                                                                                                    ..................................................................................................23  
2     Materials                                                                                                                         .......................................................................................................................25  
2.1     Chemicals, reagents, basal media and enzymes                                                      ....................................................25  
2.2     Commercial kits                                                                                                       .....................................................................................................28  
2.3     Buffers and solutions for molecular biological analyses                                         .......................................28  
2.4     Media supplements, factors and solutions for cell culture                                      ....................................32  
2.5     Cell culture media                                                                                                    ..................................................................................................34  
2.6     Cell lines                                                                                                                  ................................................................................................................36  
2.7     Oligonucleotides                                                                                                      ....................................................................................................37  
2.8     Antibodies                                                                                                                ..............................................................................................................39  
i
 Table of contents
2.8.1     Primary antibodies                                                                                           .........................................................................................39  
2.8.2     Secondary antibodies and fluorophore-conjugated probes                              ............................41  
2.9     DNA plasmids                                                                                                          ........................................................................................................41  
2.9.1     pEIGW roGFP2-Orp1                                                                                      ....................................................................................41  
2.9.2      pGIPZ-Grx1-roGFP2                                                                                      ....................................................................................42  
2.9.3     pMD2.G                                                                                                           .........................................................................................................43  
2.9.4     psPAX2                                                                                                            ..........................................................................................................44  
2.10     Disposable items                                                                                                    ..................................................................................................45  
2.11     Laboratory equipment                                                                                            ..........................................................................................46  
2.12     Software                                                                                                                 ...............................................................................................................47  
3     Methods                                                                                                                          ........................................................................................................................48  
3.1     Cell culture                                                                                                              ............................................................................................................48  
3.1.1     Isolation and cultivation of human primary dermal fibroblasts                       .....................48  
3.1.2     Isolation and cultivation of mouse embryonic fibroblasts                               .............................48  
3.1.3     Generation of hiPSC lines                                                                                ..............................................................................48  
3.1.4     Cultivation of hiPSCs on MEFs or geltrex                                                      ....................................................49  
3.1.5     Freezing of dermal fibroblasts and iPSCs on MEFs and geltrex                     ...................49  
3.1.6     Thawing of HEK cells and iPSCs on MEFs or geltrex                                    ..................................50  
3.1.7      Spontaneous  i n vitro   differentiation                                                                ...............................................................50  
3.1.8     Cardiac differentiation of hiPSCs and metabolic selection                             ...........................51  
3.1.9     Preparation and preservation of cell samples for analyses                              ............................51  
3.1.10     Cultivation of HEK-293T cells                                                                      ....................................................................51  
3.1.11     Lentivirus production                                                                                     ...................................................................................52  
3.1.12     Lentiviral transduction of iPSC-CMs                                                            ..........................................................52  
3.1.13     Engineered heart muscle                                                                                ..............................................................................52  
3.2     Molecular biology techniques                                                                                 ...............................................................................53  
3.2.1     Isolation of genomic DNA and sequencing of SNPs                                       .....................................53  
3.2.2     Alkaline phosphatase staining                                                                          ........................................................................53  
3.2.3     Gene expression analysis                                                                                 ...............................................................................54  
3.2.3.1     Isolation of mRNA                                                                                   .................................................................................54  
3.2.3.2     Reverse transcription                                                                                ..............................................................................54  
3.2.3.3     Polymerase chain reaction (PCR) analysis                                              ............................................55  
ii
 Table of contents
3.2.3.4     Quantitative real-time polymerase chain reaction (qRT-PCR) analysis   .56  
3.2.4     Immunocytochemistry                                                                                     ...................................................................................57  
3.2.5     Western blot analysis                                                                                        ......................................................................................57  
3.2.5.1     Protein isolation                                                                                       .....................................................................................57  
3.2.5.2     SDS-polyacrylamide electrophoresis                                                       .....................................................58  
3.2.5.3     Protein transfer and detection                                                                   .................................................................58  
3.2.6     Amplex Red Hydrogen Peroxide Assay                                                           .........................................................58  
3.2.7     Plasmid isolation from E. coli culture                                                              ............................................................59  
3.2.8     roGFP2-based biosensor analysis                                                                    ..................................................................59  
3.2.9     Annexin V affinity assay and flow cytometry                                                  ................................................60  
3.2.10     Calcium imaging                                                                                            ..........................................................................................61  
3.3      In vivo   teratoma formation and histological analysis                                             ............................................61  
3.4      Analysis of α-actinin regularity                                                                              ............................................................................62  
3.5      Statistical analyses                                                                                                  ................................................................................................62  
4     Results                                                                                                                             ...........................................................................................................................63  
4.1     Recruitment of donors                                                                                             ...........................................................................................63  
4.2     Generation and characterization of hiPSCs                                                             ...........................................................66  
4.2.1     Generation of hiPSCs                                                                                       .....................................................................................66  
4.2.2     Expression of pluripotency-related genes                                                        ......................................................66  
4.2.3     Differentiation potential  in vitro   and in vivo                                                    ..................................................68  
4.3      Generation of iPSC-derived cardiomyocytes                                                         .......................................................72  
4.4     Modeling ACT in hiPSC-CMs                                                                                 ...............................................................................74  
4.4.1     NADPH oxidase                                                                                               .............................................................................................74  
4.4.2     ROS generation                                                                                                ..............................................................................................77  
4.4.2.1     Amplex Red Hydrogen Peroxide Assay                                                   .................................................77  
4.4.2.2     roGFP2-based biosensor analyses                                                            ..........................................................79  
4.4.3     Calcium Handling                                                                                            ..........................................................................................83  
4.4.4     Apoptosis                                                                                                          ........................................................................................................89  
4.4.5     Sarcomeric integrity                                                                                         .......................................................................................91  
4.4.6     Mechanical functionality                                                                                 ...............................................................................93  
5     Discussion                                                                                                                       .....................................................................................................................97  
5.1     Reprogramming and cardiac differentiation                                                            ..........................................................98  
iii
 Table of contents
5.1.1     Generation of hiPSCs from ACT patients and controls                                   .................................98  
5.1.2      Generation of hiPSC-CMs from ACT patients and controls                           .........................99  
5.2     Modeling ACT with hiPSC-CMs from ACT patients and controls                       .....................100  
5.2.1     NADPH oxidase                                                                                             ...........................................................................................101  
5.2.2     ROS generation                                                                                              ............................................................................................103  
5.2.2.1      A  lternative approaches for ROS analysis                                              ............................................108  
5.2.3     Calcium Signaling                                                                                          ........................................................................................110  
5.2.4     Apoptosis and cell death                                                                                ..............................................................................113  
5.2.5     Sarcomeric integrity                                                                                       .....................................................................................114  
5.2.6     Mechanical functionality                                                                                ..............................................................................116  
5.2.7     Screening for protectants against ACT using the iPSC-CM model               .............118  
5.2.8     Limitations of this work                                                                                 ...............................................................................119  
5.2.9      Conclusions and   p  roposed model                                                                  ................................................................120  
5.2.10     Outlook                                                                                                        ......................................................................................................121  
6     References                                                                                                                    ..................................................................................................................123  
7     Appendix                                                                                                                       .....................................................................................................................151  
    Acknowledgments                                                                                                                 ................................................................................................................xiv  
    Curriculum vitae                                                                                                                   ..................................................................................................................xvi  
    Affidavit                                                                                                                              .............................................................................................................................xviii  
iv
 Abbreviations
Abbreviations
·O2- Superoxide radical
·OH Hydroxyl radical
°C Degree Celsius
A Adenine
ABCC ATP Binding Cassettes Subfamily C Member 2
ACT Anthracycline-induced cardiotoxicity
AFP Alpha fetoprotein
ALB Albumin
ANOVA Analysis of variance
APS Ammonium persulfate
ATP Adenosine triphosphate
BMP Bone morphogenic protein
bp Base pair
BSA Bovine serum albumin
C Cytosine
c-myc V-myc myelocytomatosis viral oncogene homolog 
Ca2+ Calcium ion
CaCl2 Calcium chloride
CaM Calmodulin 
CaMKII Ca2+/calmodulin-dependent protein kinase II
CamKII Ca2+/calmodulin-dependent protein kinase II
cAMP Cyclic adenosine monophosphate 
Cas9 CRISPR-associated-9
CASQ2 Calsequestrin 2
cDNA Complementary DNA
CHF Congestive heart failure
CIU Collective infectious unit
CM Cardiomyocyte
CO2 Carbon dioxide
CPVT Catecholaminergic polymorphic ventricular tachycardia
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
CSA Cross-sectional area
v
 Abbreviations
CT Cycle threshold 
cTNT Cardiac troponin T
Ctrl Control
Cy Amplification cycles of PCR
CYBA Cytochrome B-245 alpha chain
d Day
DAPI 4',6-Diamidino-2-phenylindole
DEX Dexrazoxane
DMEM Dulbecco's modified eagle medium
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
dNTPs Deoxyribonucleotide
DOX Doxorubicin
DPBS Dulbecco's phosphate buffered saline
DR4/5 Death receptor 4/5
DTT Dithiothreitol
E Redoxpotential
E8 Essential 8
EBs Embryoid bodies
ECCs Embryonic carcinoma cells
EDTA Ethylenediaminetetra-acetic acid
EGCs Embryonic germ cells
EHM Engineered heart muscle
EpiSCs Epiblast-derived stem cells
ErbB2/4 Epidermal growth factor receptor
ESCs Embryonic stem cells
FBS Fetal bovine serum
FDA United States Food and Drug Administration
Fe Iron
FGF Fibroblast growth factor
FGF2 Fibroblast growth factor-2
For Forward primer
Fp Flavoprotein
FS Fractional shortening
vi
 Abbreviations
g Gram
G Guanine
g Gravitational force
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
Gata4 GATA binding protein 4
GDF3 Growth differentiation factor-3 
GFP Green fluorescent protein
Grx1 glutaredoxin-1
GSH Reduced glutathione
GSK3 Glycogen synthase kinase 3
GSSG Oxidized glutathione
h Hour
H+E Haematoxylin eosin staining
H2O Water
H2O2 Hydrogen peroxide
hbFGF Human basic fibroblast growth factor
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hES-medium Human embryonic stem cell medium
Hey2 Hairy/enhancer-of-split related with YRPW motif protein 2
HFB-medium Human fibroblast medium
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
IgG Immunoglobulin G
IgM Immunoglobulin M
IMDM Iscove's modified Dulbecco's medium
iPSC-CMs Induced pluripotent stem cell-derived cardiomyocytes
iPSCs Induced pluripotent stem cells
ISO Isoprenaline hydrochloride
kb Kilobase
KCl Potassium chloride
KLF4 Krüppel-like factor
L Liter
LIF Leukemia inhibitory factor
LIN28 Cell lineage abnormal 28
LTCC L-type calcium channel
vii
 Abbreviations
LVEF Left ventricular ejection fraction
M Mol per liter
Mb Megabase
MDa Megadalton
MEF Mouse embryonic fibroblast
Mef2c Myocyte enhancer factor 2C
mg Milligram
MgCl2 Magnesium chloride
mGSCs Multipotent germline stem cells
min Minute
mL Milliliter
MLC2a Myosin regulatory light chain 2 atrial isoform
MLC2v Myosin regulatory light chain 2 ventricular isoform
mm Millimeter
MMC Mitomycin
MnCl2 Manganese chloride
MOI Multiplicity of infection
mRNA Messenger RNA
ms Milliseconds
MTG 1-Thioglycerol
mV Millivolt
MYH6/7 Myosin heavy chain isoform 6/7
N2B Small titin isoform
N2BA Large titin isoform
Na+ Sodium ion
Na3VO4 Sodium orthovanadate
NaCl Sodium chloride
NADPH Nicotinamide adenine dinucleotide phosphate
NaF Sodium fluoride
NaOH Sodium hydroxide
NCF Neutrophil oxidase factor
NCX Na+/Ca2+ exchanger
NEAA Non-essential amino acid
viii
 Abbreviations
NFATC4 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
ng Nanogram
nm Nanometer
NOX1-5 NADPH oxidase isoform 1-5
NRG1 Neuregulin-1
O2 Molecular oxygen
OCT4 Octamer binding transcription factor 4
Orp1 Oxidant receptor protein-1
OxD Degree of oxidation
P/S Penicillin / streptomycin
PCR Polymerase chain reaction
PFA Paraformaldehyde
pH Potential of hydrogen
Phox Phagocyte oxidase
PI Propidium iodide
PKA Protein kinase A
PLN Phospholamban
ps Patient-specific
PSC Pluripotent stem cell
PTPN11 Tyrosine-protein phosphatase non-receptor type 11
R Arginine
RAC1/2 Ras-related C3 botulinum toxin substrate 1/2
RAN Ranolazine
redox Reduction-oxidation
Rev Reverse primer
RICOVER60 Rituximab with CHOP over age 60 years
RNA Ribonucleic acid
roGFP2 Reduction-oxidation-sensitive GFP
ROS Reactive oxygen species
rpm Rounds per minute
ix
 Abbreviations
rs Reference SNP ID number
RT-PCR Reverse transcriptase polymerase chain reaction
RYR2 Ryanodine receptor isoform 2
S16 Serine at position 16 of PLN aa sequence
S2808 Serine at position 2808 of RYR2 aa sequence
S2814 Serine at position 2814 of RYR2 aa sequence
SCN5 Sodium voltage-gated channel alpha subunit 5
SDS Sodium dodecyl sulfate
sec Seconds
SEM Standard error of mean
SERCA Sarco/endoplasmic reticulum Ca2+-ATPase
SNP Single nucleotide polymorphism
SOD Superoxide dismutase
SOX2 SRY-box2
SR Sarcoplasmic reticulum
SRY Sex-determining region of Y
SSEA-4 Stage specific embryonic antigen 4
Stat3 Signal transducer and activator of transcription 3
T Thymine
T-X-100 Triton-X-100
T/E Trypsin/EDTA
TA Annealing temperature
TB-buffer Tris/boride buffer
TBST Tris-buffered saline with Tween20
Tbx5 T-box transcription factor-5
TEMED Tetramethylethylenediamine
TGFβ Transforming growth factor type β
TH Tyrosine hydroxylase
Thr17 Threonine at position 17 of PLN aa sequence
TNFR1 Tumor necrosis factor receptor 1
x
 Abbreviations
TOP2α/β Topoisomerase II isoform alpha/beta
TRA-1-60 Tumor rejection antigen 1-60
TZV Thiazovivin
U Unit
UV Ultraviolet
V Volt
α-MHC α myosin heavy chain
α-SMA α smooth muscle actin 
β-III-Tub β-III-Tubulin
β-ME β-mercaptoethanol
µg Microgram
µL Microliter
µm Micrometer
xi
 Summary
Summary
The anthracycline doxorubicin (DOX), one of the most effective chemotherapeutic drugs for 
the treatment of various cancers, is limited in its clinical applications due to cumulative dose-
dependent cardiotoxicity. The mechanisms of anthracycline-induced cardiotoxicity (ACT) and 
potential  risk  factors  are  still  not  fully  understood.  There  is  good  evidence  that  the 
pathophysiology of  ACT is  multifactorial.  Increased production of  reactive oxygen species 
(ROS), topoisomerase II poisoning, disturbances in calcium signaling and sarcomere disarray 
are discussed as key pathomechanisms of ACT in cardiomyocytes. Recent studies suggest 
that single nucleotide polymorphisms (SNPs) in genes encoding for NADPH oxidase subunits 
are associated with the risk to develop ACT. In this study, we aimed to establish a human 
model of ACT. For this purpose, we used human induced pluripotent stem cells (hiPSCs) as a 
powerful means to analyze the cardiac phenotype of ACT and to investigate potential genetic 
risk factors.
Integration-free hiPSCs were generated from five patients who were treated with DOX as 
part of chemotherapy. Three patients with SNPs in the NADPH oxidase subunits RAC2 and 
p22phox developed ACT. Two patients without these SNPs did not develop ACT and were 
used as controls (Ctrl). The generated hiPSCs met criteria for pluripotency and were directly 
differentiated into cardiomyocytes (iPSC-CMs) with high purity. We analyzed the expression 
of NADPH oxidase subunits, generation of ROS, calcium homeostasis, apoptosis, sarcomeric 
integrity and mechanical functionality in Ctrl- and ACT-iPSC-CMs on the basal level and upon 
DOX  application.  We  found  a  dose-dependent  increase  of  oxidative  stress  upon  DOX 
treatment  in  Ctrl-  and  ACT-iPSC-CMs using  Amplex Red and genetically  encoded sensors 
Grx1-roGFP2 and roGFP2-Orp1. The amount of ROS was significantly higher in ACT-iPSC-CMs 
upon treatment with 0.5 µM DOX.  Furthermore,  DOX application caused disturbances  in 
iPSC-CM  calcium  transients  in  both  groups.  Low  and  high  DOX  concentrations  had 
contradicting effects on calcium transients indicating a biphasic mechanism. DOX application 
resulted in a significantly higher increase of apoptosis in ACT-iPSC-CMs compared to Ctrl-
iPSC-CMs. Furthermore, the sarcomeric integrity was significantly decreased in ACT-iPSC-CMs 
but  not  in  Ctrl-iPSC-CMs  upon  treatment  with  clinically  relevant  DOX  concentrations. 
Engineered heart muscles (EHMs) were generated from Ctrl- and ACT-iPSC-CMs to analyze 
mechanical functionality. DOX application caused an increase in EHM beating frequency and 
arrhythmia in both groups. Importantly, the maximal force of contraction decreased more in 
ACT-EHMs than in Ctrl-EHMs upon DOX application. 
Taken together,  we established a human iPSC-CM-based model  of  ACT that  recapitulates 
critical  pathomechanisms.  Our  findings  indicate  that  the  genetic  background  of 
chemotherapy patients determines the risk  to develop ACT. In the future,  the generated 
xii
 Summary
iPSC-CM ACT model may be used to analyze the mechanisms of ACT in a human cardiac  
context, to screen and develop cardioprotectants and to find new biomarkers of ACT.
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1 Introduction
1 Introduction
1.1 Anthracycline-induced cardiotoxicity
Anthracyclines  are  a  class  of  antineoplastic  drugs,  which  are  commonly  used  in 
chemotherapy. Doxorubicin (DOX) is one of the most prominent anthracyclines and was first 
isolated in the 1960s from Streptomyces peucetius (Arcamone et al., 1969; Di Marco et al., 
1981).  It  is  very effective against a broad range of solid and haematopoietic cancers and 
therefore has been a part of chemotherapy for over five decades. Thereby, it contributed to 
the overall  increase in  5-year  survival  rate  from 35% in the 1950s to 70% in  2006-2012 
(Magdy et al., 2016).  
Despite its widespread application, the precise mechanism of action of DOX in cancer cells is 
still not fully understood, but it is evident that the topoisomerase II (TOP2) is a main target. 
Further distinct pathways are also discussed which all result in apoptosis and cell death. The 
great effectivity of DOX against cancer cells may be attributed to this multifactorial mode of 
action. DOX binds to the alpha and beta isoform of TOP2, an enzyme that is located in the 
cell nucleus and untangles the genomic DNA during replication and translation. By binding to 
TOP2, DOX stabilizes an intermediate reaction complex of covalently linked TOP2 and cleaved 
DNA strands.  Thereby,  resealing of  DNA strands is  prevented,  ultimately  leading  to DNA 
double-strand breaks and subsequent growth arrest and apoptosis (Chen, 2012; Hong et al., 
1990; Tewey et al., 1984). Because of this mechanism, DOX is also classified as TOP2 poison, 
contrary to TOP2 inhibitors, which inhibit ATPase activity or trap the enzyme and thereby 
interrupt DNA binding. Cancer cells are especially affected by this mechanism of action, since 
the alpha isoform (TOP2α) is highly expressed in proliferative cells but not in quiescent cells. 
DOX further intercalates into double-stranded DNA, forms DNA crosslinks and alkylates DNA, 
causing inhibition of  DNA replication and protein biosynthesis.  The formation of  reactive 
oxygen species (ROS) may be another mechanism of DOX activity in tumor cells (Minotti et 
al., 2004). Metabolism of DOX and the formation of a complex with intracellular molecular 
iron results in the formation of ROS and will be discussed in detail in chapter 1.1.1.1. A high 
amount of ROS can cause direct cellular damage such as DNA damage and lipid peroxidation 
of  organelle  membranes.  A  milder  increase  of  ROS  also  causes  impairments  in  cell 
functionality since tightly controlled redox signaling pathways can get disturbed. The direct 
involvement  of  ROS  in  antitumor  activity  has  been  doubted  because  respective  in  vitro 
experiments were performed with DOX concentrations that were considerably higher than 
clinical concentrations. Additionally, the antitumor activity of DOX is partly mediated by the 
S26 proteasome. DOX binds to the allosteric site of the proteasomal S20 core particle and 
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acts as a reversible noncompetitive inhibitor causing ubiquitinated proteins to accumulate 
(Minotti et al., 2004). 
In spite of being highly effective in the treatment of cancer, the clinical use of DOX is limited 
by severe adverse drug events. Of these, anthracycline-induced cardiotoxicity (ACT) is the 
most prominent one and was first  described in 1971  (Middleman et al.,  1971).  No clear 
definition of ACT exists because clinical studies vary broadly in cancer types, DOX application, 
detection methods and follow-up procedures. It may be defined “as subclinical or clinical, 
causing  manifestations  that  include  disturbance  in  ventricular  de-/repolarization  and  QT 
interval, arrhythmia, bradycardia, tachycardia, decrease in left ventricular ejection fraction  
(LVEF) and fractional shortening (FS) and irreversible congestive heart failure (CHF),  all  of 
which lead to increased morbidity and mortality”  (Magdy et al., 2016). Commonly, ACT is 
described  as  a  type  1  cardiotoxicity  that  is  dose-dependent,  irreversible  and  caused  by 
cardiomyocyte (CM) death. Furthermore, three types of ACT can be distinguished according 
to  the  time of  occurrence  and severity,  namely  the  acute  form,  the  early-onset  chronic 
progressive  and  the  late-onset  chronic  progressive  form.  The  acute  form  of  ACT  is 
characterized by mostly mild symptoms such as transient rhythm disturbances or low blood 
pressure. Acute ACT occurs during or immediately after DOX application and disappears after 
treatment  with  antiarrhythmic  drugs  (Steinberg  et  al.,  1987).  The  chronic  form  of  ACT, 
however, is clinically relevant, characterized by the aforementioned symptoms and can be 
lethal. It can have an early onset directly after chemotherapy or a late onset years to even 
decades  later  (Steinherz  et  al.,  1991).  It  is  accompanied  by  ultrastructural  changes  like 
myofibril  loss,  sarcoplasmic  reticulum (SR)  dilation,  cytoplasmic  vacuolization,  swelling  of 
mitochondria and increase in lysosome number  (Minotti et al.,  2004). More recently, the 
paradigm that an acute form and chronic irreversible forms of ACT exist has been challenged. 
A potential for reversibility has been proposed in a prospective study  with 2625 patients 
(Cardinale et al., 2015; Groarke and Nohria, 2015). With advances in detection of cardiotoxic 
effects, it becomes clear that ACT is not separable into three independent diseases. It may 
rather be a single progressing phenomenon, which previously has been detected in different 
stages.  The earlier assumption might has been a result  of the fact that most studies are 
retrospective, meaning most of the cardiac cases were found on random evaluations or when 
clinical  symptoms  already  developed.  When  diagnosed  and  treated  early,  ACT  might  be 
reversible.
The estimation of ACT prevalence is hampered by the unclear definition, varying detection 
methods and differences in cancer type, DOX application and follow-up time used in clinical 
studies.  The  incidence  is  especially  influenced  by  the  cumulative  DOX  dose,  which  was 
already found in early studies. In 399 cancer patients, CHF was diagnosed in 4%, 18% or 36% 
of patients who received cumulative DOX doses of 501-550, 551-600 or over 600 mg/m 2, 
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respectively. No patient that received less than 501 mg/m2 DOX developed CHF (Lefrak et al., 
1973). Further studies with 630 and 3941 patients report an amount of DOX-induced CHF of 
3 and 5%, 7 and 26% and 18 and 48% after cumulative doses of 400, 550 and 700 mg/m 2, 
respectively (Swain et al., 1997; Von Hoff et al., 1979). As a result, the life-long cumulative 
DOX dose is now set to 500 mg/m2, which unfortunately also limits neoplasticity. However, 
cardiotoxicity is still present at low doses. For example, 5.1% of patients in a retrospective 
study showed evidences of CHF (Swain et al., 2003) and in a more recent study the incidence 
of  ACT was 9%  (Cardinale et  al.,  2015).  A meta-analysis  including 18 studies and 49,017 
patients reported 6% clinical and 18% subclinical cardiotoxicity after a median follow-up of 
nine years (Lotrionte et al., 2013). 
1.1.1 Pathomechanisms of ACT
Similar to the anticancer activity of DOX, the pathophysiology of ACT is multifactorial. As a 
result of an unclear definition of ACT, the use of different in vitro and in vivo models and the 
varying methodology and experimental designs, the current state of knowledge is confusing 
and  at  times  contradictory.  However,  a  consistent  result  of  most  of  the  suggested 
pathomechanisms is loss of CMs by apoptosis, which cannot be compensated by the heart. 
Additionally,  pathomechanisms  that  disturb  the  overall  integrity  of  CMs  have  also  been 
suggested. Below, the most commonly accepted pathomechanisms will be described.
1.1.1.1 Increased ROS production
The term ROS loosely describes a variety of reactive molecules or free-radicals derived from 
oxygen. The one electron reduction product of molecular oxygen, superoxide radical (·O2-), is 
one of the most important ROS in the cell as it serves as a progenitor for the majority of ROS. 
For  example,  dismutation  of ·O2- produces  hydrogen  peroxide  (H2O2),  which  in  turn  can 
generate the hydroxyl radical (·OH). Highly reactive ROS such as ·OH and peroxynitrite are 
usually short-lived and contribute to the overall oxidative stress by irreversible modifications 
of molecules. ·O2- and H2O2 are also involved in pathological oxidative stress. However, they 
are  less  reactive  and  therefore  involved  in  reversible,  physiological  signaling  processes. 
Contrary  to  highly  reactive  ROS,  ·O2- and  H2O2 are  generated  enzymatically,  are  highly 
compartmentalized and modulate many cell signaling pathways by oxidation. This complex 
process is termed redox signaling and it is essential for normal cardiovascular physiology. 
Compartmentalization is partially achieved by specific localization of proteins, which remove 
ROS,  such  as  superoxide  dismutase  (SOD)  and  catalases.  Localization  of  ROS-generating 
enzymes  to  organelles  or  microdomains  contribute  to  ROS compartmentalization.  In  the 
physiological  context  of  CMs,  ROS  contribute  to  the  excitation-contraction  coupling  by 
targeting key proteins in Ca2+ handling, such as the protein kinase A (PKA), Ca2+/calmodulin-
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dependent protein kinase II (CamKII), ryanodine receptor 2 (RYR2), the sarco/endoplasmic 
reticulum  Ca2+-ATPase  (SERCA)  and  phospholamban  (PLN)  (Burgoyne  et  al.,  2012). 
Furthermore, ROS are involved in the proliferation and differentiation of CMs (Buggisch et al., 
2007; Hom et al., 2011). Hence, dysregulation of redox signaling has been linked to various 
cardiac heart conditions, such as contractile dysfunction, hypertrophy, CM death, alterations 
in gene expression, arrhythmia and chamber dilation  (Burgoyne et al.,  2012; Kwon et al., 
2003; Sabri et al., 2003; Siwik et al., 1999). 
The production of ROS combined with resulting oxidative stress and cellular damage is one of 
the most  widely  accepted hypothesis  for  ACT  (Angsutararux  et  al.,  2015).  On one hand, 
highly reactive ROS such as ·OH may cause ACT by directly damaging DNA, RNA, proteins and 
lipids.  However,  the  aforementioned  pathological  consequences  of  more  subtle 
dysregulation of redox cycling have also been implicated in ACT. As in cancer cells, DOX can 
increase ROS in CMs in two ways (Figure 1). First, it can be reduced to a semiquinone, which 
in turn auto-oxidates and forms ·O2-. This redox cycling is catalyzed by flavoproteins, which 
transfer electrons from nicotinamide adenine dinucleotide phosphate (NADPH) to DOX, such 
as NADPH oxidases, NADPH-P450 reductase, xanthine oxidase, NO synthase and complex I of 
the  mitochondrial  electron  chain  (Davies  and  Doroshow,  1986;  Doroshow,  1983). 
Dismutation of ·O2- produces H2O2, which in turn can generate toxic ·OH, a reaction catalyzed 
by iron (Štěrba et al., 2013). In the second mechanism, DOX directly forms a complex with 
molecular iron causing an iron cycling between Fe(II) and Fe(III)  and ·O2- production. This 
reaction is catalyzed by NADH cytochrome P450 reductases or thiols  (Xu et al., 2005). The 
DOX-Fe(II) complex can also form ·OH by reduction of H2O2 and it can auto-oxidate into a 
free-radical, which in turn reacts with O2 to ·O2- (Štěrba et al., 2013).
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As stated above, NADPH oxidases take part in ROS-producing redox cycling of DOX. There is 
accumulating evidence to support  a  particular  important  role of  NADPH oxidases  in  ACT 
(Gilleron et al.,  2009; McLaughlin et al.,  2017; Wojnowski et al.,  2005; Zhao et al., 2010). 
NADPH oxidases are multi-subunit enzymes, which sole purpose is the production of ROS 
(Brandes et  al.,  2014).  Thereby,  they  contribute  to  the  tightly  regulated redox  signaling. 
Seven isoforms are reported and two are expressed in the heart, namely isoform 2 and 4 
(Figure  2).  In  both  isoforms,  the  transmembrane  proteins  NOX  and  p22phox  form  a 
heterodimer.  The isoform-specific  NOX is  the catalytic  subunit  and p22phox is  a  scaffold 
protein.  NOX2  and  NOX4  share  about  60%  of  their  sequence,  resulting  in  significant 
differences in activity and localization. NADPH oxidase 2 activation relies on RAC1 or RAC2 
and a complex of p40phox, p47phox and p67phox, which are all cytosolic proteins. NADPH 
oxidase 2 produces ·O2- and is localized mainly in the cell membrane (Lassègue et al., 2012). 
NADPH oxidase 4, on the other hand, produces H2O2 and is constitutively active, meaning 
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Figure 1: Schematic illustration of anthracycline-dependent ROS production. The top left molecular 
structural formula depicts the basic structure of anthracyclines. The left side shows the redox cycling  
of the quinone and semiquinone form of anthracyclines, which is catalyzed by flavoproteins (Fp) and 
generates ·O2-.  The right side illustrates iron-cycling of anthracycline-iron complexes. Flavoproteins 
and thiol-containing compounds such as glutathione (GSSG/GSH) catalyze this ·O2- generating process. 
SOD generates H2O2 from ·O2-. Subsequently, highly reactive ·OH can be formed during the Haber-
Weiss reaction of H2O2, which can be catalyzed by molecular iron. From Štěrba et al., 2013.
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that  it  is  only  regulated  by  its  biosynthesis.  It  has  been  reported  to  be  localized  in 
intracellular membranes of organelles such as mitochondria, the endoplasmic reticulum and 
the nucleus (Anilkumar et al., 2013; Block et al., 2009; Lassègue et al., 2012). Two research 
groups could show that NOX2 depletion in mice resulted in attenuated DOX-induced damage 
(Wojnowski et al., 2005; Zhao et al., 2010), which was further validated in vitro (Gilleron et 
al., 2009; Ma et al., 2013).
Mitochondria are especially involved in DOX-induced ROS production and are also one of 
their main targets  (Berthiaume and Wallace, 2007; Gratia et al., 2012; Štěrba et al., 2011; 
Wallace, 2003). DOX accumulates in these organelles due to a high affinity for cardiolipin, 
which is part of the inner mitochondrial membrane (Goormaghtigh et al., 1990). Thereby, it 
gets in close proximity to complex I of the electron transport chain and to NADPH oxidase 4.  
Furthermore,  DOX  also  causes  molecular  iron  to  accumulate  in  mitochondria,  further 
increasing ROS production (Ichikawa et al., 2014). By the partial diversion of electrons from 
the electron chain,  DOX may increase the basal  respiration state  (Gosalvez et  al.,  1974). 
Further impairments of the respiratory chain have been reported, but it remains unclear, if  
they are directly induced by DOX or a consequence of previous damage (Ohkura et al., 2003; 
Oliveira and Wallace, 2006; Yen et al., 1999). Mitochondria contain their own genome, which 
is damaged by DOX-induced oxidation (Serrano et al., 1999). 
Although DOX-induced ROS production is also discussed as a mechanism of action in cancer 
cells  and should happen in other cell  types  as  well,  CMs are suggested to be especially 
vulnerable to oxidative stress. This can be attributed to their dependency on mitochondria, 
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Figure 2: Schematic illustration of multi-subunit complexes NADPH oxidase 2 and 4. In both 
isoforms, NOX and p22phox form a heterodimer, which is membrane-located. NADPH oxidase 2 is 
regulated by RAC1/2, p40phox, p47phox and p67phox. The influence of p40phox is still controversial,  
as it likely activates and inhibits the enzyme depending on the situation (illustrated by a question 
mark). NADPH oxidase 4 is constitutively active. From Brandes et al., 2014.
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which are highly dense in CMs and seem to be at the same time the main source and target 
of DOX-induced ROS. It was shown that cardiac mitochondrial DNA is more impaired by DOX 
than liver  mitochondrial  DNA  (Serrano et  al.,  1999).  Furthermore,  it  is  claimed that  the 
endogenous antioxidant state in CMs is lower in comparison to other cell types (Doroshow et 
al.,  1980),  which would be a reason for  their  vulnerability,  but little convincing evidence 
actually seems to exist. Interestingly, it was shown that parts of the oxidative stress defense 
system are inhibited upon DOX application (Li et al., 2002; Siveski-Iliskovic et al., 1995). 
Experimental studies show conflicting results regarding the oxidative stress hypothesis, since 
treatment with antioxidants decreased DOX-induced cell damage in some cases  (Doroshow 
et al., 1981; Ichihara et al., 2007; Myers et al., 1977), but also had no protective effect in 
other cases (Berthiaume et al., 2005; Herman et al., 2000). In clinical trials, antioxidants such 
as  vitamin E,  N-acetylcysteine and 7-monohydroxyethylrutoside could not  protect against 
ACT (Bruynzeel et al., 2007; Dresdale et al., 1982; Legha et al., 1982).
1.1.1.2 Topoisomerase II poisoning
Contrary to TOP2α, the beta isoform (TOP2β) is ubiquitously expressed in quiescent cells 
such as CMs (Capranico et al., 1992). Since no significant clinical translation of the oxidative 
stress hypothesis could yet be achieved, TOP2β poisoning of DOX is discussed as alternative 
explanation for  ACT.  The  best  experimental  evidence  was  reported by  Zhang et  al.  who 
showed that CM-specific depletion of Top2b protected mice from developing ACT (Zhang et 
al., 2012). Furthermore,  Top2b depletion in CMs resulted in less DNA double-strand breaks 
upon  DOX  application  and  reduced  changes  in  expression  of  genes,  responsible  for 
mitochondrial  functionality.  Importantly,  DOX-induced  mitochondrial  damage  and  ROS 
production was also decreased in Top2b depleted CMs, suggesting that these are secondary 
mechanisms and not the primary cause of ACT. This theory is supported by the findings that 
dexrazoxane (DEX), which is an iron chelator and TOP2 inhibitor, protects against ACT (see 
1.1.2) but other more efficient metal chelators do not (Martin et al., 2009). Isoform-specific 
inhibition of TOP2β seems to be a promising way to protect against ACT without hampering 
antineoplastic effects. Clinical application and conformation of the theory is still missing.
1.1.1.3 Disturbance of Calcium signaling
Calcium ion (Ca2+) homeostasis is critical for CM functionality since it determines contraction 
and  relaxation,  electrophysiological  properties  and  gene  expression.  The  excitation-
contraction  coupling  in  CMs  is  based  on  Ca2+-induced  Ca2+ release  (Figure  3).  In  this 
mechanism,  an  action  potential  activates  voltage-dependent  L-type  Ca2+ channels  in  the 
transverse T-tubular membrane. This causes small amounts of extracellular Ca2+ to enter the 
cytosol and to bind and activate the SR-located RYR2, which is a Ca2+  release channel. Large 
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amounts of Ca2+ are subsequently released from the SR into the cytoplasm, which ultimately 
leads to muscle contraction. Muscle relaxation is achieved by the recycling of Ca2+ into the SR 
by SERCA or by the transport out of the cell by the Na+/Ca2+ exchanger (NCX) (Eisner et al., 
2017).
RYR2 is located in the SR in close proximity to T-tubules, which are part of the cell membrane 
and rich in voltage-dependent Ca2+ channels like the L-type calcium channel. It is part of a 
multiprotein complex that governs its channel open probability according to the amount of 
SR-located Ca2+ (Bers, 2004; Zalk et al., 2007). Two sites have been described, which activate 
RYR2 upon phosphorylation, namely S2808 and S2814. According to common opinion, S2808 
is  a target  of  the PKA  (Lundby et al.,  2013; Marx et  al.,  2000).  Thereby,  RYR2 activity  is 
directly linked to β-adrenergic signaling as part of the fight-or-flight response.  S2814, on the 
other  hand,  is  mainly  phosphorylated  by  CamKII  (Ai  et  al.,  2005).  Since  CamKII  is  Ca2+ 
dependent and targets RYR2 subsequently to the PKA, S2814 phosphorylation is thought of 
as a positive feedback loop. Additionally, PKA and CamKII can be activated in a cAMP and Ca2+ 
independent manner by oxidation (Burgoyne et al., 2012; Erickson et al., 2008; Santos et al., 
2016). RYR2 activity may be directly regulated by oxidation of thiol residues (Burgoyne et al., 
2012; Santos et al., 2016). Thereby RYR2 activation is coupled directly to redox cycling.
SERCA is located at the SR membrane and it is directly activated by high concentrations of  
cytosolic Ca2+ (Hove-Madsen and Bers, 1993). Additionally, SERCA Ca2+ affinity and thereby its 
activity is reduced by PLN. PLN, on the other hand, is inhibited by phosphorylation of the 
sites S16 and Thr17 by PKA and CamKII, respectively. As a result, SERCA activity is enhanced.  
Similar to RYR2 phosphorylation, PLN targeting by PKA and CamKII links SERCA activity to 
β-adrenergic-,  Ca2+-  and  redox  signaling.  Furthermore,  SERCA  activity  may  be  directly 
regulated by oxidation of thiol  residues (Burgoyne et al.,  2012; Santos et al.,  2016).  NCX 
function and regulation is more complex. It is located in the cell membrane and exchanges 
three  molecules  of  sodium (Na+)  for  one molecule  of  Ca2+.  The  direction of  exchange  is 
determined  by  the  electrochemical  gradients  of  Na+ and  Ca2+ and  predominately  Ca2+ is 
excluded out of the cell (Bers et al., 2003). Ca2+ efflux by NCX is inhibited by high cytosolic Na+ 
concentrations.  Additionally  NCX  is  negatively  regulated  by  phospholemman  upon 
phosphorylation of the later by PKA and CamKII (Cheung et al., 2013; Wang et al., 2011).
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DOX application causes an increase of cytosolic Ca2+ in CMs  (Kim et al.,  2006; Sag et al., 
2011), which is attributed to altered activity of Ca2+-channels. DOX binds to RYR2 and causes 
activation by increasing the channel open probability  (Hanna et al., 2014; Kim et al., 1989; 
Ondrias et al., 1990; Zorzato et al., 1986) thereby causing more Ca2+ to enter the cytoplasm. 
SERCA activity, on the other hand, is reduced by DOX or its metabolites which is further  
aggravated by downregulation of SERCA gene expression  (Hanna et al., 2014; Zhang et al., 
2014).  As a result,  Ca2+ transport into the SR is  decelerated and Ca2+ accumulates in the 
cytoplasm. Ultimately, increased cytosolic Ca2+ causes a stiffening of CMs, since sarcomeres 
cannot  fully  relax  anymore,  which  leads  to  a  reduction  of  the  hearts  contractile  force. 
Furthermore,  changes  in  RYR2  and  SERCA activity  might  cause  arrhythmia,  which  could 
contribute to heart failure (Hanna et al., 2014).
1.1.1.4 Disarray of sarcomeric cytoskeleton, NRG1/ErbB2 signaling 
and the influence of non-CMs
It  should  be  noted  that  additional  pathomechanisms  have  been  suggested,  further 
complicating the situation. In most cases, it is not clear, if these are actual causes for ACT 
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Figure  3: Schematic illustration of Ca2+ signaling in CMs.  Voltage dependent L-type Ca2+ channels 
(LTCC) in the transverse T-tubular membrane are activated by an action potential and a small amount 
of Ca2+ enters the cytoplasm. This activates the RYR2, which is located in the membrane of the SR and  
a large amount of Ca2+ enters the cytoplasm, causing contraction of myofilaments (depicted by red 
arrows).  Subsequently,  Ca2+ is  transported  into  the  SR  or  out  of  the  cell  by  SERCA  and  NCX, 
respectively (depicted by black arrows). Phospholamban (PLB) regulates SERCA activity.  From Shiels 
and Galli, 2014.
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that are directly induced by DOX or if they are merely secondary results and thereby part of 
the  accumulating  cellular  impairment.  One  of  such  is  the  disarray  of  the  sarcomeric 
cytoskeleton, which is an early sign of ACT and can be observed in heart biopsies. The giant  
protein titin is of major importance for sarcomeric integrity, since it acts as a scaffold for 
sarcomere assembly and as a molecular spring, which contributes to diastolic function. It was 
shown that titin is actively degraded by calpain upon DOX application, causing myofibrillar  
disarray and necrosis of CMs  (Lim et al.,  2004). Because calpain is regulated by  Ca2+,  titin 
degradation is most likely a result of the disturbances of Ca2+ homeostasis, namely increased 
cytosolic Ca2+ concentration. Additionally, DOX-induced decrease in expression of sarcomeric 
genes have also been made responsible for loss of sarcomeric integrity.  α-actin, troponin I 
and myosin light chain 2 expression has been shown to be decreased upon DOX application 
in  vitro and  in  vivo in  mice,  as  well  as  the  expression  of  CARP  and  GATA4,  which  are 
regulators of sarcomeric gene expression (Ito et al., 1990; Chen et al., 2012).
The growth factor neuregulin-1 (NRG1) and its tyrosine kinase receptors epidermal growth 
factor  receptor  2  and  4  (ErbB2/4)  are  among  the  most  important  pro-survival  signaling 
cascades in CMs and have been suggested to be involved in ACT. Depletion of ErbB2 or NRG1 
in mice resulted in stronger ACT-associated symptoms upon DOX treatment  in vitro and  in  
vivo (Crone et al., 2002; Liu et al., 2005). Overexpression of ErbB2 or NRG1 treatment was 
beneficial in mice in vivo and in vitro (Belmonte et al., 2015; Bian et al., 2009). Interestingly, 
ErbB4 is downregulated via microRNA in hearts of mice after DOX treatment  (Horie et al., 
2010).
The  majority  of  studies,  which aim to  reveal  ACT pathomechanisms,  focus  on CMs.  Yet,  
cardiac biology involves additional cell  types, namely cardiac fibroblasts, endothelial cells, 
vascular  smooth  muscle  cells  and cardiac  progenitor  cells,  all  of  them being  involved in 
cardiac homeostasis. More recently, it was suggested that direct adverse effects of DOX on 
non-CMs  contribute  to  ACT.  For  example,  development  of  fibrosis  may  be  amplified  by 
cardiac fibroblasts  upon DOX application  (Cappetta et al.,  2016) and inhibition of cardiac 
progenitor cells causes an impaired CM turn-over (De Angelis et al., 2010).
1.1.2 Treatment and prophylactic therapy of ACT
Despite  their  adverse  drug  events,  anthracyclines  still  play  a  major  role  in  common 
chemotherapy, with 32% of breast cancer patients  (Giordano et al.,  2012),  57 to 70% of 
elderly lymphoma patients  (Chihara et  al.,  2016; Nabhan et al.,  2015) and 50 to 60% of 
childhood cancer patients  (Smith et al., 2010) receiving them. Few studies with sufficiently 
large amount of cases exists that report the mortality of ACT,  however,  the prognosis  of 
patients who developed ACT is usually poor with 50-80% (Lefrak et al., 1973; Von Hoff et al., 
1979). No official guidelines or recommendations for the treatment of cardiac dysfunction 
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specifically resulting from ACT are available  (Volkova and Russell,  2011; Zamorano et al., 
2016). Instead, usual therapy for heart failure unrelated to cardiotoxicity is applied such as 
ACE  (angiotensin-converting  enzyme)-inhibitor  or  β-blocker  therapy  (Yancy  et  al.,  2013). 
Furthermore,  permanent  therapies  such  as  heart  transplantation  or  application  of 
mechanical circulatory devices are often necessary.
Current  strategies  to  reduce  cardiotoxicity  of  DOX  include  prolongation  of  intravenous 
injection time and application of liposome-encapsulated DOX (Airoldi et al., 2011; van Dalen 
et  al.,  2009,  2010) but  convincing  long-term studies  regarding  to  their  effectiveness  are 
missing. Much effort has been made to improve on prophylactic therapy of ACT, which aims 
to find drugs that could be applied before or during DOX treatment and act as protectant 
against ACT. Thereby, the anticancer activity of DOX would remain, whereas cardiotoxicity 
would decrease.  So far,  only one drug,  DEX,  has been approved as cardioprotective  (van 
Dalen et al.,  2008; Lipshultz et al., 2004, 2010). Data on other candidates such as statins, 
ACE-inhibitors,  β-blockers, amifostine, acetylcysteine, vitamin D, calcium channel blockers, 
coenzyme Q10 and L-carnitine has been inconclusive  (van Dalen et al., 2008; Smith et al., 
2010). DEX is a derivative of EDTA and was first thought to convey cardioprotection against 
DOX by chelating metals such as iron, since iron dependent DOX-induced ROS production is 
thought  of  as  a  main pathomechanism of  ACT (see chapter  1.1.1.1).  However,  only  DEX 
metabolites, but not DEX itself, show high affinity for iron and are not cardioprotective by 
themselves  (Hasinoff et al.,  1998, 2003; Kaiserová et al.,  2006) . It  is more likely that DEX 
binds TOP2 which is also a target of DOX. Whereas DOX stabilizes TOP2 after cleaving the 
DNA and thereby induces double-strand breaks, DEX binds TOP2 before DNA cleavage and 
blocks DOX binding. TOP2 binding by DOX is also a main way of action in cancer cells. Due to 
this fact and two studies, which were already challenged, the United States Food and Drug 
Administration (FDA) restricted DEX to adult patients, who already received 300 mg/m2 DOX, 
because DEX potentially decreases anti-cancer activity of DOX  (FDA, 2011). Recent  in vitro 
experiments suggest further drugs to be potentially cardioprotective against DOX, including 
Ranolazin  (RAN).  The late  sodium current  inhibitor  RAN is  used to  treat  angina  and has 
experimentally been reported to improve recovery after heart failure (Hwang et al., 2009). In 
mice  and  rat  models,  RAN  decreased  cardiotoxicity  of  DOX which  was  accompanied  by 
reduction of H2O2 (Cappetta et al., 2017; Tocchetti et al., 2014).
1.1.3 Pharmacogenetics of ACT
As mentioned before (chapter 1.1), the risk to develop ACT depends on the cumulative dose. 
Apart from that, further risk factors for the development of ACT have been reported, such as 
female gender, African-American ethnicity, very young or old age or previous cardiac diseases 
(Lipshultz et al., 1995; Lotrionte et al., 2013). Importantly, these clinical and demographic risk 
11
1 Introduction
factors still cannot explain the high interindividual variation of cardiotoxicity severity when 
similar DOX treatment schedules are applied. It seems that some individuals can survive high 
doses of DOX without cardiac conditions, whereas others develop ACT after application of 
low doses. Hence, a genetic predisposition for ACT has been postulated and studied intensely 
in the current decade. 
A recent systematic review until May 2016 identified 28 independent studies which report on 
the association of genetic variants with ACT (Leong et al., 2017). According to the review, 84 
genes and 147 single nucleotide polymorphisms (SNPs) have been investigated and 87 SNPs 
have  been  reported  by  at  least  one  study  to  be  significantly  associated  with  ACT.  The 
majority  of  this  studies  investigated  candidate  genes  that  are  involved  in  anthracycline 
metabolism and handling, oxidative stress or general cardiac function. The authors were able 
to  perform  a  meta-analysis  of  SNPs  with  those  studies  that  provided  sufficient  data. 
Interestingly,  only  three  SNPs  significantly  increased  odds  of  cardiotoxicity  in  individuals 
treated with anthracyclines, namely  ABCC2 (ATP Binding Cassettes Subfamily C Member 2) 
rs8187710,  CYBA  (Cytochrome  B-245  alpha  chain)  rs4673  and  RAC2 rs13058338.  ABCC2 
belongs to a superfamily of transmembrane proteins, which transport substrates, including 
DOX,  across  the  cell  membrane  using  ATP.  The  rs8187710  SNP results  in  an  amino acid  
change which has been shown to reduce ATPase activity and causes a reduced efflux activity 
(Elens et al., 2011). While a theoretical rationale is thereby given, no experimental data exists 
that shows a reduction of ACT by rs8187710. Both p22phox (encoded by CYBA) and RAC2 are 
part of NADPH oxidases (see chapter  1.1.1.1), with p22phox being an essential subunit of 
most isoforms and RAC2 being an activator of certain isoforms, such as NADPH oxidase 2. 
CYBA rs4673 causes histidine at  position 72 of  p22phox to be replaced by tyrosine.  The 
molecular  consequence  of  rs4673  remains  elusive,  since  the  p22phox  histidine  is  not 
involved  in  binding  of  heme,  which  is  part  of  the  complex  between  p22phox  and  NOX 
(Biberstine-Kinkade  et  al.,  2001).  Furthermore,  substitution  of  p22phox  histidine  with 
tyrosine does not  influence NADPH oxidase functionality  or  complex stability  (Biberstine-
Kinkade et  al.,  2002).  In  neutrophils  ·O2- production was  higher  upon stimulation in  the 
presence of the ACT-associated allele of rs4673 (Shimo-Nakanishi et al., 2004). On the other 
hand, vascular O2- production has been reported to be reduced by the same allele of rs4673 
(Guzik  et  al.,  2000).  rs8187710 of  RAC2 is  located in an intron and no direct link to the 
protein functionality has been reported. However, the gene expression of  RAC2 and  NCF4 
(neutrophil  oxidase  factor4;  encoding  for  the  NADPH  oxidase  subunit  p40phox)  was 
increased in the presence of the ACT-associated allele of rs8187710 (Schirmer et al., 2007). 
Similar to ABCC2 rs8187710, no experimental data regarding cardiotoxicity was reported for 
rs4673 and rs13058338. Both SNPs are located on independent genes that encode subunits 
of one enzyme complex. Additionally, NADPH oxidases are implicated in DOX-induced ROS 
12
1 Introduction
production. For this reasons rs4673 and rs13058338 are particularly promising candidates for 
prognostic biomarkers of ACT outcome. In conclusion, various SNPs could be shown to be 
statistically associated with ACT, but no satisfying experimental data has yet been reported.
1.2 Induced pluripotent stem cells in cardiovascular 
medicine
1.2.1 Characteristics of pluripotent stem cells
Stem  cells  are  characterized  by  the  ability  to  self-renew  through  cell  division  and  to 
differentiate into specialized cell  types  (National  Institutes of  Health,  2016).  They can be 
classified according to their differentiation potential or to their origin  (Jaenisch and Young, 
2008).  A  totipotent  cell  is  capable  of  producing  all  differentiated  cells  in  an  organism, 
including extraembryonic  tissues.  Only  the zygote and the first  cleavage blastomeres are 
totipotent (Kelly, 1977). Pluripotency is defined by the capacity to give rise to somatic cells of 
all three germ layers and the germ line. In vivo, pluripotent cells make up the inner cell mass 
of the blastocyst and later the epiblast. Several pluripotent cells of different origins have 
been successfully cultured, with embryonic stem cells (ESCs) being the most prominent ones. 
Stem cells that are found in adult stages, are multipotent or unipotent. They are necessary in  
the adult organism for tissue homeostasis and tissue regeneration after injury. Multipotent 
stem cells have the capacity to give rise to several differentiated cell types that belong to one 
cell lineage, for example hematopoietic stem cells, which are the origin of all blood cells.  
Spermatogonial stem cells and epidermal stem cells are examples for unipotent stem cells 
because they produce exclusively one cell type, sperm cells and keratinocytes, respectively. 
The differentiation potential of stem cells is entirely lost upon terminal differentiation.
Since  pluripotent  stem  cells  (PSCs)  have  the  greatest  developmental  and  therapeutic 
potential, they have been intensely investigated for five decades. The first pluripotent cell  
lines were established from teratocarcinomas, germ cell tumors, and were called embryonic 
carcinoma cells (ECCs) (Kleinsmith and Pierce, 1964; Stevens and Little, 1954). Although ECCs 
were used as a model for early mouse development, they are aneuploid and contribute only 
poorly to adult somatic tissue upon injection into blastocysts and transplantation into foster 
females (Brinster, 1974). In 1981 ESCs were first derived from the inner cell mass of mouse 
blastocysts  (Evans  and  Kaufman,  1981;  Martin,  1981) and  subsequently  from  human 
embryos  (Thomson et  al.,  1998).  Both mouse and human ESCs are capable of  efficiently 
differentiating into tissues of all germ layers and the germ line  (Nagy et al., 1990), can be 
expanded in vitro without limitations and maintain a normal karyotype. Furthermore, ESCs 
are characterized by the expression of OCT4 (Octamer binding transcription factor 4),  SOX2 
(SRY-box2; SRY: Sex-determining region of Y) and NANOG, which are key pluripotency genes, 
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and a high telomerase and alkaline phosphatase activity (Hanna et al., 2010b). Despite these 
similarities, there are major differences between human and mouse ESCs, for example, in the 
morphology. Mouse ESCs grow in domed and compacted colonies and human ESCs in flat 
colonies. Furthermore, the culture conditions that keep the ESCs in an undifferentiated state 
differ. Mouse ESCs depend on signaling through the Stat3 pathway, activated by leukemia 
inhibitory factor (LIF), while human ESCs depend on fibroblast growth factor-2 (FGF2)/Activin 
signaling (Hanna et al., 2010b). These differences reflect the fact that pluripotency itself can 
be classified into various grades of stringency, distinguishable by different in vivo functional 
assays. The naive state of ESCs corresponds to the inner cell mass of the primordial embryo, 
whereas the primed state resembles the postimplantation epiblast (Nichols and Smith, 2009; 
Theunissen et al., 2016). Traditionally, mESCs and miPSCs are described as naive, whereas 
hESCs and hiPSCs are primed, however, several groups have already reported the generation 
of naive hESCs (Gafni et al., 2013; Hanna et al., 2010a; Takashima et al., 2014; Theunissen et 
al.,  2014;  Ware et  al.,  2014).  For  this  reasons,  it  can be difficult  to  determine,  whether 
differences are based on variations between species or stages of pluripotency.
Pluripotent cell  lines have been derived from other embryonic and adult tissues, such as 
epiblast-derived stem cells  (EpiSCs)  from post implantation embryos  (Brons et al.,  2007), 
embryonic germ cells (EGCs) from primordial germ cells (Matsui et al., 1992) and multipotent 
germline stem cells (mGSCs) from neonatal (Kanatsu-Shinohara et al., 2004) and adult mouse 
spermatogonial cells (Guan et al., 2006). PSCs provide a powerful tool to study early human 
development  and hold  great  potential  for  clinical  applications.  However,  major  concerns 
about  the  use  of  hESCs  are  also  discussed.  The  embryonic  origin  and  the  associated 
destruction of human embryos cause ethical and political problems. Adult stem cells on the 
other hand are difficult to isolate and to culture. Furthermore, potential tumorigenicity of 
PSCs and the immune rejection of stem cell-derived tissue grafts are issues that still need to 
be solved.
1.2.2 Induced pluripotency
The transfer of nuclei from somatic cells into oocytes (Briggs and King, 1952) and the fusion 
of somatic cells with embryonic stem cells (ESCs) (Tada et al., 2001) showed that terminally 
differentiated  cells  can  be  reprogrammed  by  factors  contained  by  oocytes  and  ESCs. 
Furthermore,  lineage  conversion  experiments  were  performed  in  which  the  ectopic 
expression of cell type-specific transcription factors switched one cell type into another (Xie 
et  al.,  2004).  These findings  motivated attempts  to generate  PSCs  from somatic cells  by 
reprogramming, using factors that are specifically expressed in ESCs or are important for the 
maintenance of  their  pluripotency.  In 2006,  PSCs were generated for  the first  time from 
mouse  fibroblasts  and  named  induced  pluripotent  stem  cells  (iPSCs)  (Takahashi  and 
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Yamanaka, 2006).  The fibroblasts were reprogrammed by retroviral  transduction with the 
four  transcription  factors  OCT3/4,  SOX2,  C-MYC and  Krüppel-like  factor  4  (KLF4). 
Subsequently, human iPSCs were generated from fibroblasts using the same combination of 
transcription  factors  (Takahashi  et  al.,  2007) or  different  combinations  like  OCT4,  SOX2, 
NANOG and LIN28 (Yu et al., 2007). IPSCs resemble ESCs in defining features like morphology, 
expression  of  pluripotency  markers,  self-renewal,  teratoma  formation  and  chimera 
development. In the past decade since first-generation iPSCs were reported, rapid progress 
was made concerning the reprogramming, culture conditions, safety and applications. 
The molecular mechanisms behind pluripotency and reprogramming of somatic cells into 
iPSCs are complex and not fully understood. The transcription factor NANOG belongs to the 
key players of pluripotency and its disruption causes loss of pluripotency  (Chambers et al., 
2003; Mitsui et al., 2003). SOX2 and OCT4 are additional transcription factors that form a 
heterodimer  (Masui et al.,  2007; Nichols et al.,  1998). Together with NANOG, these three 
transcription factors are  thought  to be the major  regulators in a  complex transcriptional 
network that maintains the pluripotency of a cell. They act both as activators of pluripotency 
genes and inhibitors of differentiation-related genes and often co-occupy their target genes. 
Furthermore, they activate their own gene expression in an autoregulatory loop (Boyer et al., 
2005; Chen et al.,  2008; Kim et al.,  2008).  LIN28 is  among the activated target genes of 
NANOG, OCT4 and SOX2. It encodes for an RNA binding protein that inhibits the activity of  
let7 microRNA and thereby suppresses differentiation (Heo et al., 2009; Melton et al., 2010). 
Another  transcription  factor,  which  is  in  close  functional  relationship  with  the  core 
transcription factors, is KLF4. It is involved in the self-renewal and maintenance of ESCs and 
regulates the expression of NANOG (Zhang et al., 2010). Furthermore, MYC was found to be 
involved in self-renewal and pluripotency  (Cartwright et al.,  2005). Additional markers for 
undifferentiated cells are the glycosphingolipid SSEA-4 and the Tra-1-60 antigen, which are 
located at the cell membrane. However, their function in pluripotency is not known (Brimble 
et  al.,  2007;  Schopperle  and  DeWolf,  2007).  Alkaline  phosphatase  is  an  enzyme  that 
dephosphorylates  nucleotides,  proteins  and  alkaloids.  Since  its  activity  is  high  in 
undifferentiated cells, it can be used as a stem cell marker  (O’Connor et al., 2008).
While the exact mechanisms remain elusive, reprogramming is thought of as a stochastic and 
deterministic mechanism with various events occurring sequentially or in parallel (Takahashi 
and Yamanaka, 2016). In the early phase of reprogramming, C-MYC binds to genomic loci 
with methylated histone 3 lysine 4 (H3K4) and thereby inhibits expression of somatic genes. 
Furthermore,  the  four  reprogramming  factors  bind  to  enhancers  and  promoters  of 
pluripotency-related genes and induce their expression  (Soufi et al.,  2012). In the second 
phase, the reprogramming factors activate further pluripotency-related genes, which were 
not accessible in the beginning  (Buganim et al., 2012). As a result of the changes in gene 
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expression,  mesenchymal-to-epithelial  transition  and  glycolysis-based  metabolism  is 
activated (Panopoulos et al., 2012; Samavarchi-Tehrani et al., 2010).
Various  different  approaches  for  the  generation  of  iPSCs  have  been  described.  In  the 
beginning, reprogramming factors were stably integrated into the genome of somatic cells by 
retroviral  or  lentiviral  transduction.  While  being  sufficient  for  iPSC  generation,  random 
integration of transgenes into the genome can lead to insertional mutagenesis and disrupt 
the  functionality  of  neighboring  genes.  Furthermore,  silencing  of  retroviral  and lentiviral 
vectors  occurs  during  reprogramming  (Hotta  and  Ellis,  2008). Incomplete  or  untimely 
silencing  may  cause  partial  reprogramming  with  continued  dependence  on  exogenous 
pluripotency  genes,  disturbance  in  the  developmental  potential  and  tumor  formation  in 
chimeras.  To avoid these problems,  inducible  vector  systems have been designed,  which 
allow the control of transgene expression (Brambrink et al., 2008). An alternative approach is 
the use of integrating vectors with high reprogramming efficiencies that can be excluded 
from the genome subsequently to reprogramming. More recently, integration-free methods 
have  been  developed  that  rely  on  transient  expression  of  reprogramming  factors  using 
adenoviral vectors (Stadtfeld et al., 2008) or sendai virus  (Fusaki et al., 2009; Nishimura et 
al., 2011). The sendai virus system is based on single-strand RNA vectors, which replicate in 
the cytoplasm and have a low cytotoxicity.  Furthermore,  transgene expression decreases 
with cell division, making it one of the most commonly used means of reprogramming. The 
generation of  integration-free iPSCs  has  also  been described using  non-viral  approaches, 
such as transfection of DNA plasmids (Okita et al., 2008) or RNA and even the introduction of 
purified  recombinant  proteins  (Zhou  et  al.,  2009).  Often,  these  approaches  have  a  low 
efficiency,  however. Finally,  the use of chemical  compounds for  reprogramming has been 
described that do not require the introduction of transcription factors, allowing for stable 
conditions and outcome. Despite these advances, the mechanisms behind reprogramming 
remain mostly elusive. 
Simultaneously to the advances in reprogramming,  culture conditions of  iPSCs were also 
improved.  First-generation  iPSCs  depend  on  the  cocultivation  with  mouse  embryonic 
fibroblasts  (MEFs)  and were cultured in  serum-supplemented medium. To reduce animal 
components  and  thereby  making  iPSCs  more  useful  for  future  clinical  applications, 
chemically defined media are currently used, such as Essential 8 (E8)  (Chen et al.,  2011). 
Furthermore, xeno-free conditions were developed, which rely on the use of recombinant 
matrix proteins such as matrigel, geltrex, vitronectin or laminin. Additionally to being xeno-
free,  the  improved  culture  conditions  also  lead  to  higher  consistency  during  prolonged 
cultivation.
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1.2.3 Cardiac differentiation of hiPSCs
Currently, three approaches were described to obtain CMs from somatic cells, namely the 
derivation from iPSCs,  the direct transdifferentiation without an intermediate pluripotent 
status  and  the  combination  of  both  (Kolanowski  et  al.,  2017).  During  direct 
transdifferentiation,  cardiac  transcription factors  such as  GATA Binding Protein  4 (Gata4), 
myocyte  enhancer  factor  2C  (Mef2c)  and  T-box  transcription  factor-5  (Tbx5)  are 
overexpressed in somatic cells like primary cardiac fibroblasts to induce reprogramming into 
CMs  (Mohamed et  al.,  2016).  This  seems especially  promising  for  regenerative medicine 
since the risk of tumor development is small. Recently chemical-induced CM-like cells were 
generated  by  transiently  inducing  a  pluripotent  state  followed  by  immediate  cardiac 
differentiation.  Importantly,  the  cells  were  not  genetically  modified  since  only  chemical 
cocktails were used  (Fu et al., 2015). The CM yield was increased compared to the direct 
transdifferentiation,  whereas  risk  for  teratoma formation  remained  small.  Induction  of  a 
stable pluripotent state and subsequent derivation of CMs is the most common approach. 
This approach offers great advantages for basic research, since iPSCs renew themselves and 
great yields of CMs can be generated for long periods of time. 
In early studies CMs were derived from PSCs by using the embryoid body method. Therefor, 
the PSCs are cultured in suspension in small aggregates, called embryoid bodies (EBs), which 
causes  spontaneous  differentiation into  cells  of  all  three germ layers.  Often,  EBs  display 
spontaneous contraction and CMs with ventricular features can be isolated. However, the 
efficiency of cardiac differentiation is low and the yield of CMs is too small for regenerative 
applications. For this reason, approaches are developed to directly differentiate PSCs into 
cardiac cells with high efficiency and purity, by mimicking the embryonic heart development 
in vitro. 
Heart  development  is  a  complex  process  and  starts  early  in  embryogenesis  during 
gastrulation. First cardiac precursor cells occur in the heart-forming fields of the anterior 
lateral  plate mesoderm. The formation of the mesoderm and the specification of cardiac 
precursor cells are tightly regulated by families of signaling molecules such as transforming 
growth factor type β (TGFβ), bone morphogenic protein (BMP), fibroblast growth factor (FGF) 
and  WNT.  It  has  been  shown  that  especially  canonical  WNT  signaling  inhibits  early 
specification of  cardiac  cells  and that  WNT antagonists  are  located at  the heart-forming 
fields.  BMP  signaling,  on  the  other  hand,  induces  cardiac  specification.  During  later 
development, the cardiac precursor cells migrate towards the midline, fuse and thereby form 
the heart tube which will subsequently loop and form the heart chambers.
In vitro,  addition of cytokines that are involved in embryonic heart development such as 
Activin A, FGF2 or bone morphogenetic protein 4 (BMP4) increases the efficiency of cardiac 
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differentiation in EBs  (Laflamme et al., 2007; Yang et al., 2008). These principles have also 
been successfully applied in 2D differentiation systems of iPSCs to obtain CMs (iPSC-CMs).  
The modulation of the canonical WNT pathway has proven to be particularly effective and 
can be easily accomplished with small molecules (Gonzalez et al., 2011; Lian et al., 2012; Ren 
et al., 2011). By activating the canonical WNT pathway via inhibition of GSK3, the cells are 
directed  to  a  mesodermal  fate,  which  can  be  observed  by  upregulation  of  the  protein 
brachyury. These multipotent mesodermal progenitor cells can be further differentiated into 
CMs by inactivation of canonical WNT signaling. Yields of up to 90% iPSC-CMs have been 
reported using a simple three-step protocol with chemically defined media and recombinant 
matrix proteins  (Burridge et al.,  2014). Analytical  and medical  applications require a high 
purity of hiPSC-CMs. To accomplish this, the use of antibodies against vascular cell adhesion 
molecule 1 (VCAM-1)  and signal-regulatory protein alpha (SIRPA) has  been described for 
sorting of hiPSC-CMs (Dubois et al., 2011; Uosaki et al., 2011). However, the use of metabolic 
selection via glucose depletion and lactate supplementation has proven to be highly efficient 
and is now most commonly used (Tohyama et al., 2013). HiPSC-CMs that are generated in the 
aforementioned way are a mixture of ventricular-, atrial- and nodal-like cells. They depict 
distinct electrophysiological properties. Effective protocols to attain homologous populations 
are still in development  (Blazeski et al., 2012; Ma et al., 2011). The majority of iPSC-CMs, 
generated with common protocols, are ventricular-like cells and their production may further 
be facilitated by cultivation at normoxia (5% O2) (Blazeski et al., 2012; Weng et al., 2014). A 
bigger yield of atrial- and nodal-like cells may be achieved by manipulation of BMP signaling 
or retinoic acid application at the right differentiation stages (Devalla et al., 2015; Protze et 
al.,  2017). By now, standardized hESC-CMs and hiPSC-CMs are commercially available, for 
example  iCELL  cardiomyocytes  (Cellular  Dynamics)  and  Cor.4U  cardiomyocytes  (Axio 
Genesis). These cells enable quick analyses of hPSC-CMs without previous cultivation and 
differentiation of hPSCs. 
HiPSC-CMs  and  hESC-CMs,  like  many  other  PSC  derived  cell  types,  depict  an  immature 
phenotype. This may be a result of the rejuvenation that takes place during reprogramming 
of  somatic  into  pluripotent  cells  (Mora  et  al.,  2017).  In  vivo,  maturation  of  CMs  is 
accompanied by changes in the transcriptome such as increased expression of the calcium 
handling proteins RYR2, SERCA and NCX or subtype-specific proteins like Hairy/enhancer-of-
split related with YRPW motif protein 2 (Hey2) and ventricular myosin regulatory light chain 2 
(Mlc2v) or Hey1 and Mlc2a (atrial). Also, the isoform ratio of certain proteins like titin N2BA 
and N2B changes.  Expression of  myosin heavy chain isoform 6 (MYH6)  decreases during 
maturation in human CMs whereas MYH7 is expressed in a similar level (Yang et al., 2014a). 
While  most  genes  are  expressed  in  iPSC-CMs,  the  expression  levels  often  differ  when 
compared to adult CMs. This also leads to structural and electrophysiological differences. 
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Adult CMs undergo hypertrophic growth after birth and depict a typical rod shape, whereas 
iPSC-CMs are smaller  and often circular  or  multi-angled.  Furthermore,  adult  CMs have a 
higher  organization  of  the  sarcomeric  cytoskeleton  and  the  SR  and  possess  specialized 
structures like T-tubules in  the membrane.  As  a  result  on the functional  level,  iPSC-CMs 
depict a slower conduction velocity across cells and weaker force of contraction. Different 
approaches have been followed to promote maturation of hiPSC with mild success, including 
chemical,  physical  tissue  engineering  or  prolonged  cultivation.  In  conclusion,  hiPSC-CMs 
currently resemble embryonic to neonatal CMs.
1.2.4 Cardiac applications of hiPSCs
IPSCs  are  a  powerful  tool  to  study  developmental  processes  as  well  as  mechanisms  of 
reprogramming.  However,  the  greatest  potential  of  the  iPSC  technology  lies  in  medical 
applications  such  as  regenerative  medicine,  disease  modeling  and  patient-specific  drug 
screening (Figure 4). Contrary to hESCs, the use of hiPSCs does not cause ethical problems 
because the destruction of embryos is not involved. Importantly, hiPSCs retain the donor-
specific genetic background, thereby making them disease- and patient-specific (ps-hiPSCs). 
This feature is a major advantage of hiPSCs over hESCs and opens new possibilities which 
could not be achieved with hESCs.
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Figure 4: Applications of ps-hiPSCs. Somatic cells can be isolated from a patient, reprogrammed into 
iPSCs and derived into specialized differentiated cells such as iPSC-CMs. These cells can be used for 
disease modeling, drug screening or regenerative medicine. From Bellin et al., 2012.
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1.2.4.1 Regenerative medicine
While regenerative medicine is influenced by and overlaps with many other medical fields 
and is thereby hard to define, according to Manson and Dunnill it “replaces or regenerates 
human cells, tissue or organs, to restore or establish normal function” (Mason and Dunnill, 
2008). Immune rejection is a major problem in organ transplantation and cell therapy. By 
transplanting  hiPSC-derived  differentiated  cells  or  tissue  grafts,  the  patient-specificity  of 
hiPSCs might be used to circumvent this hurdle. On the other hand, the use of hiPSCs in  
regenerative  medicine  also  involves  risks,  as  residual  undifferentiated  hiPSCs  may  form 
teratoma. Advances have been made to detect these cells  (Choudhary and Whiting, 2016; 
Kuroda et al.,  2012) or  to eliminate them by high differentiation efficiency and purifying 
differentiated  cells  (Hattori  et  al.,  2010;  Tohyama  et  al.,  2016).  Xenotransplantation 
experiments  with  hiPSC-derived  cells  have  already  been  performed  in  the  fields  of 
Parkinson’s  disease,  spinal  cord  injury,  corneal  disease,  liver  dysfunction  and  platelet 
transfusion-refractory.  In  2013,  the first  transplantation in  a  human was  performed with 
hiPSC-derived retinal-pigmented epithelium (Aoi, 2016).
Regenerative medicine is of special interest for the cardiovascular field, since cardiovascular 
disease is globally the leading cause of death. However, medical treatment of severe diseases 
such as heart  failure is  often limited to the improvement of  symptoms or prevention of 
disease progression. One reason for this is the deficiency of the heart to regenerate muscle 
tissue after injury. Furthermore, human CMs are hard to acquire and cannot be cultured or 
expanded  in  an  amount  necessary  for  transplantation or  disease  research.  HiPSCs  are  a 
promising source for patient-specific CMs. Research of different approaches using hiPSCs and 
hESCs  has  been  reported  ranging  from  transplantation  of  single  PSC-CMs,  over 
transplantation  of  in  vitro engineered  patches,  sheets  or  tissues,  to  even  the  in  vitro 
generation of entire hearts by repopulation of extracellular matrix scaffolds (Anderson et al., 
2017). Transplantations of single hPSC-CMs into animal models have often been ineffective in 
regenerating injured myocardium due to low survival and integration rates of transplanted 
PSC-CMs  (Caspi et al.,  2007; van Laake et al.,  2007; Laflamme et al.,  2007). However, the 
successful transplantation of hPSC-CMs has been described in a monkey model (Chong et al., 
2014). Engineered grafts showed a better survival and improved cardiac function in small 
animal  models  and  also  a  pig  model.  In  2015,  hESC-derived  cardiac  progenitors  were 
transplanted for the first time in a human (Menasché et al., 2015a, 2015b).
1.2.4.2 Disease modeling and drug screening
Disease  modeling  is  another  application  of  hiPSCs  and  is  based  on  the  principle  to 
recapitulate a disease in vitro by differentiating ps-hiPSCs into the affected cell type. These 
cells can subsequently be used to study the development, progression and mechanisms of 
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the disease in a cell type-specific way. Furthermore, a hiPSC disease model may be used to 
efficiently  screen  for  and  develop  new  drugs,  thereby  contributing  to  a  patient-specific 
therapy. Traditionally, human diseases are modeled by using various animals in which the 
disease phenotype is mimicked by genetic alterations or other means. While animal models 
played  a  crucial  part  in  the  understanding  of  numerous  diseases,  they  have  several 
shortcomings,  which  often  cause  results  to  not  be  reproducible  in  humans.  Modeling 
diseases with hiPSCs provides distinct advantages. Although the genome of higher animal 
models and humans is often very similar, crucial differences in development and physiology 
still exist. For example, the electrophysiology of mouse and human CMs differs with mice 
action  potentials  being  shorter.  Furthermore,  mice  CMs beat  faster  and  are  more  often 
binucleated  than  human  CMs.  In  vivo,  disease  phenotypes  may  result  from  distinct 
pathomechanisms. Compensatory effects between cell types can be observed, which makes 
identification of separate pathomechanisms difficult. Contrary to animal models, ps-hiPSCs 
possess the disease-specific genetic background, which may contribute to the identification 
of disease-associated mutations or SNPs. Combination of ps-hiPSCs with the recent clustered 
regularly  interspaced  short  palindromic  repeats  (CRISPR)/CRISPR  Associated-9  (Cas9) 
technology creates even further possibilities for disease modeling since isogenic cell  lines 
may be produced with only a single altered basepair. It should also be mentioned that the 
use  of  hiPSCs  may  contribute  to  the  reduction  and  replacement  of  animals  in  scientific 
research.  Various  hiPSCs  disease models have already been generated in different  fields, 
which recapitulate disease-specific abnormalities  in vitro and contributed to the finding of 
new pathomechanisms. 
Long QT syndrome,  which can be separated into three forms,  is  one of  the first  cardiac 
arrhythmia  diseases  that  has  been  modeled  with  ps-hiPSCs.  It  is  characterized  by 
prolongation of the depolarization of the action potential, is potentially lethal and is caused 
by mutations in KCNQ1 (potassium voltage-gated channel subfamily KQT member 1), KCNH2 
(potassium voltage-gated channel subfamily H member 2) or SCN5A (sodium voltage-gated 
channel alpha subunit 5) coding for potassium and sodium channels (Tester and Ackerman, 
2014). Ps-hiPSC-CMs recapitulate disease-associated phenotypes such as prolonged action 
potential durations, decreased rectifier potassium currents and increased frequency of early 
afterdepolarizations  and  triggered  activity  (Yoshida  and  Yamanaka,  2017).  Another 
potentially lethal disease characterized by cardiac arrhythmias and modeled with hiPSCs is 
catecholaminergic polymorphic ventricular tachycardia (CPVT). Mutations in either  RYR2 or 
CASQ2 cause CPVT. Ps-iPSC-CMs show an increase of intracellular calcium concentration and 
calcium spark frequency upon stimulation. Importantly, the beneficial effects of the drugs 
dantrolene,  thapsigargin,  S107,  propranolol  and  flecanide  were  validated  in  these  CPVT 
models (Jung et al., 2012; Sasaki et al., 2016; Yoshida and Yamanaka, 2017). These findings 
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demonstrate the potential of ps-hiPSC-CMs to model cardiac arrhythmia and their usefulness 
in drug screening. Despite cardiac arrhythmias, cardiomyopathies have also been modeled 
such  as  the LEOPARD syndrome,  which results  from mutations  in  the  PTPN11 (tyrosine-
protein  phosphatase  non-receptor  type  11)  gene.  Ps-iPSC-CMs  showed  phenotypes 
associated  with  hypertrophy such as  increased size  and nuclear  translocation of  nuclear 
factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (NFATC4)  (Carvajal-Vergara 
et al., 2010). Phenotypes regarding the sarcomeric integrity, contractility, calcium handling, 
nuclear  senescence,  β-adrenergic  signaling and apoptosis  were recapitulated in ps-hiPSC-
CMs-based  models  of  hypertrophic  cardiomyopathy,  dilated  cardiomyopathy,  lamin  A/C 
(LMNA)-related cardiomyopathy and takotsubo syndrome (Borchert et al., 2017; Streckfuss-
Bömeke et al., 2017; Yoshida and Yamanaka, 2017). In conclusion, despite the immature state 
of  hiPSC-CMs,  important  cardiac  diseases  could  be  modeled  and  a  broad  range  of 
phenotypes were analyzed covering various important CM-specific mechanisms.
1.3 Modeling ACT using PSC-CMs
Since robust differentiation protocols became available, several groups analyzed the effects 
of DOX and other chemotherapeutic agents on hPSC-CMs. Most of them used commercially 
available  hPSC-CMs,  which  are  not  ACT  patient-specific,  to  test  applicability.  Upon  DOX 
treatment,  hiPSC-CMs  depicted  morphological  changes,  increased  beating  frequency, 
arrhythmic beating, cytotoxicity,  gene expression changes, apoptosis, increased amount of 
ROS and reduced contractility  (Burridge et al.,  2016; Chaudhari  et  al.,  2015, 2016, 2017; 
Eldridge et al., 2014; Grimm et al., 2015; Zhao and Zhang, 2017). These data demonstrate 
that hiPSC-CMs recapitulate key features of DOX cardiotoxicity and highlight their potential 
for modeling ACT. Similar data has also been reported in studies with hESC-CM (Holmgren et 
al.,  2015;  Maillet  et  al.,  2016).  Importantly,  novel  biomarkers,  pathways  and 
pathomechanisms have been suggested in several hiPSC-CM based studies. Using the same 
DOX application protocol in three separate studies, Chaudhari et al. showed the DOX-induced 
deregulation  of  35  genes,  14  microRNAs  and  pyruvate,  acetate  and  formate  signatures 
(Chaudhari et al., 2015, 2016, 2017). The authors propose the clinical use of these changes as 
early biomarkers of DOX-induced cardiotoxicity. Investigating signaling and cellular response 
pathways in hiPSC-CMs, NRG/ErbB signaling was validated to be involved in DOX-induced 
cardiotoxicity  (Eldridge  et  al.,  2014).  When  NRG/ErbB  signaling  was  activated,  the  DOX-
induced damage of iPSC-CMs was reduced, whereas inhibition of ErbB caused the cells to be 
more sensitive towards DOX. Recently, a novel pathomechanism of ACT has been reported in 
hiPSC-CMs, namely the DOX-induced gene expression upregulation of the death receptors 
tumor necrosis factor receptor 1 (TNFR1), Fas-receptor (FasR) and death receptor 4 and 5 
(DR4/5) (Zhao and Zhang, 2017). This upregulation would cause an increased susceptibility of 
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CMs  to  TNF-related  cytokines  and  lead  to  spontaneous  apoptosis.  This  study  suggests 
extrinsic  apoptosis  as  a  part  of  ACT and thereby  expands established intrinsic  apoptosis 
models. On the basis of their data, the authors further suggest the use of elevated TNF-
related cytokine serum levels as means to identify ACT risk groups before chemotherapy.
Currently, there is only one report of ps-iPSC-CMs being used to model ACT (Burridge et al., 
2016).  Here,  iPSC-CMs were generated from eight  breast  cancer  patients,  four  of  whom 
developed ACT after chemotherapy and four of whom did not. Four healthy donors were 
used as controls. The authors show DOX-induced cytotoxicity, mitochondrial and metabolic 
impairment, defects in calcium handling, decrease of antioxidants and increase of ROS in 
iPSC-CMs. Importantly, the phenotypes were more severe in iPSC-CMs from ACT patients 
compared to non-ACT chemotherapy patients and healthy donors. These data showed for 
the first  time, that  ACT can be modeled with ps-iPSC-CMs and suggest,  that the genetic 
background may convey  a  susceptibility  to  the  development of  ACT after  chemotherapy 
(Burridge et al., 2016). 
1.4 Aims of this thesis
This work aimed to establish a human model system of ACT by using the iPSC technology. 
Furthermore,  functional  consequences of  ACT-associated SNPs in subunits  of  the NADPH 
oxidase were to be investigated in a cardiac background. A human model system of ACT is 
highly needed because pathomechanisms still remain elusive. Additionally, results that were 
obtained in animal models are often not reproducible in human studies. A human ACT model 
could contribute to determine risk factors and biomarkers, discover protective drugs or to 
develop patient-specific therapies. For this purpose, three patients who suffer from ACT and 
two controls without cardiac disease after chemotherapy were recruited. The patients had 
ACT-associated alleles of SNPs in the genes  RAC2 and  CYBA, whereas the controls did not. 
The main objectives were:
1. Generation  of  integration-free  ps-iPSCs  and  subsequent  characterization  of 
pluripotency state and developmental potential.
2. Generation of ps-iPSC-CMs with high purity.
3. Analyses of NADPH oxidase subunit expression on mRNA and protein level and of 
NADPH oxidase activity. 
4. Comparison  of  DOX-induced  changes  between  iPSC-CMs  from  ACT  patients  and 
controls in ROS production, gene expression, calcium handling, apoptosis, sarcomeric 
integrity and functionality.
23
1 Introduction
Following hypotheses were made:
1. Untreated iPSC-CMs from ACT patients and controls  do not  differ in functionality, 
since no cardiac phenotype was reported in either group before chemotherapy.
2. DOX treatment causes ACT-associated abnormalities in iPSC-CMs.
3. iPSC-CMs from ACT patients react more sensitive to DOX treatment than control iPSC-
CMs.
4. Differences  between  iPSC-CMs  from  ACT  patients  and  controls  in  DOX-induced 
phenotypes are associated with SNPs in NADPH oxidase subunits.
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2 Materials
2.1 Chemicals, reagents, basal media and enzymes
Name Provider and product number
0.25% Trypsin-EDTA Thermo Fisher Scientific #25200056 
4′, 6-Diamidino-2-phenylindole dihydrochloride 
(DAPI) 
Sigma-Aldrich #D9542 
Agar Serva Electrophoresis #200201 
Albumin, human recombinant Sigma-Aldrich #A0237/A9731 
6-Aminohexanoic acid PanReac AppliChem ITW Reagents 
#A2266,0500
Ammonium persulfate (APS) Roth #9178 
B-27 serum free supplement (50x) Thermo Fisher Scientific #17504044 
B-27 Supplement, minus insulin Thermo Fisher Scientific #A1895601
Boric acid Sigma-Aldrich #15663 
Bovine albumin fraction V solution (BSA, 7.5%) Thermo Fisher Scientific #15260037 
Bromophenol blue sodium salt Roth #A512.2
Calcium chloride dihydrate (CaCl2) Roth #HN04 
CHIR99021 Merck Millipore #361559 
Collagenase IV Worthington Biochemical #CLS-4 
cOmplete (protease inhibitor cocktail tablets) Roche #04693132001 
Di-Sodium hydrogen phosphate dihydrate 
(Na2HPO4 · 2 H2O) 
Roth #T877 
Diamide Santa Cruz #sc-211289
Dimethyl sulfoxide (DMSO) Sigma-Aldrich #D2650 
Dithiothreitol (DTT) Roth #6908 
Dulbecco’s Modified Eagle Medium (DMEM) Thermo Fisher Scientific #11960044 
DMEM/F-12 Thermo Fisher Scientific #31331028 
dNTP mix Bioline #BIO-39029 
Doxorubicin hydrochloride Sigma-Aldrich #D1515
Dulbecco’s Phosphate-Buffered Saline (DPBS), 
no calcium, no magnesium
Thermo Fisher Scientific #14190144
Essential 8 basal medium Thermo Fisher Scientific #A1517001 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich #E6758
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Name Provider and product number
Fetal bovine serum (FBS) Sigma-Aldrich #F7524 
FGF2 Peprotech #AF-100-18B
Fluo-4/AM, cell permeant Thermo Fisher Scientific #F14201 
Fluoromount-G eBioscience #00-4958-02 
Formalin (37 %) (PFA) Merck Millipore #1039991000 
Gelatin Sigma-Aldrich #48720 
Geltrex Thermo Fisher Scientific #A1413301 
GeneAmp 10X PCR Buffer II & MgCl2  Thermo Fisher Scientific  #4379878
GeneRuler 100 bp Plus DNA Ladder Thermo Fisher Scientific #0321 
Glucose Sigma-Aldrich #G8270 
Glycerol Roth #3783 
Glycine Roth #3908 
GoTaq G2 DNA polymerase Promega #M7845 
HEPES Roth #9105 
HEPES sodium salt solution (1 M) Sigma-Aldrich #H3662 
Hexadimethrine bromide (Polybrene) Sigma Aldrich #107689
Hydrochloric acid fuming 37% (HCl) Merck Millipore #100317 
IGEPAL CA-630 Sigma-Aldrich #I3021 
IGF1 Peprotech #AF-100-11
Iscove´s modified Dulbecco´s medium with 
GlutaMax (IMDM) 
Thermo Fisher Scientific #31980022 
Isoprenaline hydrochloride (ISO) Sigma-Aldrich #II5627 
Isopropanol Merck Millipore #109634 
IWP2 Merck Millipore #681671 
Kanamycin sulfate Roth #T832 
Knockout serum replacement Thermo Fisher Scientific #10828028 
L-ascorbic acid 2-phosphate Sigma-Aldrich #A8960 
L-glutamine (200 mM, 100x) Thermo Fisher Scientific #25030024 
LB bouillon (Miller) Merck #1102850500
Magnesium chloride (MgCl2) Sigma-Aldrich #M8266 
Methanol Merck Millipore #106009 
Midori Green Advance Biozym #617004 
Mitomycin C (MMC) Serva Electrophoresis #29805.02 
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Name Provider and product number
Monothioglycerol (MTG) Sigma-Aldrich #M6145-25ML 
MuLV reverse transcriptase (50 U/μl) Thermo Fisher Scientific #N808-0018 
Non-essential amino acids (NEAA, 100x) Thermo Fisher Scientific #11140035 
Nonfat dry milk Roth #T145 
Nuclease-free water Thermo Fisher Scientific #AM9932 
Oligo d(T)16 (50 μM) Thermo Fisher Scientific #N808-0128 
Opti-MEM Thermo Fischer Scientific #4309155
Paraformaldehyde (PFA) Sigma-Aldrich #158127 
Penicillin-streptomycin solution (P/S) (100x) Thermo Fisher Scientific #15140122 
PeqGold protein marker V Peqlab #27-2210 
peqGold universal agarose Peqlab #35-1020 
pH neutralized medical grade bovine collagen LLC Collagen Solutions
PhosStop (phosphatase inhibitor cocktail tablets) Roche #04906837001 
Pluronic F-127 Thermo Fisher Scientific #P3000MP 
Polyfect Qiagen #301105
Potassium chloride (KCl) Sigma-Aldrich #P9541 
Recombinant human basic fibroblast growth 
factor (hbFGF)
PeproTech #100-18B 
RNase inhibitor (20 U/μl) Thermo Fisher Scientific #N808-0119 
Rotiphorese gel 30 Roth #3029 
RPMI 1640 with HEPES with GlutaMax Thermo Fisher Scientific #72400021 
RPMI 1640, no Glucose Thermo Fisher Scientific #11879020 
Sodium chloride (NaCl) Roth #9265.1 
Sodium DL-lactate solution 60% (w/w) Sigma-Aldrich #L4263 
Sodium dodecyl sulfate (SDS) Roth #2326 
Sodium fluoride (NaF) Roth #P756 
SYBR Green PCR Master Mix Thermo Fischer Scientific #4309155
Tetramethylethylenediamine (TEMED) Roth #2367 
TGF-b1 Peprotech #AF-100-21C
Thiazovivin (TZV) Merck Millipore # 420220 
Tricin PanReac AppliChem ITW Reagents 
#A1085,0100
Tris Roth #5429 
Triton X-100 Sigma-Aldrich #3051.3 
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Name Provider and product number
TrypLE Express Enzyme (1x), no phenol red Thermo Fisher Scientific  #12604013
Tween 20 Bio-Rad #170-6531 
VEGF165 Peprotech #AF-100-20
Versene solution (0.48 mM EDTA) Thermo Fisher Scientific #15040066 
β-Mercaptoethanol (β-ME) Serva Electrophoresis #28625 
2.2 Commercial kits
Name Provider
Alkaline phosphatase staining kit Sigma-Aldrich #86R-1KT 
Amplex Red Hydrogen Peroxide/Peroxidase 
Assay Kit
Thermo Fisher Scientific #A22188
APC Annexin V Apoptosis Detection Kit with PI BioLegend #640932
CytoTune-iPS 2.0 Sendai reprogramming kit Thermo Fisher Scientific #A16517 
Immobilon Western Chemiluminescent HPR 
Substrate
Merck Millipore #WBKLS0500
Maxwell 16 cell DNA purification kit Promega #AS1020 
NucleoBond Xtra Maxi Plus EF Kit Macherey-Nagel #740426.10 
Pierce BCA protein assay kit Thermo Fisher Scientific #23225 
QIAquick gel extraction kit Qiagen #28706 
SV total RNA isolation system Promega #Z3105 
2.3 Buffers and solutions for molecular biological analyses
Name Composition and specifications
Triton-X-100 (0.1 %) DPBS
0.1 % Triton-X-100
Agarose-Gel (1 – 1.5%) 1 x TB-buffer
1 – 1.5 % Agarose
0.07 
µL/mL
Midori Green Advance
TB-buffer (5x) Deionized H2O
54 g/L Tris
27.5 g/L Boric acid
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Name Composition and specifications
DAPI Deionized H2O
2 
mg/mL
DAPI
For Working solution diluted 1:5000 in    
1 % BSA in DPBS
PFA (4%) DPBS
4 % PFA
Store at -20°C
Tris-HCl, pH 7.4 (2 M) Deionized H2O
2 M Tris
pH adjusted to 7.4; stored at room 
temperature
Protein lysis buffer Deionized H2O
20 mM Tris-HCl, pH 7.4
200 mM NaCl
20 mM NaF
1 % Igepal
1 mM Na3VO4
1 mM DTT
1 Tablet
/10 mL
PhosStop
1 Tablet
/ 20 mL
Complete
Freshly prepared
TBST-Buffer Deionized H2O
20 mM Tris
150 mM NaCl
0.1 % Tween 20
Running buffer Deionized H2O
25 mM Tris
192 mM Glycine
0.1 % SDS
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Name Composition and specifications
Tris-HCl / SDS, pH 6.8 Deionized H2O
0.5 mM Tris
0.4 % SDS
pH adjusted to 6.8; stored at room 
temperature
Tris-HCl / SDS, pH 8.8 Deionized H2O
1.5 mM Tris
0.4 % SDS
pH adjusted to 8.8; stored at room 
temperature
8 % Separating gel 5.8 mL Deionized H2O
3.2 mL Rotiphorese gel 30
3 mL Tris-HCl / SDS, pH 8.8
48 µL 10 % APS
18 µL TEMED
15 % Separating gel 3 mL Deionized H2O
6 mL Rotiphorese gel 30
3 mL Tris-HCl / SDS, pH 8.8
48 µL 10 % APS
18 µL TEMED
Stacking gel 4.62 mL Deionized H2O
1 mL Rotiphorese gel 30
1.88 mL Tris-HCl / SDS, pH 6.8
37.5 µL 10 % APS
15 µL TEMED
Anode buffer Deionized H2O
300 mM Tris
54 mM Tricin
pH adjusted to 8.8; stored at room 
temperature
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Name Composition and specifications
Cathode buffer Deionized H2O
30 mM Tris
300 mM 6-Aminohexanoic acid
pH adjusted to 8.7; stored at room 
temperature
SDS sample buffer (5x) Deionized H2O
313 mM Tris-HCl pH 6.8
10 % SDS
0.05 % Bromophenol blue
50 % Glycerol
5 mM EDTA
150 mM DTT
Stored at -20°C
DTT (110 mM) Tyrode’s solution
110 mM DTT
Diamide (5.5 mM) Tyrode’s solution
5.5 mM Diamide
Tyrode’s solution Deionized H2O
150 mM NaCl
5.4 mM KCl
1.8 mM CaCl2
1 mM MgCl2
10 mM HEPES
10 mM Glucose
pH adjusted to 7.4; stored at 4°C
Amplex Red working solution 1 DPBS
50 nM Amplex Red
50 
mU/mL
Horseradish peroxidase
Amplex Red working solution 2 DPBS
100 nM Amplex Red
100 
mU/mL
Horseradish peroxidase
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2.4 Media supplements, factors and solutions for cell 
culture
Name Composition and specifications
Gelatin (1 %) Deionized H2O
1 % Gelatin
Autoclaved and stored at 4°C.
EDTA (50x) DPBS
1 % EDTA
pH adjusted to 7, sterile filtrated and 
stored at 4°C
Trypsin (0.2 %) DPBS
0.2 % Trypsin
Sterile filtrated and stored at 4°C
Trypsin/EDTA (T/E; 0.1 %) 1 mL 50x EDTA
50 mL 0.2 % Trypsin
49 mL DPBS
Stored at 4°C
MTG (150 mM) IMDM
150 mM MTG
Sterile filtrated and freshly prepared
β-ME (10 mM) DPBS
10 mM β-ME
Sterile filtrated and stored at 4°C
BSA (1%) 6.5 mL DPBS
1 mL 7.5% BSA solution
Stored at 4°C
CHIR (12 mM) 894 µL DMSO
5 mg CHIR99029
Stored at -20°C
Collagenase IV (2000 U/mL) 1 mL DMEM/F12
2000 U Collagenase IV
Sterile filtrated and stored at -20°C; 
working solution 200 U/mL
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Name Composition and specifications
Polybrene (1 mg/mL) 1 mL Deionized H2O
1 mg Polystyrene
Sterile filtrated and stored at 4°C
HbFGF (100 ng/μL) 1 mL 5 mM Tris
100 mg hbFGF
Stored at -20°C. For a working solution of 
5 ng/µL the stock solution was diluted 
1:20 in 0.1% BSA and stored at 4°C not 
longer than two weeks. 
ISO (200 mM) 1 mL Deionized H2O
49.44 
mg
ISO
IWP2 (5mM) 4.28 mL DMSO
10 mg IWP2
Dilution at 37°C for 10min. Stored at 
-20°C
Mitomycin C (200 µg/mL) 1 mL DPBS
0.2 mg Mitomycin C
Stored at -20°C
TZV (2 mM) 6.8 mL DMSO
10 mg TZV
Stored at -20°C
DOX (5mM) Deionized H2O
5 mM DOX
Stored at -20°C
Lactate/HEPES (1 M) 3 mL Sodium DL-lactate solution 60% (w/w)
18 mL 1M HEPES sodium salt solution
Stored at -20°C
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2.5 Cell culture media
Name Composition and specifications
Human Embryonic Stem Cell 
Medium (hES-medium)
DMEM/F12 with GlutaMAX 
20 % Knock-Out Serum Replacement 
1 x NEAA
1 x β-ME
10 ng/mL hbFGF
Iscove medium IMDM with GlutaMAX
20 % Heat-inactivated FBS
1 x NEAA
450 μM MTG
Freezing medium 1 DMEM
20 %  Heat-inactivated FBS
8 % DMSO 
Human Fibroblast Medium (HFB-
medium)
DMEM
10 % Heat-inactivated FBS
1 x L-Glutamine
1 x NEAA
1 x β-ME
10 ng/mL hbFGF
Essential 8 medium (E8 medium) Essential 8 basal medium
1 x Essential 8 Supplement 
Differentiation medium RPMI 1640 with HEPES and GlutaMAX
500 
µg/mL
Albumin, human recombinant 
100 
µg/mL
L-ascorbic acid 2-phosphate
Sterile filtrated
Cardiac culture medium RPMI 1640 with HEPES and GlutaMAX
1 x B27 Serum-free Supplement 
Freezing medium 2 E8 medium
20 % DMSO
4 µM TZV
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Name Composition and specifications
Digestion medium Cardiac culture medium
20 % Heat-inactivated FBS
2 µM TZV
Mouse embryonic fibroblast-
medium (MEF-medium)
DMEM
15 % Heat-inactivated FBS
1 x L-Glutamine
Selection medium RPMI 1640, no glucose
4 mM Lactate/HEPES
500 
µg/mL
Albumin, human recombinant 
100 
µg/mL
L-Ascorbic acid 2-phosphate
Sterile filtrated
HEK transfection-medium DMEM
0.5 % Heat-inactivated FBS
1 x L-Glutamine
HEK-medium DMEM
10 % Heat-inactivated FBS
1 x L-Glutamine
EHM-reconstitution mixture 2 x RPMI
8 % B27 without insulin
0.4 
mg/EHM
pH neutralized medical grade bovine 
collagen
200 U/ml Penicillin
200 
μg/ml
Streptomycin
35
2 Materials
Name Composition and specifications
EHM-culture medium Iscove medium
4 % B27 without insulin
1 % NEAA
2 mM Glutamine
300 µM Ascorbic acid
100 
ng/mL
IGF1
10 ng/mL FGF2
5 ng/mL VEGF165
5 ng/mL TGF-b1
100 
U/mL
Penicillin
100 
µg/mL
Streptomycin
2.6 Cell lines
Cell type Internal 
identification
Donor Specifications
human 
primary 
dermal 
fibroblasts 
ACT1 Patient 1 Derived from skin biopsies of a 69-year-old male 
patient with ACT and alleles C/T of rs4673 and 
alleles A/A of rs13058338.
ACT2 Patient 2 Derived from skin biopsies of a 71-year-old male 
patient with ACT and alleles C/T of rs4673 and 
alleles T/A of rs13058338.
ACT3 Patient 3 Derived from skin biopsies of a 66-year-old female 
patient with ACT and alleles C/T of rs4673 and 
alleles T/A of rs13058338.
ACT.K1 Control 1 Derived from skin biopsies of a 66-year-old male 
donor without heart condition after chemotherapy 
with alleles C/C of rs4673 and alleles T/T of 
rs13058338.
ACT.K2 Control 2 Derived from skin biopsies of a 68-year-old male 
donor without heart condition after chemotherapy 
with alleles C/C of rs4673 and alleles T/T of 
rs13058338.
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Cell type Internal 
identification
Donor Specifications
hiPSCs 
and iPSC-
CMs 
is.ACT.1.9 Patient 1 Generated from respective human primary dermal 
fibroblasts with the CytoTune-iPS 2.0 
reprogramming Kit (Thermo Fisher Scientific).
is.ACT.1.10
is.ACT.2.11 Patient 2
is.ACT.2.14
is.ACT.3.1 Patient 3
is.ACT.3.11
is.ACT.K1.2 Control 1
is.ACT.K1.8
is.ACT.K2.7 Control 2
is.ACT.K2.9
FB1 Healthy Generated in-house from primary dermal fibroblasts 
of a healthy donor (University Medical Center 
Göttingen). Characterization and proof of 
pluripotency was published earlier (Streckfuss-
Bömeke et al., 2013).
Mouse 
embryonic 
fibroblasts
(MEFs)
- - Derived from E14.5 embryos of Naval Medical 
Research Institute (NMRI) mice; central animal 
facility, University Medical Center, Göttingen.
Human 
embryonic 
kidney 
cells 
(HEK)
HEK-293T - Human embryonic kidney cells transformed with 
adenovirus 5 and SV40 Large T-antigen DNA.
2.7 Oligonucleotides
Name Sequence (5’ → 3’) Purpose bp TA 
[°C]
Cy
rs4673 For: CAACCCTTTGGTGCTTGTGG Sequencing 288 60 33
Rev: CAAGCCCTCCTGAGCCCTA
rs13058338 For: TTGCCCTGAGAACCAAGACC Sequencing 299 60 33
Rev: CGCTGCTATTTCATGGCTGG
NANOG For: AGTCCCAAAGGCAAACAACCCACTTC PCR 164 64 36
Rev: ATCTGCTGGAGGCTGAGGTATTTCTGTCT
C
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Name Sequence (5’ → 3’) Purpose bp TA 
[°C]
Cy
OCT4 For: GAC AAC AAT GAA AAT CTT CAG GAG A PCR 473 59 36
Rev: TTC TGG CGC TTA CAG AAC CA
LIN28 For: AGTAAGCTGCACATGGAAGG PCR 410 52 30
Rev: ATTGTGGCTCAATTCTGTGC
SOX2 For: ATG CAC CGC TAC GAC GTG A PCR 437 60 34
Rev: CTT TTG CAC CCC TCC CAT TT
GDF3 For: TTCGCTTTCTCCCAGACCAAGGTTTC PCR 311 54 30
Rev: TACATCCAGCAGGTTGAAGTGAACAGCA
CC
GAPDH For: AGAGGCAGGGATGATGTTCT PCR, 
qRT-PCR
258 60 30/
40Rev: TCTGCTGATGCCCCCATGTT
AFP For:  ACTCCAGTAAACCCTGGTGTTG PCR 255 60 33
Rev: GAAATCTGCAATGACAGCCTCA
α-MHC For: GTCATTGCTGAAACCGAGAATG qRT-PCR 413 60 40
Rev: GCAAAGTACTGGATGACACGCT
TH For: GCGGTTCATTGGGCGCAGG PCR 215 60 34
Rev: CAAACACCTTCACAGCTCG
cTNT For: GAC AGA GCG GAA AAG TGG GA PCR, 
qRT-PCR
305 62 26/
40Rev: TGA AGG AGG CCA GGC TCT AT
NOX2 For: GCAGCCTGCCTGAATTTCA qRT-PCR 93 60 40
Rev: TGAGCAGCACGCACTGGA
NOX4 For: GCAGGAGAACCAGGAGATTG qRT-PCR 125 60 40
Rev: CACTGAGAAGTTGAGGGCATT
CYBA For: GTACTTTGGTGCCTACTCCA qRT-PCR 167 60 40
Rev: CGGCCCGAACATAGTAATTC
RAC1 For: AAGCTGACTCCCATCACCTATCCG qRT-PCR 199 60 40
Rev: CGAGGGGCTGAGACATTTACAACA
RAC2 For: CTGTCACCACCGACACTCTC qRT-PCR 150 60 40
Rev: TGTCAAACACGGTGGGGATG
NCF1 For: GTCCTGACGAGACGGAAGAC qRT-PCR 171 60 40
Rev: TGACGTCGTCTTTCCTGATGA
NCF2 For: CAGAAAGTGAACACCTTGGGG qRT-PCR 382 60 40
Rev: GCCAAATCATATTTCTCTGTCTGGT
NCF4 For: CCTCCTCAGTCGGATCAACAA qRT-PCR 181 60 40
Rev: CTCCCAGGCCACAGACTTGAT
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Name Sequence (5’ → 3’) Purpose bp TA 
[°C]
Cy
HPRT For: CAAAGATGGTCAAGGTCGC qRT-PCR 81 60 40
Rev: CAAATCCAACAAAGTCTGGCT
RYR2 For: TGCATGAAAGCATCAAACGCA qRT-PCR 213 60 40
Rev: CTTGTGCAAAAACCGCAGGA
CamKII For: ACCAGATGGAGTAAAGGAGTCAAC qRT-PCR 171 60 40
Rev: AAAGCAGTAAGGCCTGGGTC
SERCA For: ACAGAGTGGAAGGTGATACTTGTTC qRT-PCR 384 60 40
Rev: AGTAAACCGACATTGACTTTCTGTC
PLN For: ACAGCTGCCAAGGCTACCTA qRT-PCR 191 60 40
Rev: GCTTTTGACGTGCTTGTTGA
NCX For: AAGTGACTGAAAATGACCCTGTTAG qRT-PCR 401 60 40
Rev: AAAAATAGTTACAGTGGCAGTGGAG
α-actinin For: AGG AGG AAG AAT GGC CTG AT qRT-PCR 291 60 40
Rev: GAT GCA GTA CTG GGC CTG AT
β-MHC For: AGACTGTCGTGGGCTTGTATCAG qRT-PCR 101 60 40
Rev: GCCTTTGCCCTTCTCAATAGG
bp: Base pairs; TA: Annealing temperature; Cy: Amplification cycles of PCR.
2.8 Antibodies
2.8.1 Primary antibodies
Antigen Host and 
isotype
Dilution Supplier
WB IF
AFP Rabbit, IgG - 1:100 Dako A0008
CamKII Rabbit, IgG 1:5000 - Thermo fisher scientific PA5-22168
cTNT Mouse, IgG - 1:500 Thermo Fisher Scientific 
MS295PABX 13-11
GAPDH Mouse, IgG 1:500 - Merck Millipore MAB374
LIN28 Goat, IgG - 1:300 R&D systems AF3757
NANOG Goat, IgG - 1:200 Abcam PA5-18406
NCX Rabbit, IgG 1:5000 - Swant ∏ 11-13
NOX2 Mouse, IgG 1:500 - kindly provided by Dr. D. Roos,
Amsterdam (Burritt et al., 2000)
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NOX4 Rabbit, IgG 1:500 - Abcam ab109225
OCT4 Goat, IgG - 1:40 R&D systems AF1759
p40phox Rabbit, IgG 1:1000 - Merck Millipore 07-503
PLN Mouse, IgG 1:5000 - Thermo fisher scientific MA3-922
PLN S16p Rabbit, IgG 1: 5000 - Badrilla A010-12AP
PLN 
Thr17p
Rabbit, IgG 1:5000 - Badrilla A010-13
RAC1 Mouse, IgG 1:1000 - Merck Millipore 05-389
RYR2 Rabbit, IgG 1:5000 - Sigma-Aldrich HPA020028
RYR2 
S2808p
Rabbit, IgG 1:1000 - Badrilla A010-30
RYR2 
S2814p
Rabbit, IgG 1:5000 - Badrilla A010-31
SERCA Mouse, IgG 1:20,000 - Thermo fisher scientific MA3-919
SOX2 Mouse, IgG - 1:50 R&D systems MAB2018
SSEA4 Mouse, IgG - 1:200 Abcam MC813
TRA-1-60 Mouse, IgM - 1:200 R&D systems MAB4770
α-actinin Mouse, IgG 1:10,000 1:1000 Sigma-Aldrich A7811
α-SMA Mouse, IgG - 1:3000 Sigma-Aldrich A2547
β-actin Mouse, IgG 1:5000 - Santa Cruz sc-47778
β-III-Tub Mouse, IgG - 1:2000 Covance MMS-435P
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2.8.2 Secondary antibodies and fluorophore-conjugated probes
Antigen / 
Probe
Conjugate Host Dilution Supplier
Mouse IgM FITC Goat 1:200 Jackson ImmunoResearch
Laboratories 115-095-020
Rabbit IgG Cy3 Goat 1:600 Jackson ImmunoResearch
Laboratories 111-165-045
Goat IgG Alexa Fluor 555 Donkey 1:1000 Thermo Fisher Scientific 
A21432
Mouse IgG Alexa Fluor 488 Donkey 1:1000 Thermo Fisher Scientific 
A21202
Mouse IgG HRP Donkey 1:10.000 Thermo Fisher Scientific 
A16011
Rabbit IgG HRP Donkey 1:10.000 Thermo Fisher Scientific 
A16023
Phalloidin Alexa Fluor 555 - 1:200 Thermo Fisher Scientific 
A34055
2.9 DNA plasmids
2.9.1 pEIGW roGFP2-Orp1
The plasmid pEIGW roGFP2-Orp1 was a gift from Tobias Dick (Addgene plasmid #64993). It is  
a  lentiviral  vector  for  the  mammalian  expression  of  cytosolic  roGFP2-Orp1.  Details  are 
depicted in the map of the plasmid (Figure 5).
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2.9.2  pGIPZ-Grx1-roGFP2
The plasmid pGIPZ-Grx1-roGFP2 was a kind gift from Prof. Zimmermann from the institute of  
pharmacology and toxicology of the University Medical Center Göttingen. It was generated in 
the work of Dr. Heta from pLPCX-Grx1-roGFP2 (Heta, 2017). Details are depicted in the map 
of the plasmid (Figure 6).
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Figure 5: Map of plasmid pEIGW roGFP2-Orp1. From https://www.addgene.org/64993/ as of 
November 20, 2017.
2 Materials
2.9.3 pMD2.G
The plasmid pMD2.G was a gift from Didier Trono (Addgene plasmid # 12259). The vector is  
designed for  the mammalian expression of  lentiviral  envelope protein  VSV-G. Details  are 
depicted in the map of the plasmid (Figure 7).
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Figure 6: Map of plasmid pGIPZ-Grx1-roGFP2. From (Heta, 2017).
2 Materials
2.9.4 psPAX2
The plasmid psPAX2 was a gift from Didier Trono (Addgene plasmid # 12260).  The vector is  
designed for the mammalian expression of lentiviral packaging proteins. Details are depicted 
in the map of the plasmid (Figure 8).
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Figure 7: Map of plasmid pMD2.G. From https://www.addgene.org/12259/ as of November 20, 
2017.
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2.10 Disposable items
Name Provider
10-cm dish, TC-treated CytoOne Starlab #CC7682-3394 
12-well plate, TC-treated CytoOne Starlab #CC7682-7512 
6-cm dish, TC-treated CytoOne Starlab #CC7682-3359
6-cm dish, untreated Sarstedt #82.1194.500
6-well plate, TC- treated CytoOne Starlab #CC7682-7506 
96 -well microplate, black Berthold Technologies #23302
96 -well microplate, black, clear bottom Berthold Technologies #38840
Cell scraper: 2-Posit. Blade 25 Sarstedt #83.1830 
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Figure 8: Map of plasmid psPAX2. From https://www.addgene.org/12260/ as of November 20, 2017.
2 Materials
Name Provider
Filter tips: 0.1–1000 μL Starlab #S1120-3810, #S1122-1830, 
#S1120-1840 
Flow cytometry tube: 5 mL Polystyrene Round-
Bottom Tubes 
BD Falcon #352058 
Pipette tips: 0.1–1000 μL Starlab #S1111-3700, #S1111-1706, 
#S1112-1720 
Pipettes: 5 mL, 10 mL, 25 mL Sarstedt #86.1253.001, 
#86.1254.001, #86.1685.001 
PVDF membrane: Amersham Hybond P Western 
blotting membranes 
Sigma-Aldrich #GE10600023 
Slides and coverslips: 76 x 26 mm, 18 x 18 mm, 
round 25 mm 
Thermo Fisher Scientific 
#10143562CE, Thermo Fisher 
Scientific #4004672; R. 
Langenbrinck, #1049251 
Sterile filters: Millex-GS, 0.22 μm; Steriflip 50 mL, 
0.22 μm; Steritops 500 mL, 0.22 μm 
Merck Millipore #GLGS0250S 
Merck Millipore #SCGP00525 
Merck Millipore # SCGPT05RE 
Whatman gel blotting paper, Grade GB003 Sigma-Aldrich #WHA10426890 
2.11 Laboratory equipment
Name Provider
Balances: Extend ED153-CW, CPA225D Sartorius
Blotting chamber: Trans-Blot Turbo Transfer System Bio-Rad 
Cell stimulator: MyoPacer ES IonOptix 
Centrifuges: 5810R, 5415D, 5415R Eppendorf 
Chemiluminescence detection system: ChemiDoc 
MP Imaging System Universal Hood III 
Bio-Rad 
Confocal laserscanning microscope: LSM 710 
confocal microscopic system 
Carl Zeiss 
Counting chamber: Neubauer improved Marienfeld Superior 
DNA Isolation: DNA Maxwell 16 System Promega 
Electrophoresis chambers: Mini-PROTEAN Tetra 
Vertical Electrophoresis Cell 
Bio-Rad 
Flow cytometer: FACS Canto II BD Biosciences
Freezing box: Mr. Frosty Thermo Fisher Scientific 
Gel documentation: MultiImage Light Cabinet Alpha Innotech Corporation 
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Name Provider
Incubator: HERACELL VIOS 160i CO2 Incubator Thermo Fisher Scientific 
Microplate reader: Mithras LB 940, Mithras2 LB 943 Berthold Technologies
Microscopes: Axio Oberserver A1, Axio Oberserver 
Z1, Primo Vert, Axiovert 25 
Carl Zeiss 
NanoDrop 2000c/2000 UV-Vis Spectrophotometer Thermo Fisher Scientific 
PCR cycler: Thermocycler 48 SensoQuest 
pH meter: inoLab pH 7110 WTW 
Pipet controller: Accu-jet pro Brand 
Pipettes: Reference, Research plus (10/100/1000 μL) Eppendorf 
Power supply: Power Pac 3000-Power supply Bio-Rad 
qPCR cycler: iCycler Thermal Cycler, iQ5 
Multicolor Real-Time PCR Detection System
Bio-Rad
Sterile work bench:  CleanAir CA/RE 5
Tissue embedding system: Benchtop Tissue 
Processor 1020 
Leica Biosystems 
Water preparation system 
Milli-Q Reference 
Merck Millipore 
2.12 Software
Name Provider / Author
ImageJ / FIJI National Institutes of Health (Schindelin 
et al., 2012, 2015; Schneider et al., 2012)
Prism 6/7 GraphPad Software, Inc
LabChart AD Instruments
Mikrowin 2000/2010 Mikrotek Laborsysteme GmbH 
ApE A plasmid editor M. Wayne Davis
LibreOffice The Document Foundation
Inkscape Inkscape Community
AxioVision Carl Zeiss
Zen Carl Zeiss
IQ optical system software Bio-Rad
Flowing Software Perttu Terho
Image Lab Software Bio-Rad
Office Microsoft
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3 Methods
3.1 Cell culture
All cells were cultured under humidified air conditions with 5% CO2 and 20% O2 at 37°C. 
3.1.1 Isolation and cultivation of human primary dermal fibroblasts
Donor skin biopsies were sent to the University Medical Center Göttingen in 15 mL conical  
tubes  containing  DMEM and 1x P/S.  Using  scalpels,  the dermis  was  separated  from the 
epidermis and subcutaneous layer and was cut into pieces of about 1 mm2. hFB-medium was 
added and the biopsies were cultured on 6-cm dishes for about one week without medium 
change  to  ensure  attachment  and  proliferation  of  fibroblasts.  Primary  fibroblasts  were 
cultured in hFB-medium, which was replaced every second day and the cells were passaged 
every  four  to  six  days.  For  this  purpose,  the  cells  where  quickly  washed  with  0.1% 
Trypsin/EDTA and afterwards shortly incubated in 0.1% Trypsin/EDTA at room temperature 
until cells started to detach. Finally, the Trypsin/EDTA was carefully removed and the cells 
were  detached from  the  dish  using  hFB-medium  and  transferred  into  new  dishes  in  an 
appropriate ratio.
3.1.2 Isolation and cultivation of mouse embryonic fibroblasts
Mouse embryos at stage E14.5 were used to isolate MEFs (Wobus et al., 2002), which were 
cultured on 0.1% gelatine-coated dishes up to passage number 4 in MEF-medium. The cells 
were mitotically  inactivated by treatment with 10 µg/mL MMC for  3  h.  Then they were 
plated on 0.1% gelatine-coated dishes in an appropriate ratio. The MEFs were cultured over-
night and used as feeder layer for hiPSCs.
3.1.3 Generation of hiPSC lines
hiPSCs were generated from primary dermal fibroblasts using the CytoTune-iPS 2.0 Sendai 
Reprogramming Kit (Thermo Fisher Scientific). For this purpose, 7.5 x 104 cells were plated 
per well of a 6-well culture plate and two wells were prepared. Two days later, cells from one 
well were trypsinyzed as described above and counted to estimate the cell number of the 
remaining  well.  The  required  amount  of  virus  was  calculated  with  MOI  (multiplicity  of 
infection in CIU (collective infectious unit) per cell)) of 5 for the viruses KOS and hc-Myc and 3 
for hKlf4:
Volume of virus [µL]= MOI [CIU /cell]⋅number of cells
titer of virus[CIU /mL]⋅10−3[µL /mL] .                                              (1)
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The titer of each virus was lot-dependent. To thaw the viruses, the bottom of the tube was 
immersed in a 37°C water bath for 10 sec.  Subsequently,  the virus was thawed at room 
temperature and shortly centrifuged. The calculated amount of each virus was added to 1 mL 
pre-warmed hFB-medium and carefully mixed by pipetting. Afterwards, the cell medium was 
aspirated from the remaining attached cells and the prepared virus suspension was added. 
24 h after transduction, medium was replaced with hFB-medium every day. On day 7 after 
transduction, cells were trypsinyzed as described above and transferred onto geltrex-coated 
6-cm culture dishes in an appropriate ratio. The medium was changed to E8-medium at day 8 
after transduction and replaced daily. Emerging iPSC-like colonies of appropriate size were 
manually transferred onto geltrex-coated 12-well culture plates about two to three weeks 
after transduction.
3.1.4 Cultivation of hiPSCs on MEFs or geltrex
hiPSCs were either cultured on MMC-inactivated MEFs in hES-medium or on geltrex in E8-
medium  and  the  medium  was  replaced  every  day.  During  the  cocultivation  with  MEFs, 
passaging was done every five to seven days, depending on the density and size of hiPSC 
colonies. Therefore, hiPSCs were washed once with DMEM/F12 and subsequently incubated 
in  collagenase IV  (200 U/mL)  at  37°C for  5  min.  After  washing  the cells  two times with 
DMEM/F12, they were mechanically detached from the culture dish in hES-medium using a 
cell scraper. To receive appropriately sized cell aggregates, the cells were resuspended one to 
three times with a 1000 µL handpipette and transferred in an appropriate ratio onto 6-cm 
culture dishes containing MMC-inactivated MEFs and hES-medium.
To  adapt  hiPSCs  to  feeder-free  culture,  they  were  processed  as  described  before  and 
transferred onto geltrex-coated 6-well culture plates. To passage hiPSCs that were cultured 
on geltrex, the cells were washed two times with versene. Afterwards, they were incubated 
in versene for 3 - 5 min at room temperature. The versene was carefully aspirated and the 
cells were detached from the dish using E8-medium with 2 µM TZV and resuspended three 
to five times. Finally, an appropriate amount of cells were transferred onto geltrex-coated 6-
well plates containing E8-medium with 2 µM TZV.
3.1.5 Freezing of dermal fibroblasts and iPSCs on MEFs and geltrex
hiPSCs and fibroblasts were frozen in liquid nitrogen for long-term storage. In the case of 
hiPSCs cocultured with MEFs, colonies were frozen five to seven days after passaging when 
they reached 70-80% confluence. Fibroblasts and feeder-free hiPSCs were frozen about four 
days after passaging when they reached 80-100% confluence. HiPSCs and fibroblasts were 
detached from the culture dish as described in chapter 3.1.1 and 3.1.4 using Trypsin/EDTA, 
collagenase IV or Versene, respectively. Afterwards, fibroblasts and iPSCs that were cultured 
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on MEFs were transferred into 15 mL conical tubes with basal medium and centrifuged for 3 
min at 200 x g. The cell pellet was carefully resuspended in 1 mL freezing medium 1 and 
transferred into a 2 mL cryovial. Finally, the cryovial was frozen for at least 24 h at -80°C using 
a  Nalgene  Cryo  1°C  Freezing  Container  and  was  placed  into  liquid  nitrogen  storage 
afterwards. 
hiPSCs that were cultured on geltrex were resuspended in 1 mL E8-medium per 6-well after 
detachment. Afterwards, 1 mL freezing medium 2 was added drop-wise and the cell solution 
was transferred equally into two 2 mL cryovials. The cryovials were stored in the same way as 
described above. 
3.1.6 Thawing of HEK cells and iPSCs on MEFs or geltrex
To thaw cells, the cryovial was placed in a 37°C water bath immediately after removal from 
liquid nitrogen storage for about 1 min. The cell suspension was transferred gently into a 
15 mL conical  tube containing  10 mL of  cold  basal  medium (DMEM or  DMEM/F12)  and 
centrifuged for  3 min at  200 x g.  The supernatant  was removed and the cell  pellet  was 
carefully resuspended in the respective culture medium. Finally, the cells were transferred 
onto respective culture dishes (see chapter  3.1.1 and  3.1.4). 2 µM TZV was added to the 
culture medium of iPSCs cultured on geltrex.
3.1.7 Spontaneous in vitro differentiation
Differentiating hiPSC in vitro was done to observe their potential to give rise to derivatives of 
all  three  germ  layers  and  to  analyze  the  efficiency  of  cardiac  lineage  differentiation.  A 
spontaneous differentiation protocol was applied without the use of factors that direct the 
differentiation into a specific cell type. First, at day 0 hiPSCs of about 80 % confluence on 
MEFs were detached from the culture dish using collagenase IV as described above (see 
chapter  3.1.4). The cell clumps were transferred with hES-medium into a non-coated 6-cm 
suspension culture dish and incubated at 37°C over-night. When embryoid bodies (EBs) had 
formed,  they  were  transferred  with  the  culture  medium  into  a  15  mL  conical  tube. 
Subsequently to the sedimentation of the EBs, they were carefully washed with IMDM and 
transferred into a non-coated 6-cm suspension culture dish with Iscove medium. The EBs 
were cultured in suspension at 37°C for 8 days and the medium was changed on day 4 and 7  
after differentiation start. On day 8, the EBs that were to be analyzed by semiquantitative RT-
PCR were plated on 0.1% gelatin-coated culture plates. For immunofluorescence analyses 
EBs were plated on 0.1% gelatin-coated culture plates containing glass cover-slips. About 30 
EBs were transferred into a 6-cm culture dish. The EBs were cultured for another 25 days in  
Iscove medium, which was replaced every two days.  To analyze the efficiency of  cardiac 
lineage differentiation, the number of plated EBs and EBs which developed beating areas 
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were counted.  The counting was  usually  performed at  days  11,  14,  18,  25 and 33 after 
differentiation start.
3.1.8 Cardiac differentiation of hiPSCs and metabolic selection
To obtain iPSC-CMs the iPSCs were plated on geltrex-coated 12-well plates and cultured for 
two  to  four  days  in  E8  medium  until  they  reached  about  90%  confluency.  To  start  the 
differentiation,  the E8 medium was replaced by differentiation medium containing 4 µM 
CHIR. 48 h later, the medium was replaced by differentiation medium with 5 µM IWP2. On 
day 4 and 6 after differentiation start, the medium was replaced by differentiation medium. 
The medium was changed to cardiac culture medium on day 7 to 9 when first beating or CM-
like cells were visible. From there on, the medium was replaced every 2 to 3 days. 
Three  to  four  weeks  after  differentiation  start,  the  cells  were  singularized  by  15  min 
incubation  with  0.25%  Trypsin/EDTA  at  37°C  and  resuspension.  Afterwards,  the  cell 
suspension was diluted in two volumes of digestion medium and centrifuged at 200 x g for 3 
min. After removing the supernatant, the cells were plated onto geltrex-coated 6-well pates 
in a ratio appropriate to obtain a monolayer of CMs. Two days after recovery in digestion 
medium, the CMs were purified by cultivation in selection medium for two to eight days until 
only beating CMs were remaining. From there on, iPSC-CMs were cultured in cardiac culture 
medium which was replaced every two to three days.
Two to three month after differentiation start, the iPSC-CMs were used for analyses. For this 
purpose,  they  were  singularized  by  treatment  with  0.25%  Trypsin/EDTA  for  5  min  as 
described  above,  pooled  and  plated  in  ratios  and  onto  geltrex-coated  culture  plates  as 
needed  for  the  respective  methodology.  After  one  week  of  cultivation  the  iPSC-CMs 
recovered from digestion and were processed.
3.1.9 Preparation and preservation of cell samples for analyses
For long-term storage of cell samples, cells were washed three times with DPBS, detached 
from the culture dish with a cell scraper and transferred into a 1.5 mL conical tube. After 
centrifugation  at  200  x  g  for  3  min,  the  supernatant  was  removed  and  the  tube  was 
incubated in liquid nitrogen for several minutes to snap-freeze the cells. The samples were 
stored at -80°C.
3.1.10 Cultivation of HEK-293T cells
HEK-293T cells were cultured on 10-cm culture dishes in HEK-medium, which was replaced 
every three days. For passaging, the cells were washed once with DPBS and incubated in 
TrypLE Express for about 3 min until the cells started to detach. After adding HEK-medium, 
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the  cells  were  singularized  by  pipetting and  transferred  onto  fresh  culture  dishes  in  an 
appropriate ratio.
3.1.11 Lentivirus production
To  obtain  roGFP2-Orp1  or  Grx1-roGFP2  containing  lentiviruses,  HEK-293T  cells  were 
transfected with plasmid DNA using Polyfect (Qiagen). For this purpose, 70% confluent cells,  
which  were  plated  about  two  days  prior,  were  washed  once  with  PBS  and  7  mL  HEK 
transfection-medium was added. 3 µg target vector, 3 µg vector psPAX2, 2 µg vector pMD2.G 
and 80 µL Polyfect were added to Opti-MEM medium to receive a final volume of 300 µL. 
After addition of 80 µL Polyfect, the suspension was immediately vortexed for 10 sec and 
incubated for 10 min at room temperature. Subsequently, 620 µL HEK transfection-medium 
was added and the transfection mixture was transferred drop-wise to the HEK-293T cells. 
After three days of incubation, debris was removed from the cell  supernatant by filtering 
with 0.45 µm syringe filters and the flow-through was stored at 4°C. 10 mL HEK transfection-
medium was added to the transfected cells which were incubated for another 24 h. The cell  
supernatant was filtered as before and added to the previous flow-through. Finally, 2 mL 
aliquots of virus containing cell supernatant were prepared, snap-frozen in liquid nitrogen for 
several minutes and stored at -80°C.
3.1.12 Lentiviral transduction of iPSC-CMs 
The lentivirus containing HEK-293T cell supernatant was thawed at room temperature. For 
transduction, a virus containing suspension was made, consisting of one volume HEK-293T 
cell  supernatant,  five  volumes  cardio  culture  medium  and  6  µg  /  mL  polybrene.  For 
reduction-oxidation-sensitive GFP2 (roGFP2)-based biosenor measurements, 1.5 x 104  iPSC-
CMs per well were cultured for one week and transduced in 96-well culture plates with black  
walls and clear bottoms. 300 µL virus suspension was added per well and incubated for three 
days. Afterwards, medium was replaced by cardio culture medium and cells were used for 
analyses  two days  later  if  a  sufficient  amount  expressed the  biosensors  as  observed by 
fluorescence microscopy.
3.1.13 Engineered heart muscle
The generation of EHMs and experiments were done in cooperation with the institute of  
pharmacology and toxicology of the University Medical Center Göttingen by the group of Dr. 
med. Malte Tiburcy. To generate an EHM, iPSC-CMs and human foreskin fibroblasts (ATCC) 
were  reconstituted in  a  ratio  of  70/30  % in  EHM-reconstitution  mixture.  The  cells  were 
cultured for 3 days in EHM-culture medium. Subsequently, EHMs were transferred to flexible 
holders. Analyses were performed on 4-week old EHMs by Irina Eckhardt.
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3.2 Molecular biology techniques
3.2.1 Isolation of genomic DNA and sequencing of SNPs
The Maxwell 16 instrument and the Maxwell 16 DNA Purification Kit (Promega) were used to 
automatically isolate genomic DNA from fibroblasts. A stored cell sample (see chapter 3.1.9) 
was resuspended in 350 µL DPBS and transferred into the respective well  of a cartridge.  
300 µL elution buffer was placed into the elution tube. After loading the plunger into the 
respective well, the cartridge was placed into the Maxwell 16 instrument and the program 
“cells”  was run.  Remaining beats were filtered with a  magnetic rack and the eluate was 
transferred  into  a  conical  1.5  mL  tube.  The  DNA  concentration  was  assessed 
photospectroscopically at 260/280 nm.
100 ng DNA was used as template in a polymerase chain reaction (see chapter  3.2.3.3) to 
amplify a DNA fragment, containing the SNP of interest. The PCR product was purified for 
sequencing  using  the  QIAquick  Gel  Extraction  Kit  (Qiagen).  Therefore,  three  volumes  of 
buffer QG was mixed with one volume of PCR product and one volume of isopropanol and 
transferred into a QIAquick column. After centrifugation at 13.000 x g for 1 min, the flow-
through was discarded and the DNA washed by addition of 750 µL buffer PE to the column 
and centrifugation at 13.000 x g for 1 min. The flow-through was discarded and the column 
was centrifuged dry as before.  The DNA was eluted into a fresh conical  1.5 mL tube by 
addition of 50 µL nuclease-free water and centrifugation as before. Subsequently the DNA 
concentration was measured photospectroscopically at 260/280 nm. A mix containing 67.5 
ng DNA and 10 pmol forward primer in a final volume of 15 µL nuclease-free water was 
made and sequencing was performed by Seqlab Sequencing Laboratories GmbH, Göttingen. 
The generated chromatograms were analyzed with the software “ApE, A plasmid Editor” by 
M.  Wayne  Davis  (http://biologylabs.utah.edu/jorgensen/wayned/ape/;  as  of  October  10, 
2017).
3.2.2 Alkaline phosphatase staining
To observe the activity of the alkaline phosphatase in hiPSCs and iPSC-like colonies after 
transduction,  the  Alkaline  Phosphatase  Kit  (Sigma-Aldrich)  was  used.  The  fixative  was 
prepared in a glass flask by mixing 5 mL citrate solution with 13 mL acetone and 1.6 mL 37% 
formaldehyde. To prepare the staining solution, one volume of the provided sodium nitrate 
was mixed with one volume of FRV-Alkaline solution and incubated at room temperature for 
2 min. 45 volumes of water were added and one volume of Naphthol AS-B was added shortly 
before usage. The cells were washed with DPBS, incubated in fixative solution for 30 sec at 
room  temperature  and  subsequently  washed  two  times  with  deionized  water.  Staining 
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solution was added for 15 min at 37°C in the dark. Finally, the cells were washed two times 
with deionized water and air-dried.
3.2.3 Gene expression analysis
3.2.3.1 Isolation of mRNA
To observe the gene expression of specific markers in hiPSCs, differentiated EBs and human 
primary fibroblasts on the mRNA level, RT-PCR analysis was performed. The SV Total RNA 
Isolation  System  (Promega)  was  used  to  isolate  RNA.  For  this  purpose,  undifferentiated 
hiPSCs of at least 70% confluency, 100% confluent fibroblasts and differentiated EBs were 
washed  three  times  with  DPBS  and  were  resuspended  in  400-600  µL  RNA-lysis  buffer 
supplemented with β-ME (200 µL/10 mL). The resulting lysate could be stored at -20°C. The 
lysate was mixed in a 1:1 ratio with 95% ethanol. The solution was transferred into the Spin 
Basket Assembly and centrifuged at 12,000 x g for 1 min. The flow-through was discarded 
and 600 µL RNA wash solution was added. To prepare the DNase mix, 40 µL Yellow core 
buffer, 5 µL 0.09 M MnCl2 and 5 µL DNase I were mixed. After centrifugation and removal of 
the flow-through, 50 µL of DNase mix was added and incubated at room temperature for 15 
min. Subsequently, 200 µL of DNase stop solution was added and the Spin Basket Assembly 
was  centrifuged.  Two  washing  steps  were  performed  by  first  adding  600  µL  RNA  wash 
solution and centrifuging for 1 min and thereafter adding 250 µL RNA wash solution and 
centrifuging for 2 min. Finally, 100 µL of nuclease free water was added and the RNA was 
eluted  by  centrifuging  for  1  min.  The  RNA  concentration  was  measured  with  a 
spectrophotometer at 260/280 nm and the samples were stored at -80°C.
3.2.3.2 Reverse transcription
In the reverse transcription reaction the reverse transcriptase uses the isolated RNA as a 
template to generate complementary DNA (cDNA). For this purpose, the following reaction 
mix was prepared:
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RNA 100 ng
10x PCR buffer II 2 µL
25 mM MgCl2 4 µL
100 mM dNTPs 0.8 µL
RNase Inhibitor (20 U/µL) 1 µL
50 µM Oligo (dt)16 1 µL
MuLV Reverse Transcriptase (50 U/µL) 1 µL
Nuclease free H2O x µL
Final volume 20 µL
The reaction was run in a thermal cycler (SensoQuest) using the following program.
Step 1 Step 2 Step 3 Step 4
Temperature 22°C 42°C 95°C 4°C
Time 10 min 50 min 10 min ∞
3.2.3.3 Polymerase chain reaction (PCR) analysis
The cDNA that was generated in the reverse transcription reaction was amplified by PCR 
using primers specific for the analyzed genes (see chapter 2.7). Following reaction mix was 
prepared:
cDNA 1 µL
5x Green GoTaq Reaction Buffer I 5 µL
10 mM dNTPs 1.6 µL
Primer forward (10 pmol/µL) 1 µL
Primer reverse (10 pmol/µL) 1 µL
GoTaq DNA Polymerase 0.1 µL
Nuclease free H2O x µL
Final volume 25 µL
The PCR reactions were run according to the following general program. For details on the 
annealing temperatures and cycle repeats see chapter 2.7.
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Step Temperature [°C] Time Cycles
Denaturation
95
3 min 0
15 sec
30-43Annealing 52-65 15 sec
Elongation
72
30 sec
10 min 0
The PCR product could be stored at 4°C. To observe the amplified DNA fragments, agarose 
gel  electrophoresis was performed. For this  purpose,  a 1.5% agarose gel  containing 6 µL 
Midori Green per 100 mL gel was loaded with 15 µL PCR product and 7 µL GeneRuler 100 bp 
Plus DNA Ladder (Fermentas). The DNA fragments were separated at 100 V for about 30 min 
depending on the gel size and visualized with UV light.
3.2.3.4 Quantitative real-time polymerase chain reaction (qRT-PCR) 
analysis
For quantification of specific mRNA by real-time PCR a serial dilution of the respective DNA 
was made, to get standards of known concentration. For this purpose, a PCR (see chapter 
3.2.3.3) was performed with template cDNA that contained the gene of interest and the PCR 
product was purified (see chapter 3.2.1) subsequently. After measuring the concentration of 
DNA, standards with concentrations ranging between 1 ng/µL to 0.125 fg/µL were produced 
and stored at -20°C.
As described above, mRNA was isolated from samples of interest (see chapter 3.2.3.1) and 
cDNA  was  generated  (see  chapter  3.2.3.2).  For  qRT-PCR  the  following  reaction  mix  was 
prepared for one well of a 96-well plate:
cDNA 1 µL
SYBR Green Mix 10 µL
Primer forward (10 pmol/µL) 1 µL
Primer reverse (10 pmol/µL) 1 µL
Nuclease free H2O 7 µL
Final volume 20 µL
Duplicates  were  pipetted  for  each  sample  and  standard.  The  DNA  was  amplified  using 
following program on a real-time PCR instrument:
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Step Temperature [°C] Time Cycles
Denaturation
95
2 min -
15 sec
40Annealing 60 10 sec
Elongation 72 20 sec
Denaturation 95 10 min -
Melting curve 95.5 – 60 10 sec -
Calculation  of  the  threshold  cycle  (CT)  and  quantification  of  DNA  was  automatically 
performed by the system software iQ5. 
3.2.4 Immunocytochemistry
The expression of specific markers in different cell types was investigated on the protein level 
by immunofluorescence analysis. For this purpose, cells were cultured on respective dishes 
containing glass cover slips. The cells were washed three times with DPBS and fixed with 4% 
PFA for 20 min at room temperature. Following fixation, the cells were washed three times 
with DPBS and blocked in 1% BSA/DPBS for at least 12 h at 4°C. The cells were treated with 
0.1% Triton X-100 for 10 min at room temperature for permeabilization and washed three 
times with DPBS, except for staining of membrane-locating antigenes. The primary antibody 
was added to the cells and incubated at 4°C over-night in a humid chamber. Subsequently to 
three washing steps with DPBS, the secondary antibody was added to the cells and incubated 
at 37°C for 1h in a humid chamber. The cells were washed three times with DPBS and stained 
with DAPI for 10 min in the dark at room temperature. Finally, the cells were washed two 
times with DPBS and once with distilled water, mounted onto glass slides using Vectashield 
Mounting Medium (Liniaris  Biologische Produkte GmbH) and sealed with nail  polish.  The 
slides were stored at 4°C and analyzed using a Zeiss Axio Observer.Z1 microscope and a Zeiss 
AxioCam MRm 1.4MP camera.
3.2.5 Western blot analysis
3.2.5.1 Protein isolation
Stored cell samples (see chapter  3.1.9) were resuspended on ice in 80-120 µL protein lysis 
buffer, depending on the sample size. After incubation for 10 min on ice, the lysates were 
vortexed and centrifuged for 5 min at 5000 rpm and 4°C. The supernatant was transferred 
into a fresh conical 1.5 mL tube and the protein concentration was assessed. Therefore, the 
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BCA Protein Assay Kit (Pierce) was used. Samples were diluted 1:20 and the working solution 
was prepared by adding 4 µL solution B to 196 µL solution A for one well of a 96-well plate.  
25 µL samples and provided standards were transferred in triplicates onto a 96-well plate 
and 200 µL working solution was added. After incubation for 30 min at 37°C, the protein 
concentration was assessed photospectroscopically at 562 nm. Protein lysates were stored at 
-80°C until use.
3.2.5.2 SDS-polyacrylamide electrophoresis
In order to separate proteins from each other SDS-polyacrylamide gels were made, consisting 
of a 15% separating gel, an 8% separating gel and a stacking gel, from bottom to top, and 
loaded into a respective tank containing running buffer. Protein lysates were thawed on ice 
and diluted in DPBS and 5x SDS sample buffer to receive a concentration of 2 µg/µL protein 
and 1x SDS sample buffer. The prepared lysates were incubated at 37°C under shaking at 300 
rpm for 5 min and 15 µL lysate and 7 µL protein ladder were loaded into one gel well each.  
The protein separation was done using 30 mA current and constant voltage.
3.2.5.3 Protein transfer and detection 
The  proteins  were transferred  from the  SDS-polyacrylamide gel  onto  a  PVDF membrane 
using  the  semi-dry  Trans-Blot  Turbo  Transfer  System  (Bio-Rad).  Therefore,  the  protein 
containing gel was equilibrated in anode buffer for 5 min. The PVDF membrane was activated 
in methanol for 2 min, washed in H2O for 10 min and equilibrated in cathode buffer for 5 
min. Subsequently, three cathode buffer-soaked whatman paper, the membrane, the gel and 
three anode buffer-soaked whatman paper were stacked in a blotting cassette. The transfer 
was performed for 15 min at 2.5 A and 25 V. To assess the quality of transfer and to fix  
proteins, the membrane was incubated for 10 min in Ponceau Red solution and washed with 
H2O until protein bands were visible. The membrane was washed for 10 min in TBST and 
blocked for 1 h in 5% milk/TBST at room temperature with mild shaking. Subsequently the 
membrane was incubated in the first antibody solution overnight at 4°C and washed three 
times  with  TBST  for  10  min.  Second  antibody  solution  was  applied  for  1  h  at  room 
temperature  before  washing  three  times  with  TBST.  Afterwards,  immobilon  western 
chemiluminescent HPR substrate (Merck Millipore) was used to visualize antibody labeled 
proteins. 
3.2.6 Amplex Red Hydrogen Peroxide Assay
The Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Thermo Fisher Scientific) was used 
to assess the amount of H2O2 in the supernatant of iPSC-CMs. The assay is based on the 
colorless substrate Amplex Red which reacts to fluorescent resorufin in combination with 
horseradish peroxidase.  Standards  of  0.1,  0.2,  0.5,  1 and 2 µM H2O2 were prepared and 
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duplicates  of  50  µL  were  transferred  into  a  black  96-well  plate.  1  x  10 5 iPSC-CMs were 
cultured in a well of a 12-well culture plate for one week. The cells were washed two times 
with  DPBS  and incubated in  320µL Amplex  Red working  solution  1  for  30  min  at  37°C. 
Immediately after treating the cells, 50 µL Amplex Red working solution 2 was added to each 
H2O2 standard and also incubated for 30 min at 37°C. After transferring the cell supernatant 
into a 1.5 mL conical tube, triplicates of 100 µL were placed into the 96 well plate. Finally,  
fluorescence was measured at 540 nm excitation and 620 nm emission with a lamp energy of  
5000 for 0.1 sec per well, using a Berthold Mithras LB 940 microplate reader. The standards 
were used to quantify H2O2 concentration in samples.
3.2.7 Plasmid isolation from E. coli culture
The NucleoBond Xtra Maxi Plus EF Kit (Macherey-Nagel) was used to isolate DNA plasmids. A 
starter E. coli culture of 2 mL LB-medium containing an appropriate antibiotic was inoculated 
with a glycerol stock and incubated for 8 h. The starter culture was added to 200 mL LB-
medium and incubated overnight at 37°C with mild shaking. The E. coli were harvested by 
centrifugation at 6000 x g for 15 min at 4°C and resuspended in 12 mL buffer RES. 12 mL 
buffer LYS was added,  inverted five times and incubated at room temperature for 5 min 
during which the NucleoBond Xtra column and filter were equilibrated with 25 mL buffer 
EQU. After addition of 12 mL buffer NEU, the lysate was immediately inverted three times 
and transferred onto the prepared column. 15 mL buffer EQU was applied and the filter 
removed. The column was washed with 15 mL buffer WASH and the DNA was eluted into a 
conical tube with 15 mL buffer ELU. To concentrate and desalt the plasmid DNA, 10.5 mL 
isopropanol was added and incubated for 2 min. Using a 30 mL syringe, the precipitate was  
loaded onto the NucloBond Finalizer and the flow-through was discarded. After washing the 
Finalizer with 4 mL 70% ethanol, it was dried by pressing air through it at least six times until 
no more ethanol was leaking out. Plasmid DNA was eluted with 800 µL TE buffer and the 
concentration was measured photospectroscopically. 
3.2.8 roGFP2-based biosensor analysis
The  culture  medium  of  roGFP2-Orp1  or  Grx1-roGFP2  expressing  iPSC-CMs  (see  chapter 
3.1.12) was replaced with 100 µL tyrode’s solution per well.  Fluorescence was measured 
using a Berthold LB 943 Mithras2 microplate reader with following program:
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Parameter Detail
Temperature 37°C
Detector position Bottom read
Label 1 Ex: 405 nm / Em: 535 nm
counting time: 1 sec
lamp energy: 70 %
Label 2 Ex: 485 nm / Em: 535 nm
counting time:  0.5 sec
lamp energy: 40 %
One  repeat  comprised  of  a  label  1  measurement  followed  immediately  by  a  label  2 
measurement. Ten repeats were measured to receive a baseline and sextuplicats were used 
for  each  condition.  Subsequently,  10  µL  5.5  mM  diamide  and  10  µL  110  mM  DTT  was 
automatically injected to each three wells per conditions, resulting in final concentrations of 
500 µM diamide and 10mM DTT. The triplicates of fully oxidized (diamide) and fully reduced 
(DTT) cells were then measured with ten more repeats to obtain the new baselines.
The mean of fluorescence intensities for each label was calculated so that following six sets 
of values obtained: Intensities of starting baseline (I405 and I485), intensities of fully reduced 
baseline (I405Red and I485Red) and intensities of fully oxidized baseline (I405Ox and I485Ox). 
Using Equation  2,  the oxidation degree (OxD) of  roGFP2 was obtained  (Meyer and Dick, 
2010):
Using the Nernst Equation, the redox potential of GSH (EGSH) was calculated (Equation  3), 
assuming that EroGFP2 = EGSH with the midpoint potential of roGFP2 E°’roGFP2 being -280 mV. In the 
equation, R is the gas constant, T the absolute temperature and F the Faraday constant.
EGSH=EroGFP 2=E roGFP 2
° ' −RT
2 F
ln(
1−OxDroGFP2
OxDroGFP 2
)
.                                                                    (3)
3.2.9 Annexin V affinity assay and flow cytometry 
To analyze apoptosis, the APC-Annexin V Apoptosis Detection Kit with PI (BioLegend) was 
used. For this purpose, 1.5 x 105 iPSC-CMs were cultured in a well of a 6-well plate and the 
supernatant was transferred into a conical tube prepared with 500 µL FCS. The cells were 
treated with 0.25 % Trypsin/EDTA for 5 min, singularized by pipetting and transferred into to 
conical tube. Afterwards, the cells were washed three times by centrifugation at 200 x g for 3 
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3 Methods
min and subsequent resuspension in 1 mL PBS. After the last centrifugation step, cells were 
resuspended in 500 µL Annexin V binding buffer and 100 µL suspension was transferred into 
each four cytometry tubes. Following staining combinations were prepared by addition of 5 
µL APC-Annexin V and 10 µL propidium iodide (PI): unstained, only APC-Annexin V, only PI, 
APC-Annexin V / PI double staining. The suspensions were incubated for 15 min in the dark 
and 400 µL Annexin V binding buffer was added to each tube. Finally, the stained cells were 
measured using a BD FACSCanto II  (BD Biosciences).  Unstained and single stainings were 
used to set up analysis grids to distinguish populations.
3.2.10 Calcium imaging
Cytosolic Ca2+ was visualized in iPSC-CMs with Fluo-4, which exhibits increased fluorescence 
upon Ca2+ binding. For this purpose, 2.5 x 105 cells were plated in a well of a 6-well plate 
containing a round 20 mm glass cover-slip and cultured for one week. The cover-slip was 
mounted onto the measuring chamber and the cells were incubated in 400 µL Fluo-4 staining 
solution for 30 min in the dark before they were washed two times with tyrode’s solution 
and finally covered with 800 µL tryrodes solution. The measuring chamber was mounted 
onto  a  LSM  720  confocal  microscope  (Zeiss)  and  the  software  Zen  2009  was  used  for 
measurement.  The  microscope  was  set  up  with  following  parameters:  laser  488  nm, 
excitation  0.5  –  2  %,  pinhole  6  AU,  gain  700,  offset  0,  line  scan  mode,  zoom 3,  12  bit  
unidirectional, 512 pixel, maximal speed, 20.000 cycles, no delay. The iPSC-CMs were paced 
during measurement at 0.25 Hz with 18 V and 3 ms duration. Measuring lines were placed in 
the cytoplasm of iPSC-CMs without crossing cell organelles.
The fluorescence intensities of the obtained linescans were plotted and normalized with the 
software  FIJI  and  smoothed  with  the  software  Prism6  (GraphPad).  Subsequently,  Ca2+ 
transients  were automatically  analyzed with the  software Labchart  (ADInstruments).  The 
transient rise time is the time interval from transient start to transient peak, whereas the 
decay time was defined as  time interval  from peak to the time point  where half  of  the 
fluorescence signal is diminished. To calculate the peak amplitude the baseline fluorescence 
intensity was subtracted from the peak fluorescence intensity and subsequently divided by 
the baseline fluorescence intensity (see Figure 23).  
3.3 In vivo teratoma formation and histological analysis
iPSCs were cultured on three 6-cm culture dishes with MEFs and digested as described above 
(see chapter 3.1.4). The cells were pooled, centrifuged at 200 x g for 3 min and resuspended 
in 300 µL DPBS. Subsequently, they were injected subcutaneously into immunodeficient mice 
by Prof.  Dr.  med.  Ralf  Dressel  from the Institute for  Cellular  and Molecular  Immunology, 
University Medical Center Göttingen. About three month later, the mice were killed and the 
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tumors collected. After fixing the tumors in phosphate buffered formalin (pH 7) for 4 h at 
room  temperature  or  over-night  at  4°C,  they  were  washed  in  H2O,  dehydrated  and 
paraffinized  with  a  Benchtop  Tissue  Processor  1020  (Leica  Biosystems).  Using  a  tissue 
embedding system (Leica Biosystems), the tumors were embedded into paraffin and 6 µm 
sections were attached onto glass specimen holders. Hematoxilin and eosin stainings (H+E) 
were produced by the Department of Pathology, University Medical Center Göttingen.
3.4  Analysis of α-actinin regularity
α-actinin was visualized in iPSC-CMs by immunofluorescence staining as described above 
(3.2.4). Using the software FIJI, the integrated plugin “Tubness” was applied to the obtained 
images,  which  emphasizes  tubular  structures  such  as  the  sarcomeric  cytoskeleton  and 
reduces  artifacts.  Subsequently,  the  fast  Fourier  transform  algorithm  was  applied  and 
resulting frequency domains were radially integrated with the open source plugin “Radial 
Profile Plot” from Paul Baggethun (https://imagej.nih.gov/ij/plugins/radial-profile.html as of 
October  19,  2017).  The  software  LabChart  (BDInstruments)  was  used  to  automatically 
analyze the relative amplitude of the first peak in the intensity profile. This amplitude was 
used to assess the regularity of α-actinin striations in iPSC-CMs.
3.5  Statistical analyses
Data is depicted as mean + standard error of mean (SEM). Two-tailed students t-test was 
applied to data sets consisting of two groups. Two-way analysis of variance (ANOVA) was 
applied to data sets with more than two groups. Multiple comparisons between control and 
patient  group were corrected according  to Sidak,  whereas  multiple  comparisons  of  DOX 
treatment conditions with basal condition were corrected according to Dunnett. Statistical 
significance is depicted as * p < 0.05, ** p < 0.01, *** p < 0.001. Statistical analysis was 
performed with Prism6/7 (GraphPad). 
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4.1 Recruitment of donors
For this study, five donors were recruited who were participants of the “rituximab with CHOP 
over age 60 years” (RICOVER60) trial, which was performed from July 2000 until June 2005 
and is registered on www.clinicaltrials.gov as NCT00052936. The RICOVER60 trial aimed to 
compare the outcome in elderly patients with diffuse large-B cell lymphoma after treatment 
with either CHOP-14 (cyclophosphamide, doxorubicin, vincristine and prednisolone in two 
weeks intervals) or CHOP-14 with addition of rituximab  (Pfreundschuh et al., 2008). In the 
work of Reichwagen et al. the group of Wojinowski used the data from the RICOVER60 trial 
to analyze associations of SNPs in the genes MRP1, MRP2, CYBA, NCF4, RAC2 and SLC28A3 
with ACT (Reichwagen et al., 2015). They found an accumulation of SNPs rs4673 (genotype 
CT  and  TT)  of  CYBA and  of  rs13058338  (TA  and  AA)  of  RAC2 among  ACT  cases.  The 
investigated genes were selected on the basis of previous findings in the NHL-B1/B2 study 
from the same group. Here, the aforementioned SNPs were also found to be associated with 
ACT (Wojnowski et al., 2005).
The classification of RICOVER60 trial participants into ACT patients and controls was done by 
Reichwagen et al. and was based on records of physical examinations that were taken during 
therapy and follow-up investigations  (Reichwagen et al., 2015). Symptoms that resulted in 
ACT classification included “reduced ejection fraction or fractional shortening, arrhythmia, 
dyspnea, heart failure diagnosis and / or treatment, cardiomyopathy, coronary heart disease 
including myocardial infarction and death for cardiac reasons”. Starting 2003 and subsequent 
to  the  classification  of  ACT  patients  and  controls,  blood  samples  were  obtained  for 
genotyping. To validate the classification, the blood samples were also used to assess the NT-
proBNP concentration, which is a marker for congestive heart failure. 
According to the classification of RICOVER60 participants by Reichwagen et al. and to their 
genotypes, three patients could be recruited for our study who suffered from chronic ACT 
and have the predisposing alleles of SNPs in  CYBA and RAC2 (Table  1 and 2). Furthermore, 
two controls were recruited who did not develop cardiac symptoms after chemotherapy and 
did not possess predisposing alleles of SNPs in CYBA and RAC2. Neither the ACT patients nor 
the  controls  had  cardiac  conditions  before  chemotherapy.  All  available  information 
concerning the donors are summed up in Table 1.
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Table 1: Overview of recruited donors from the RICOVER60 trial.
Patient 1 Patient 2 Patient 3 Control 1 Control 2
Sex Male Male Female Male Male
Age in 2007 69 71 66 66 68
DOX dose
[mg / m2]; median of 
patients and controls
309 318
Developed ACT Yes
 (chronic)
Yes 
(chronic)
Yes
 (chronic) No No
NT-proBNP 
concentration by the 
time of genotyping 
(2007) [pg / mL]
220.1 160.5 500.9 11.91 149.9
LVEF at the time of 
biopsy extraction 
(2014)
Not 
available ca. 45% 45 – 50%
Not 
available
Not 
available
Table 2: Genotypes of donors at ACT-associated SNPs. P: patient; C: Control; underlined genotypes 
are associated with ACT.
Gene SNP Possible Genotypes
Nucleotide 
position Effect of SNP
Genotype of donors
P1 P2 P3 C1 C2
CYBA rs4673 CC/CT/TT 242 C>T
Amino acid 
substitution 
(H72Y)
CT CT CT CC CC
RAC2 rs13058338 TT/TA/AA 7508 T>A
No amino acid 
substitution; SNP 
in intronic region
AA TA TA TT TT
Skin biopsies were taken from the donors in respective medical centers near their residences 
and delivered to the University Medical Center Göttingen. Here, the biopsies were incubated 
under cell culture conditions, causing dermal fibroblasts to proliferate and grow out of the 
biopsy in about one week. The dermal fibroblasts were cultured and used for the generation 
of hiPSCs and further analysis. To confirm the presence of SNPs in CYBA and RAC2, genomic 
DNA was isolated from dermal fibroblasts and used for sequencing (Figure 9). The expected 
alleles (see table 2) were found in all patients and controls. Sequencing of DNA isolated from 
hiPSCs confirmed the presence of the alleles. 
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Figure  9: Verification of ACT-associated SNPs in  CYBA and  RAC2.  ACT-associated alleles of SNPs in 
NADPH oxidase subunit encoding genes CYBA (rs4673) and RAC2 (rs13058338) were confirmed in all 
recruited ACT patients. None were found in controls. Sequencing chromatograms are depicted and 
respective SNPs are marked with bold text. 
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4.2 Generation and characterization of hiPSCs
4.2.1 Generation of hiPSCs
To generate hiPSCs from primary dermal fibroblasts, the integration-free sendai virus system 
was used, which contains the four reprogramming factors OCT4,  KLF4,  SOX2 and C-MYC on 
three  separate  vectors.  Fibroblasts  displayed  a  typical  elongated  morphology  and  were 
passaged  only  once  to  ensure  high  reprogramming  efficiency  (Figure  10 A,  D).  First 
morphological changes of fibroblasts were notable about seven days after transduction and 
single hES-like colonies were mechanically selected two to three weeks after transduction. 
Cells from about 20 colonies per donor were cultured and seven to nine cell lines per donor 
were selected for cryopreservation according to their morphology and proliferation (Figure
10 B, E). The reprogramming efficiency was very high in all transduction experiments with 
about  7 %,  estimated  by  staining  for  alkaline  phosphatase  activity.  No  differences  in 
morphology of fibroblasts and iPSCs or reprogramming efficiency were observed between 
ACT patients and controls. Two cell lines per donor were selected for characterization and 
cardiomyocyte differentiation. A high alkaline phosphatase activity was detected in those cell 
lines, which is an early marker for pluripotency (Figure 10 C, F).
4.2.2 Expression of pluripotency-related genes 
Contrary  to  somatic  cells,  iPSCs  express  a  network  of  genes  necessary  for  maintaining 
pluripotency. To estimate the level of pluripotency of the generated iPSCs, expression of the 
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Figure 10: Generation of hiPSCs and detection of alkaline phosphatase activity. A, D: Dermal 
fibroblasts of controls  and ACT patients.  B, E: hiPSCs cocultured with MEFs.  C, F: Visualization of 
alkaline phosphatase activity in hiPSCs (red staining). Depicted images (Control 1 and Patient 1) are 
representative for all cell lines. Scale bar: 200 µm.
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pluripotency markers NANOG, OCT4, LIN28, SOX2 and GDF3 (growth differentiation factor-3) 
was investigated on the mRNA level by semiquantitative RT-PCR (Figure 11). For this purpose, 
RNA of iPSCs at passage number 9 to 15 as well as RNA of the corresponding fibroblasts was 
used. RNA of the control cell line FB1 was used as positive control since these cells show 
expression of pluripotency marker genes comparable to hES cells (Streckfuss-Bömeke et al., 
2013). The housekeeping gene GAPDH was used as a reference. All investigated genes were 
upregulated in the iPSCs compared to their parental fibroblasts and at a similar expression 
level  as  control  iPSCs.  These data  suggest  an activation of  the endogenous pluripotency 
network during reprogramming.
The  expression  of  pluripotency  markers  was  also  investigated  on  the  protein  level  by 
immunofluorescence analysis (Figure 12). LIN28, NANOG, OCT4, SOX2, SSEA4 and TRA-1-60 
were stained at passage number 7 to 15. Specific signals were found in iPSC colonies but not 
in MEFs. LIN28 was located in the cytoplasm. NANOG, OCT4 and SOX2 had a distinct nuclear 
localization while SSEA4 and TRA-1-60 were observed in the cell membrane. No differences 
between cell lines from ACT patients (ACT-iPSCs) and controls (Ctrl-iPSCs) were observed.
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Figure 11: Expression of pluripotency-related genes on the mRNA level. Semiquantitative RT-PCR 
analysis confirmed expression of NANOG, OCT4, LIN28, SOX2 and GDF3 in all iPSC lines selected for 
characterization and in positive control iPSCs (FB1). Low or no expression was observed in fibroblasts 
used for reprogramming. GAPDH was used as reference gene. H2O was used as negative control.
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4.2.3 Differentiation potential in vitro and in vivo
The  characterization  of  the  iPSCs  also  included  the  investigation  of  their  spontaneous 
differentiation  potential.  For  this  purpose,  iPSCs  at  passage  number  10-18  were 
spontaneously differentiated  in vitro and the expression of specific markers for each germ 
layer was analyzed on the mRNA and protein level. The iPSCs were cultured in suspension for  
eight days. During this time the cells developed round-shaped embryoid bodies (EBs) with 
clear, smooth borders. The EBs attached to gelatine-coated cover-slips one to two days after 
plating at day 8. During the next 25 days, cells grew out of the EBs and developed into a large 
variety of cell types.
RNA was isolated at day 0, day 8 and day 33 of  in vitro  differentiation and used for gene 
expression  analyses  by  semiquantitative  RT-PCR  (Figure  13).  RNA  of  MEFs  was  used  as 
negative control. The pluripotency-related gene  NANOG was expressed in undifferentiated 
cells  and  was  downregulated  during  spontaneous  differentiation  in  most  experiments. 
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Figure  12: Expression of pluripotency-related genes on protein level.  LIN28, OCT4, NANOG, SOX2, 
SSEA4 and TRA-1-60 were observed in generated Ctrl-iPSCs and ACT-iPSCs cocultured with MEFs by 
immunofluorescence staining. Nuclei were stained with DAPI (blue). Depicted images (Control 1 and 
Patient 3) are representative for all cell lines. Scale bar: 100 µm.
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Remaining NANOG expression suggests that few cells were in an undifferentiated stage at the 
end of  differentiation.  In  all  cell  lines,  the expression of  endodermal  (AFP),  mesodermal 
(cTNT) and ectodermal (TH) markers increased with proceeding differentiation time with the 
exception of  AFP expression in cell  line 1 of control 2 and cell  line 2 of patient 2. In few 
experiments, germlayer markers were already expressed in undifferentiated cells. 
After prolonged differentiation, the cells were fixed and immunofluorescence analysis was 
performed. β-III-Tubulin (β-III-Tub), α-smooth muscle actin (αSMA) and AFP were stained as 
representatives for the ectoderm, mesoderm and endoderm, respectively (Figure 14). At day 
33 of differentiation, β-III-Tub and αSMA staining showed cytoskeletal structures of neuron-
like  and  muscle-like  cells,  respectively.  AFP  was  located  in  the  cytoplasm  at  day  18  of 
differentiation. The three markers could be observed in all cell lines and no differences were 
found between Ctrl- and ACT-iPSCs.
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Figure 13: Expression of germ layer-specific genes on mRNA level after spontaneous differentiation 
of iPSCs. A, B: Expression of germ layer-specific genes AFP, cTNT and TH after prolonged spontaneous 
differentiation  using  semiquantitative  RT-PCR  in  Ctrl-  and  ACT-iPSCs.  Downregulation  of  NANOG 
expression indicated loss of pluripotency.  GAPDH was used as reference gene. MEFs and H2O were 
used as negative control.
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Finally,  the  differentiation  potential  of  the  generated  iPSCs  was  determined  in  vivo by 
teratoma  formation  in  immunodeficient  mice  and  histological  analysis.  The  teratomas 
contained tissues derived from all three germ layers including neuronal rosettes (ectoderm, 
Figure 15 A, D), muscle (mesoderm, Figure 15 B, E) and intestinal tissue (endoderm, Figure 15 
C,  F).  Some  cell  lines  did  not  develop  teratomas  after  injection,  however  at  least  one 
teratoma per donor was received and analyzed. 
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Figure 14: Expression of germ layer-specific genes after spontaneous in vitro differentiation of iPSCs 
on protein level. Expression of β-III-Tub, α-SMA and AFP after spontaneous differentiation of iPSCs by 
immunofluorescence staining. Nuclei were stained with DAPI (blue). Depicted images (Control 1 and 
Patient 3) are representative for all cell lines. Scale bar: 100 µm.
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The  generated  iPSCs  were  to  be used as  a  source for  CMs.  Therefore,  the spontaneous 
cardiac  differentiation  potential  was  assessed  since  the  potential  to  differentiate  into  a 
specific cell type may be cell line-specific. For this purpose, EBs that developed beating areas 
were counted. 7-21 % of EBs spontaneously developed beating areas with no differences 
between controls (15.4 ± 3.45 %) and ACT patients (15.4 ± 2.51 %) (Table 3).
Table 3: Spontaneous cardiac differentiation potential. About 30 EBs were analyzed per experiment. 
Cardiac differentiation potential is depicted as mean ± SEM.
Number of
experiments
Cardiac differentiation
potential [%]
Control 1, cell line 1 2 14.9 ± 3.79
Control 1, cell line 2 2 18.5 ± 0.21
Control 2, cell line 1 1 11.1
Control 2, cell line 2 3 15 ± 9.96
Patient 1, cell line 1 3 14.3 ± 5.27
Patient 1, cell line 2 1 8.2
Patient 2, cell line 1 3 13.2 ± 1.07
Patient 2, cell line 2 3 20.8 ± 9.99
Patient 3, cell line 1 1 7.1
Patient 3, cell line 2 3 18.3 ± 4.59
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Figure 15: In vivo differentiation of generated iPSCs. Teratoma preparations were stained with H+E. 
A, D:  Neuronal rosettes.  B, E: Muscle tissue. C, F: Intestinal tissue. Depicted images (Control 1 and 
Patient 2) are representative for all generated teratomas. Scale bar: 100 µm.
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4.3  Generation of iPSC-derived cardiomyocytes
Using the spontaneous differentiation protocol, at most 21 % of the EBs per differentiation 
experiment developed beating areas (Table  3).  Since these beating areas only made up a 
small  part  of  the  cells  developed  by  one  EB,  the  CM  yield  gained  by  spontaneous 
differentiation was not sufficient for later analysis. To obtain a high amount and purity of  
CMs, the iPSCs were directly differentiated using an activator of the canonical WNT pathway, 
CHIR,  and an inhibitor,  IWP2, at  different stages of differentiation to mimic  in vivo heart 
development.  For this purpose, iPSCs were grown to 90 % confluency on geltrex without 
feeder cells before CHIR was added. During the next days, the cells formed diverse structures 
and first beating areas were usually observed at day 8-15. Often, these areas were large and 
tissue-like. Nevertheless, smaller beating clusters, which resembled EBs, were also frequently 
observed. Despite using the same conditions, the amount of beating areas strongly varied 
between different experiments of the same cell line. Estimated visually, the CM yield was 
considerably larger compared with spontaneous differentiation. Furthermore, a high purity 
of over 90 % CMs was achieved by metabolic selection with lactate, observed visually and by  
flow cytometry of cTNT stained cells (Figure 16 A). No differences were observed between 
the ACT patient and control groups regarding differentiation efficiency or CM purity.
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The two-month-old iPSC-CMs derived from ACT-iPSCs (ACT-iPSC-CMs) and Ctrl-iPSCs (Ctrl-
iPSC-CMs)  had a  heterogeneous morphology  with varying  sizes  and elongated,  round or 
multiangular shapes (Figure 16 A, D). They expressed the cardiac genes α-actinin, cTNT, α-
MHC and β-MHC as detected with qRT-PCR without significant differences between the ACT 
patient and control groups. Expression of these genes was barely found in iPSCs (Figure 16 
C). Furthermore, visualization of cTNT, α-actinin and F-actin revealed a high organization of 
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Figure 16: Characterization of iPSC-CMs. A: Flow cytometry analysis of iPSC-CMs stained against 
cTNT  (secondary  antibody  was  Alexa  Fluor488-conjugated).  Unstained  iPSC-CMs  were  used  as 
negative control and to setup the gate. Shown are results from iPSC-CMs from Patient 2 cell line 1. 
B: Morphology of iPSC-CMs. C: qRT-PCR analysis of cardiac genes in Ctrl- and ACT-iPSC-CMs and iPSCs. 
D: Immunofluorescence stainings of cTNT and  α-actinin. Alexa Fluor555-conjugated phalloidin was 
used to visualize F-actin. Nuclei were stained with DAPI (blue). Scale bars: 50 µm.
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sarcomeres  with  clear  striations  along  the  cell.  Bi-  or  multinucleated  iPSC-CMs  were 
frequently observed (Figure 16 D).
4.4 Modeling ACT in hiPSC-CMs
This  work  aimed to recapitulate  the cardiac  phenotypes  of  ACT patients  and controls  in 
response to DOX treatment. Therefor, two- to three-month-old iPSC-CMs were pooled and 
plated one week prior to the experiment to ensure comparability between tested conditions. 
To  analyze  the dose-dependency  of  phenotypes,  DOX was  added to  the cell  medium in 
concentrations of 0.1, 0.25, 0.5, 0.75, 1 and 5 µM. DOX was applied for 24 hours if not stated 
otherwise.  In  some experiments the number of  conditions was decreased on account  of 
feasibility.
4.4.1 NADPH oxidase
The expression of NADPH oxidase subunits  NOX2, NOX4, CYBA, RAC1, RAC2, NCF1, NCF2,  
NCF4 was analyzed by qRT-PCR (Figure 17).  Despite best efforts, expression of  NCF1, NCF2 
and NCF4  was  not  detectable  in  iPSC-CMs but  in  biopsies  of  left ventricles  of  a  dilated  
cardiomyopathy patient (see appendix,  Figure 35), indicating that the designed primers are 
suitable  for  amplification  in  the  presence  of  target  cDNA.  HPRT (hypoxanthine-guanine 
phosphoribosyl-transferase) was used as a reference gene for genes with low expression (see 
appendix, Table 5). At basal conditions, the expression of NOX2, NOX4, CYBA and RAC1 was 
comparable between Ctrl- and ACT-iPSC-CMs.  RAC2  was expressed 1.5-fold higher in ACT-
iPSC-CMs,  which  was  not  significant,  however.  Treatment  with  0.25  µM  DOX  caused  a 
significant downregulation of NOX2 in Ctrl-iPSC-CMs and a slight decrease in NOX4, CYBA and 
RAC2 expression, whereas  RAC1 expression was not altered. In ACT patients, on the other 
hand, expression of NOX2, NOX4, CYBA and RAC1 was significantly downregulated after DOX 
treatment, but RAC2 was unaffected. 
74
4 Results
Using SDS-PAGE and western blotting, the expression of NOX2, NOX4, p22phox (encoded by 
CYBA), RAC1, RAC2 and p40phox (encoded by  NCF4) was investigated on the protein level 
(Figure 18). Experiments were performed by Dr. med. Andreas Petry from the German Heart 
Centre, Munich. The amount of NADPH oxidase subunits in iPSC-CMs was low and in some 
cases at the detection limit. Hence, no reproducible results could be obtained for p22phox 
and RAC2. Furthermore, a high heterogeneity between cell  lines of the same donor was 
observed  (Figure  18 B).  At  basal  conditions,  ACT-iPSC-CMs  contained  significantly  more 
p40phox compared to Ctrl-iPSC-CMs, whereas a comparable amount of NOX2, NOX4 and 
RAC1 was detected (Figure 18 A, untreated). After treatment with 0.25 µM DOX for 24 hours, 
a significant increase in the amount of p40phox was observed in Ctrl-iPSC-CMs, whereas 
RAC1  was  significantly  upregulated  upon  1  µM  DOX  application  in  ACT-iPSC-CMs.  The 
proteins  were  also  analyzed  48  hours  after  finishing  DOX application  for  24  hours.  The 
amount of NOX2, NOX4, p40phox and RAC1 remained unchanged in ACT-iPSC-CMs. In the 
control group on the other hand, a significant downregulation of p40phox to about 50 % 
concentration was observed. 
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Figure 17: Expression of NADPH oxidase subunit encoding genes in iPSC-CMs on the mRNA level. 
Expression of NOX2, NOX4, CYBA, RAC1 and RAC2. Sample number: 11 Ctrl-iPSC-CM differentiations, 
18 ACT-iPSC-CM differentiations. Mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure 18: Western blot analyses of NADPH oxidase subunits in iPSC-CMs. A: Expression of NADPH 
oxidase subunits at basal conditions and 0 h or 48 h after single DOX application for 24 h. Sample 
number without treatment: 4 Ctrl-iPSC-CM differentiations, 6 ACT-iPSC-CM differentiations. Sample 
number with DOX: 2 Ctrl-iPSC-CM differentiations (expect for NOX2. Sample number: 1), 3 ACT-iPSC-
CM differentiations. Mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001  B: Western blot results used 
for quantification. Left: Untreated. Right: DOX treated.
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4.4.2 ROS generation
4.4.2.1 Amplex Red Hydrogen Peroxide Assay
The generation of ROS and the resulting subcellular damage in CMs is discussed as a key 
mechanism of ACT. Furthermore, the potentially ACT predisposing SNPs are part of genes 
that  encode  for  subunits  of  the  NADPH  oxidases,  which  are  ROS  producing  enzyme 
complexes. For these reasons, the analysis of ROS in Ctrl-  and ACT-iPSC-CMs was a main 
aspect of this work.
The Amplex Red Hydrogen Peroxide Assay was used to assess the amount of H2O2 produced 
by iPSC-CMs at basal conditions and in response to DOX treatment (Figure 19). Although not 
significant, H2O2 production was higher in ACT-iPSC-CMs compared to Ctrl-iPSC-CMs without 
DOX treatment (Figure 19 A). Treatment with low, clinically relevant DOX concentrations (0.1, 
0.25, 0.5 µM DOX) induced an increase in H2O2 amount, which was significant for 0.25 µM 
DOX in both groups and for 0.5 µM DOX only in ACT patients. ACT-iPSC-CMs produced higher 
amounts  of  H2O2 with  every tested DOX concentration which was significant  for  0.5  µM 
(Figure 19 A). The amount of H2O2 was not altered by higher DOX concentrations of 0.75, 1 
and 5 µM in both groups (Figure 19 A). Comparing the relative DOX-induced changes in H2O2 
amount, no differences between both groups were found (Figure 19 B).
77
4 Results
To address the question, if the observed DOX-induced changes in H2O2  production occurred 
only  during  or  immediately  after  the  treatment  of  the  cells,  the  Amplex  Red  Hydrogen 
Peroxide Assay was applied 7, 14 and 21 days after one-time treatment for 24 hours with 
0.25 µM DOX (Figure 19 C). The relative DOX-induced changes in H2O2 amount was analyzed 
relative to untreated cells at the same time points. Interestingly, the highest changes of H2O2 
amount was found 7 days after one-time DOX treatment in both groups. At this time point, a 
significant fourfold increase in the control group and a significant threefold increase in the 
ACT patient group was found. The H2O2  amount directly after treatment was significantly 
increased twofold in both groups. Even 14 and 21 days after one-time DOX treatment, the 
H2O2 amount  was  increased  about  twofold  in  both  groups,  which  was  not  significant, 
however.  These  findings  suggest  that  chronic  changes  were  induced  by  single  DOX 
application.
DEX and RAN are described as potential protectors against ACT that could be coadministered 
during  chemotherapy.  RAN was  directly  linked  to  a  reduction  of  DOX-induced  ROS  (see 
chapter 1.1.2). For this reason, iPSC-CMs were preincubated with either 100 µM DEX for 24 
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Figure 19: Analysis of extracellular H2O2 amount in iPSC-CMs using Amplex Red. A: H2O2 amount in 
iPSC-CMs  of  both  groups.  Sample  number:  11  Ctrl-iPSC-CM  differentiations,  17  ACT-iPSC-CM 
differentiations  B:  Relative  DOX-induced  change  in  H2O2 amount  in  iPSC-CMs of  both  groups. C: 
Relative  change  in  H2O2 amount  in  iPSC-CMs  of  both  groups  0,  7,  14  and  21  days  after  single 
treatment with 0.25 µM DOX for 24 h. Sample number: 5-17 Ctrl-iPSC-CM differentiations, 13-31 ACT-
iPSC-CM differentiations  D: H2O2 production of iPSC-CMs of both groups after coadministration of 
DOX and either DEX or RAN. Sample number: 5-10 Ctrl-iPSC-CM differentiations, 7-14 ACT-iPSC-CM 
differentiations. Mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
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hours or 10 µM RAN for 48 hours. Subsequently, iPSC-CMs were cotreated with 0.5 µM DOX 
(Figure  19 D).  DEX  caused  a  decrease  of  H2O2 amount  in  Ctrl-iPSC-CMs  without  DOX 
treatment, which was not significant. No such difference was observed in ACT-iPSC-CMs. The 
H2O2 amount in the control group cotreated with DOX and DEX was lower than in untreated 
cells, whereas DOX treatment by itself induced a twofold increase. DEX application did not 
alter the DOX-induced increase in H2O2  amount in ACT-iPSC-CMs. RAN, on the other hand, 
caused an increased amount of H2O2 in the control group without DOX. Coadministration 
even enhanced the DOX-induced rise of H2O2 significantly in Ctrl-iPSC-CMs. No RAN-induced 
changes were observed in the ACT-iPSC-CMs without or with DOX treatment.
4.4.2.2 roGFP2-based biosensor analyses
The roGFP2-based biosensors roGFP2-Orp1 and Grx1-roGFP2 were used in living iPSC-CMs to 
assess the level  of  ROS (Figure 20,  21 and  22).  Since iPSC-CMs are hard to transfect via 
lipofection with vectors as big as the biosensors, a lentiviral approach was used to generate 
biosensor  expressing  iPSC-CMs.  For  this  purpose,  HEK-293T  cells  were  transfected  with 
Addgenes second generation lentiviral system including the envelope and packaging plasmids 
pMD2.G and psPAX2.  The virus-containing cell  supernatant  was  used for  transduction of 
iPSC-CMs. Observed visually, a sufficient amount of iPSC-CMs usually expressed roGFP2-Orp1 
or Grx1-roGFP2 72 hours after transduction start (Figure 20 A, B). Also, biosensor-expressing 
iPSC-CMs still showed beating activity and no differences compared to non-transduced cells 
were  observed.  However,  when  the  cells  were  cultured  for  about  one  week  after 
transduction, usually more transduced cells died than non-transduced. To avoid this, the cells 
were used for measurements about five days after start of transduction. When excited at 405 
and 485 nm and measured at  515 nm,  the biosensor  containing cells  exhibited stronger 
fluorescence than non-transduced cells (Figure 20 C, D). As expected, addition of the oxidant 
diamide during measurement resulted in a decline of the signal at 485 nm excitation and a 
rise at 405 nm. Addition of the reductant DTT caused the opposite effect. These observations 
confirm the functionality of roGFP2-Orp1 and Grx1-roGFP2 in iPSC-CMs (Figure 20 C, D).
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roGFP2-based biosensor measurements may be used for relative comparisons but do not 
give  absolute  values.  To  enable  comparability  of  different  iPSC-CM  differentiation 
experiments,  the  degree  of  roGFP2  oxidation  (OxD)  had  to  be  determined  for  every 
measurement.  For  this  reason,  conditions  of  diamide  and  DTT  treatment  had  to  be 
determined where roGFP2 would be completely oxidized (OxD = 1) or reduced (OxD = 0). The 
405/485nm ratio of both roGFP2-Orp1 and Grx1-roGFP2 increased after treatment with 1,  
2.5, 5 and 10 µM diamide, but did not further increase with higher concentrations, indicating 
that a plateau was reached (Figure 21 A, B). Treatment of roGFP2-Orp1-expressing iPSC-CMs 
with 0.05, 0.5, 5, 50 and 90 mM DTT only caused a mild decrease of the 405/485nm ratio 
(Figure  21 C).  However,  pretreatment  of  Grx1-roGFP2  expressing  iPSC-CMs  with  H2O2 
revealed the potential of DTT to reduce the 405/485nm ratio: Adding 10 mM DTT to iPSC-
CMs pretreated with up to 20 µM H2O2 caused the ratio to drop to the level of untreated cells 
(Figure 21  D). For these reasons, the concentrations of 500 µM diamide and 10 mM DTT 
have  been  chosen  to  induce  complete  oxidation  and  complete  reduction  of  roGFP2  in 
following experiments. Using the fluorescence intensities of fully oxidized and fully reduced 
conditions, OxD of roGFP2 was calculated with equation 2 (see chapter 3.2.8).
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Figure 20: roGFP2-based biosensors roGFP2-Orp1 and Grx1-roGFP2 in iPSC-CMs. A, B: roGFP2-Orp1 
expression in iPSC-CMs (representative for Grx1-roGFP2). C, D: Detection of Grx-roGFP2 fluorescence 
intensity at 510 nm upon excitation with 405 and 485 nm. Oxidation (diamide) and reduction (DTT) 
causes  respective  dynamic  changes  in  fluorescence  intensity.  Empty:  non-transduced  iPSC-CMs. 
Depicted measurements are representative for roGFP2-Orp1.
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roGFP2-Orp1  expressing  Ctrl-  and  ACT-iPSC-CMs  showed  a  comparable  level  of  roGFP2 
oxidation without DOX treatment (Figure 22 A). DOX treatment caused a dose-dependent 
increase  in  oxidation  in  both  groups  of  up  to  2.5-fold,  which  was  significant  for  DOX 
concentrations of 0.75, 1 and 5 µM (Figure 22 A, B). 
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Figure 21: Determination of diamide and DTT concentrations for the induction of complete 
oxidation and reduction of roGFP2-Orp1 and Grx1-roGFP2 in iPSC-CMs. A: roGFP2-Orp1 oxidation in 
iPSC-CMs upon diamide application. B: Grx1-roGFP2 oxidation in iPSC-CMs upon diamide application. 
C: roGFP2-Orp1 reduction in iPSC-CMs upon DTT application. D: Grx1-roGFP2 reduction in iPSC-CMs 
pretreated with H2O2 upon DTT application.
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Analyses of Grx1-roGFP2 redox state revealed a higher oxidation in ACT-iPSC-CMs compared 
to  the  Ctrl-iPSC-CMs  without  DOX  as  well  as  after  treatment  with  all  tested  DOX 
concentrations (Figure 22 C). Upon treatment with 0.5 µM DOX, OxD of Grx1-roGFP2 was 
significantly  higher  in  ACT-iPSC-CMs,  compared  to  Ctrl-iPSC-CMs.  A  mild  decrease  of 
oxidation was observed in the control group after treatment with low DOX concentrations of 
0.25 and 0.5 µM. Overall, no clear DOX dose-dependency was observed in iPSC-CMs of both 
groups. Relative changes induced by DOX were comparable between Ctrl- and ACT-iPSC-CMs. 
5 µM  DOX treatment  caused  a  1.4-fold  increase  in  both  groups  (Figure  22 D).  EGSH was 
calculated and is shown in Table 4. Treatment with 5 µM DOX caused an oxidation of about 
6 mV. Taken together,  oxidation of  Grx1-roGFP2 was greater in iPSC-CMs of ACT patients 
compared to controls.
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Figure 22: Analysis of ROS in iPSC-CMs using genetically encoded biosensors roGFP2-Orp1 and 
Grx1-roGFP2. A:  H2O2 production in iPSC-CMs of both groups represented by roGFP2-Orp1 OxD. 
B: Relative  DOX-induced  change  in  roGFP2-Orp1  OxD.  Sample  number:  5  Ctrl-iPSC-CM 
differentiations,  8  ACT-iPSC-CM differentiations.  C: Grx1-roGFP2 oxidation in  iPSC-CMs of  both 
groups.  D:  Relative DOX-induced change in  Grx1-roGFP2 OxD.  Sample  number:  5  Ctrl-iPSC-CM 
differentiations, 6 ACT-iPSC-CM differentiations. Mean + SEM. * p < 0.05, ** p < 0.01, *** p <  
0.001.
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Table 4: EGSH in iPSC-CMs.  EGSH is depicted as mean ± SEM.  Sample number: 5 Ctrl-iPSC-CM 
differentiations, 6 ACT-iPSC-CM differentiations.
DOX [µM]
0 0.25 0.5 0.75 1 5
Control -301.46 ± 
3.83 mV
-300.79 ± 
2.72 mV
-297.95 ± 
3.74 mV
-299.02 ± 
4.33 mV
-296.60 ± 
3.03 mV
-295.16 ± 
2.74 mV
Patient -308.15 ± 
2.90 mV
-309.38 ± 
2.12 mV
-321.06 ± 
7.48 mV
-305.62 ± 
2.71 mV
-307.55 ± 
3.43 mV
-302.15 ± 
1.13 mV
4.4.3 Calcium Handling
Ca2+ belongs  to  the  most  important  second messengers  in  CMs since  it  is  the  basis  for 
contraction  and  relaxation,  determines  electrophysiological  properties  of  the  cell  and  is 
involved in gene transcription (see chapter 1.1.1.3). Cytosolic Ca2+ transients were visualized 
by loading iPSC-CMs with the Ca2+ sensitive dye Fluo-4 and the use of confocal laser scanning 
microscopy. Thereby, the Ca2+ transient rise time, the relative amplitude and the decay time 
could be assessed (Figure 23). Isoprenaline, which activates β-adrenergic signaling, was used 
to additionally stimulate the iPSC-CMs.
The Ca2+ transient rise time was comparable at basal conditions between Ctrl- and ACT-iPSC-
CMs  (Figure  24 A).  It  was  reduced  by  100  nM  isoprenaline  in  Ctrl-  and  ACT-iPSC-CMs. 
Treatment with 0.25 µM DOX caused a significant  decrease in  both groups,  whereas  no 
changes were observed after 5 µM DOX treatment. After 0.25 µM DOX treatment, Ctrl-iPSC-
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Figure 23: Ca2+ transient visualization. Ca2+ transients were analyzed using Fluo-4 live cell staining and 
confocal laser scanning microscopy. A suitable region in the cytoplasm of iPSC-CMs was measured for  
20 sec  with  the line  scanning  mode and  relative  fluorescence  intensities  were plotted.  The  Ca 2+ 
transient rise time, amplitude and decay time were analyzed.
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CMs  depicted  a  significantly  faster  rise  time  than  ACT-iPSC-CMs  (Figure  24 A).The  Ca2+ 
transient  amplitude  of  untreated  iPSC-CMs  from  both  groups  was  comparable  and  no 
changes  were  induced  by  isoprenaline  (Figure  24 B).  0.25 µM  DOX treatment,  however, 
induced a significant amplitude increase in both groups, which was significantly higher in 
Ctrl-iPSC-CMs. Interestingly, the amplitude was significantly decreased by treatment with 5 
µM DOX in both groups (Figure 24 B). 
Ctrl-iPSC-CMs depicted a significantly higher Ca2+ transient decay time at basal  conditions 
than ACT-iPSC-CMs. Furthermore, isoprenaline induced a significant decrease in Ctrl-iPSC-
CMs but not in ACT-iPSC-CMs. A significant decrease of decay time was observed in both 
groups  after  treatment  with  0.25  and  5  µM  DOX,  which  was  not  altered  by  further 
isoprenaline addition (Figure 24 C). The absolute decay time was comparable between both 
groups after DOX treatment (Figure 24 C). The relative fold change was significantly greater in 
the control group (Figure 24 D).
To  assess,  whether  the  observed  changes  of  Ca2+ transient  parameters  originate  from 
changes in gene expression, qRT-PCR and western blot analyses were performed (Figure 25, 
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Figure 24: Ca2+ transient rise time, amplitude and decay time. A: Ca2+ transient rise time in iPSC-CMs 
from both groups. B: Ca2+ transient amplitude in iPSC-CMs from both groups. C: Ca2+ transient decay 
time in iPSC-CMs from both groups. D: Relative changes of  Ca2+ transient decay time upon application 
of DOX and ISO.  Sample number: 200-61 Ctrl-iPSC-CMs from 9 differentiations, 197-119 ACT-iPSC-
CMs from 10 differentiations. Mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
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26 and  27). Ca2+ transient rise time and amplitude are directly influenced by RYR2 which 
releases Ca2+ from the SR into the cytoplasm during systole. RYR2 phosphorylation at S2808 
by  PKA  and  at  S2814  by  CamKII  causes  its  activation.  The  amount  of  RYR2 mRNA was 
significantly greater in the Ctrl-iPSC-CMs than in ACT-iPSC-CMs and  CamKII was expressed 
slightly more in the control  group. Treatment with 0.25 µM DOX resulted in significantly 
decreased expression of RYR2 in Ctrl-iPSC-CMs and no changes in CamKII expression (Figure
25).  Ca2+ transient  decay  time  is  regulated  by  expression  of  SERCA,  NCX,  PLN  and  its 
phosphorylation at S16 and Thr17. No significant differences in expression of SERCA, PLN or 
NCX was  found  on  the  mRNA  level  between  both  groups.  DOX  treatment  caused  a 
downregulation of SERCA and NCX mRNA in iPSC-CMs of both groups but not of PLN (Figure
25). 
At basal conditions, no significant differences were found between Ctrl- and ACT-iPSC-CMs 
on the protein level of RYR2 and CamKII or in the phosphorylation of RYR2 at S2808 or S2814 
(Figure 26). The amount of RYR2 in Ctrl-iPSC-CMs was increased after treatment with 0.25, 
0.5 and 1 µM DOX, but without significance. No changes were observed in ACT-iPSC-CMs 
(Figure 26 B). No significant changes were observed in phosphorylation of RYR2 at S2808 in 
both groups (Figure 26 D).  Phosphorylation of  RYR2 at S2814 increased in ACT-iPSC-CMs 
DOX-dependently with a significant increase at 5 µM DOX compared to basal conditions and 
Ctrl-iPSC-CMs. It was not changed in Ctrl-iPSC-CMs (Figure 26 F). No DOX-induced changes 
were found in the amount of CamKII (Figure 26 H).
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Figure 25: Expression of genes encoding for proteins involved in calcium signaling. Expression of 
RYR2,  CamKII,  SERCA,  PLN and NCX. Sample number: 11 Ctrl-iPSC-CM differentiations, 18 ACT-iPSC-
CM differentiations. Mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
4 Results
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Figure 26: Western blot analyses of proteins involved in Ca2+ transient rise time and amplitude. A, 
C, E, G: RYR2, RYR2-S2808p, RYR2-S2814p and CamKII in iPSC-CMs of both groups at basal conditions. 
B, D, F, H:  DOX-induced relative changes in the amount of RYR2, RYR2-S2808p, RYR2-S2814p and 
CamKII in iPSC-CMs of both groups. Sample number: 4 Ctrl-iPSC-CM differentiations, 6 ACT-iPSC-CM 
differentiations. Mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. I: Representative western blot 
results used for quantification. Left: Untreated. Right: DOX treated.
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No significant differences were found between the control  and ACT patient group in the 
amount of SERCA, NCX and PLN on the protein level in untreated iPSC-CMs (Figure 27 A, B, 
E). At basal conditions ACT-iPSC-CMs were phosphorylated about twice as much at S16 and 
Thr17 of PLN, which was not significant (Figure 27 C, D). Strikingly, DOX treatment induced an 
increase of SERCA in Ctrl-iPSC-CMs but not in ACT-iPSC-CMs. After treatment with 0.5, 1 and 
5 µM DOX, its amount was significantly greater in Ctrl-iPSC-CMs compared to ACT-iPSC-CMs 
(Figure 27 F). No DOX-induced changes were found in the amount of NCX or PLN (Figure 27 
G,  J).  However,  phosphorylation  of  PLN-S16  increased  significantly  in  a  dose-dependent 
manner in both groups (Figure 27 H). Furthermore, a decreased amount of phosphorylation 
was observed in the Ctrl-iPSC-CMs after DOX treatment at Thr17 of PLN. In ACT-iPSC-CMs, on 
the other hand, phosphorylation of PLN Thr17 was increased upon application of higher DOX 
concentrations (Figure 27 I).  In summary, these experiments point out that Ctrl-iPSC-CMs 
show  a  DOX-dependent  increase  of  SERCA  expression,  whereas  ACT-iPSC-CMs  have  an 
increase in PLN-phosphorylation upon DOX treatment.
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Figure 27: Western blot analyses of proteins involved in Ca2+ decay time. A-E: SERCA, PLN, PLN-S16p, 
PLN-Thr17p  and  NCX  in  iPSC-CMs  of  both  groups  at  basal  conditions.  F-J:  DOX-induced  relative 
changes in the amount of SERCA, PLN, PLN-S16p, PLN-Thr17p and NCX in iPSC-CMs of both groups. 
Sample number: 4 Ctrl-iPSC-CM differentiations, 6 ACT-iPSC-CM differentiations. Mean + SEM. * p < 
0.05, ** p < 0.01, *** p < 0.001. K: Representative western blot results used for quantification. Left: 
Untreated. Right: DOX treated.
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4.4.4 Apoptosis
It is widely accepted that many pathomechanisms involved in ACT result in apoptosis and cell 
death.  To  analyze  the  rate  of  DOX-induced  apoptosis  in  the  iPSC-CM  ACT  model,  the 
annexin V affinity assay was used (Figure 28). Annexin V binds to phosphatidylserine, which is 
present in the inner leaflet of the cell membrane in healthy cells. It is transported to the 
outer leaflet during early apoptosis. Costaining with PI, which only enters cells with disrupted 
cell membranes and accumulates in the DNA, enables distinction of apoptotic and dead cells. 
The annexin V affinity assay thereby is a powerful and sensible tool to quantify apoptosis. It  
was applied to iPSC-CMs, which were treated with DOX for 24 or 72 hours. Although the 
fluorescent properties of DOX caused an overall  dose-dependent signal increase in the PI 
channel,  viable,  apoptotic and dead cells  were  reliably  distinguishable  as  three  separate 
populations in scatterplots (Figure 28). 
89
Figure 28: Flow cytometry analysis of annexin V-APC / PI staining in iPSC-CMs. Apoptotic and dead 
cells were detected after staining iPSC-CMs with annexin V-APC and PI with flow cytometry. Although 
DOX fluorescence caused an overall signal increase in the PI channel, vital (bottom left), apoptotic 
(bottom  right)  and  dead  cells  (top  right)  were  clearly  distinguishable  even  at  higher  DOX 
concentrations. Images are representative for all cell lines.
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About 9 % of Ctrl-iPSC-CMs were apoptotic or dead at basal conditions and treatment for 
24 hours with concentrations of 0.25 or 0.5 µM DOX did not cause changes. A significant 
amount of apoptotic or dead cells of up to 24 % was found after 1 and 5 µM DOX. 5 % of ACT-
iPSC-CMs were apoptotic or dead at basal conditions. This amount was increased by 0.25 and 
0.5 µM DOX to about 10 % and significantly by 1 and 5 µM DOX up to 15 % (Figure 29 A). 
Although the absolute amount of apoptotic or dead cells was comparable between both 
groups after low concentrations of DOX and significantly higher in Ctrl-iPSC-CMs after high 
concentrations, the relative fold change was twice as high in ACT-iPSC-CMs after low DOX 
concentrations and comparable after high concentrations (Figure 29 B).
DOX treatment for 72 hours resulted in comparable amounts of apoptotic or dead cells in 
both groups with around 10 % after 0.25 and 0.5 µM and around 30 % after 1 and 5 µM 
(Figure 29 C). However, the relative DOX-induced change was significantly higher in ACT-iPSC-
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Figure 29: Analysis of apoptosis in iPSC-CMs. A: Amount of apoptotic and dead iPSC-CMs of both 
groups after 24 h DOX application. B: Relative changes in amount of apoptotic and dead iPSC-CMs of 
both groups after 24 h DOX application. C: Amount of apoptotic and dead iPSC-CMs of both groups 
after  72  h  DOX  application.  Sample  number:  13  Ctrl-iPSC-CM  differentiations,  11  ACT-iPSC-CM 
differentiations. D: Relative changes in amount of apoptotic and dead iPSC-CMs of both groups after 
72  h  DOX  application.  Sample  number:  10  Ctrl-iPSC-CM  differentiations,  10  ACT-iPSC-CM 
differentiations. Mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
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CMs compared to Ctrl-iPSC-CMs after 1 µM DOX treatment and also higher at every other 
tested condition (Figure 29 D). 
4.4.5 Sarcomeric integrity
The  development  of  force  and  overall  functionality  of  CMs  relies  on  the  sarcomeric 
cytoskeleton, which consists of a highly organized group of proteins that form sarcomeres. 
The  general  integrity  of  the  sarcomeric  cytoskeleton  depends  on  gene  expression  of 
respective proteins, such as α-actinin, cTNT, α- and β-MHC as well as their correct assembly 
into sarcomeres that are repeating with high regularity. The gene expression of sarcomeric 
proteins  and  their  correct  assembly  are  described  to  be  disturbed  by  DOX,  thereby 
contributing to decreased ejection fraction and ultimately ACT (see chapter 1.1.1.4). In the 
iPSC-CM  ACT  model,  the  sarcomeric  regularity  was  investigated  by  immunofluorescence 
analyses  of  α-actinin  and  subsequent  fast  Fourier  transformation  (FFT).  Thereby,  the 
frequency domain of the α-actinin staining could be depicted. High regularity of sarcomeres 
would cause a wave pattern. The first wave represents the frequency in which neighboring 
sarcomeres alternate. The peak amplitude of the first wave in the frequency domain of α-
actinin stainings was used as parameter to assess the regularity of α-actinin (Figure 30 A-F). 
Ctrl-iPSC-CMs  showed  a  similar  α-actinin  regularity  as  ACT-iPSC-CMs  at  basal  conditions 
(Figure  30 G).  DOX treatment  caused a  mild  dose-dependent  decrease  in  Ctrl-iPSC-CMs, 
which was significant at 5 µM. In contrast, in ACT-iPSC-CMs the regularity of α-actinin was 
already significantly disturbed after treatment with 0.25 µM DOX. At 0.25 and 0.5 µM DOX, 
ACT-iPSC-CM α-actinin regularity was significantly lower compared to the control group. The 
decrease of α-actinin regularity amounted for about 20 %, which was reached in the ACT-
iPSC-CMs at 0.25 µM DOX and in Ctrl-iPSC-CMs after 5 µM (Figure 30 H). 
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qRT-PCR  analysis  revealed  a  significant  DOX-induced  decrease  of  α-actinin and  β-MHC 
expression  in  Ctrl-iPSC-CMs and  of  α-actinin,  α-MHC,  β-MHC and  cTNT in  ACT-iPSC-CMs 
(Figure  31 A).  Furthermore,  no  significant  dose-dependent  DOX-induced  changes  or 
differences  between  both  groups  were  found  in  the  amount  of  α-actinin  observed  by 
western blot analysis (Figure 31 B, C).
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Figure 30: Integrity of sarcomeric cytoskeleton. A: α-actinin staining in untreated iPSC-CMs. B: FFT 
frequency domain of untreated iPSC-CMs. C: α-actinin staining in iPSC-CMs treated with 5 µM DOX. 
D: FFT frequency domain of iPSC-CMs treated with 5 µM DOX.  E:  Plot of FFT frequency domain of 
untreated iPSC-CMs.  F:  Plot of FFT frequency domain of iPSC-CMs treated with 5 µM DOX.  G: α-
actinin regularity in iPSC-CMs of both groups. H: DOX-induced relative change of α-actinin regularity 
in iPSC-CMs of both groups. Sample number: 62-60 Ctrl-iPSC-CMs from 4 differentiations, 91-85 ACT-
iPSC-CMs from 6 differentiations. Mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bars: 
50 µm.
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4.4.6 Mechanical functionality
To gain a better understanding of the influence of DOX on the functionality of iPSC-CMs in 
the ACT model, EHMs were generated. Hereby, the beating frequency, the beating regularity 
and the force of contraction could be analyzed. The generation of EHMs and experiments 
were done in cooperation with the institute of pharmacology and toxicology of the University 
Medical Center Göttingen by the group of Dr. med. Malte Tiburcy (Figure 32 and 33).
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Figure 31: Gene expression analysis of sarcomeric proteins. A: Expression of α-actinin, cTNT, α-MHC 
and β-MHC on  the  mRNA  level  in  iPSC-CMs  of  both  groups.  Sample  number:  11  Ctrl-iPSC-CM 
differentiations,  18  ACT-iPSC-CM differentiations.  B: α-actinin in  iPSC-CMs of  both groups on the 
protein level. C: DOX-induced relative changes in the amount of α-actinin in iPSC-CMs of both groups. 
D: Representative western blot results used for quantification. Left: Untreated. Right: DOX treated.  
Sample number: 4 Ctrl-iPSC-CM differentiations, 6 ACT-iPSC-CM differentiations. Mean + SEM. * p < 
0.05, ** p < 0.01, *** p < 0.001.
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Surprisingly, the cross-sectional area (CSA) of EHMs from the control group (Ctrl-EHMs) was 
significantly larger compared to the ACT patient group (ACT-EHMs). DOX treatment did not 
cause significant changes in either group (Figure 32 B). EHMs of both groups showed beating 
activity  with  a  comparable  frequency  of  about  30  beats  per  minute.  A  significant  DOX-
induced  increase  in  beating  frequency  was  observed  in  both  groups.  This  increase  was 
significantly stronger in ACT-EHMs (Figure 32 C). About 15 % of generated EHMs in both 
groups depicted irregular beating at basal conditions and DOX treatment caused the rate to 
increase to 40 % (Figure 32 D). The force of contraction of EHMs was dependent on Ca2+ 
concentration  in  the  measurement  buffer  (Figure  33 A).  The  absolute  maximal  force 
generated by EHMs was comparable between both groups at basal conditions with about 
1 mN. It was slightly decreased after DOX treatment in the control group. In ACT-EHMs, on 
the other hand, the DOX-induced decrease was significant (Figure 33 A, B, C). Interestingly, 
when set in relation to the CSA, ACT-EHMs generated significantly more force than Ctrl-EHMs 
at  basal  conditions  (Figure  33 D).  Furthermore,  when  set  in  relation  to  the  CSA,  DOX 
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Figure 32: Generation of EHMs from Ctrl- and ACT-iPSC-CMs and beating activity dynamics. A: ACT-
EHM from Patient 2 mounted on dynamic silicon stretchers. B: Cross-sectional area of Ctrl- and ACT-
EHMs. C: Beating frequency of Ctrl- and ACT-EHMs. D: Amount of Ctrl- and ACT-EHMs that depict an 
irregular spontaneous beating activity. Sample number: 12 Ctrl-EHMs from 2 differentiations, 18 ACT-
EHMs from 3 differentiations. Mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
4 Results
treatment  did  not  change  the  relative  force  of  Ctrl-EHMs,  whereas  it  was  significantly 
decreased in ACT-EHMs by about 35 % (Figure 33 D, E). Taken together,  EHMs from ACT-iPSC-
CMs showed a significantly decreased relative force after DOX treatment compared to Ctrl-
iPSC-CMs.
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Figure 33: Analysis of Ctrl- and ACT-EHM force of contraction. A: Ca2+-dependent generation of 
contractile force of  Ctrl-  and ACT-EHMs.  B: Maximal  force  of  contraction of  Ctrl-  and ACT-EHMs. 
C: DOX-induced relative change of maximal contractile force of Ctrl- and ACT-EHMs. D:  Maximal force 
of contraction of Ctrl- and ACT-EHMs relative to the EHM CSA.  E: DOX-induced relative change of 
maximal contractile force of Ctrl- and ACT-EHMs relative to EHM CSA. Sample number: 12 Ctrl-EHMs 
from 2 differentiations, 18 ACT-EHMs from 3 differentiations. Mean + SEM. * p < 0.05, ** p < 0.01, 
*** p < 0.001.
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The risk to develop ACT is a major limiting factor of anthracyclines such as DOX, which are 
otherwise  very  effective  neoplastic  drugs  used  against  a  broad  range  of  solid  and 
haematopoietic  cancers.  ACT  is  characterized  by  arrhythmia,  bradycardia,  tachycardia, 
decrease in LVEF and FS and irreversible CHF, all of which lead to increased morbidity and  
mortality. It is accompanied by histopathological changes such as myofibril loss, SR dilation, 
cytoplasmic  vacuolization,  swelling  of  mitochondria  and  increase  in  lysosome  number. 
Despite  being  intensely  used  and  studied  for  decades,  the  underlying  DOX-induced 
pathomechanisms leading to ACT are still not fully understood. According to the current state 
of knowledge, ACT is a multifactorial syndrome with elevation of oxidative stress, poisoning 
of  TOP2β and disturbances  of  Ca2+ homeostasis  in  CMs being  key  factors  that  all  cause 
apoptosis.  Additionally,  a  genetic predisposition for  ACT has  been suggested and several 
SNPs were statistically associated to ACT. Since human CMs are hard to obtain and culture, 
various animal models were used for studies of ACT. This may be a reason for contradicting 
results  and  poor  outcomes  in  clinical  trials.  After  a  decade  of  establishment,  the  iPSC 
technology holds promise as a powerful tool to model ACT. Such a model may be used to  
investigate pathomechanisms and genetic predisposition in a human system, to screen for 
protectants and to develop patient-specific treatment. 
In  this  work,  a  human  iPSC-CMs  based  model  of  ACT  was  established  using  three  ACT 
patients  and  two controls.  ACT patients  contained ACT-associated  alleles  of  SNPs  in  the 
NADPH oxidase subunits encoding genes  CYBA and  RAC2, whereas the controls did not. In 
the  first  part  of  this  work,  integration-free  hiPSCs  were  generated  that  expressed 
pluripotency markers on the mRNA and protein level and had the potential to develop cells 
of all three germ layers in vitro and in vivo. Subsequently, CMs were derived from ACT and 
control iPSCs, using a direct cardiac differentiation protocol with about 95% purity. iPSC-CMs 
expressed cardiac marker genes on the mRNA and protein level and depicted an organized 
sarcomeric structure. 
In the second part of the present study, ACT-related parameters were analyzed in Ctrl- and 
ACT-iPSC-CMs upon DOX application, namely the gene expression of NADPH oxidases and 
Ca2+ handling proteins on the mRNA and protein level, the production of ROS, Ca2+ signaling, 
apoptosis, the sarcomeric integrity and the overall mechanical functionality of iPSC-CMs.
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5.1 Reprogramming and cardiac differentiation
5.1.1 Generation of hiPSCs from ACT patients and controls
Pluripotency  is  induced  and  maintained  by  extracellular  signaling  pathways  as  well  as 
intracellular transcriptional networks. These were stimulated and manipulated in this work. 
Integration-free hiPSCs were successfully generated by transient expression of  OCT4,  SOX2, 
KLF4 and  C-MYC in dermal fibroblasts using the sendai virus system. The reprogramming 
efficiency was very high with 7.2 %. This is contrary to reported reprogramming efficiency of 
the CytoTune 2.0 kit of about 1.5 % (Beers et al., 2015). The discrepancies likely arise from 
the different means to estimate reprogramming efficiency. In our study, alkaline phosphatase 
positive iPSC colonies were counted. The efficiency was calculated using the number of cells 
plated  for  reprogramming.  However,  Beers  et  al.  state  that  some  alkaline  phosphatase 
positive colonies do not meet further criteria of pluripotency (Beers et al., 2015). Therefore, 
the authors only counted iPSC colonies that remained vital after passaging and expressed 
pluripotency markers. Taken together, in this work 24 and 16 iPSC lines were generated from 
three ACT patients and two control donors, respectively.
Prior  to  the  use  of  hiPSCs  in  disease  modeling,  the  generated  cell  lines  have  to  be 
characterized to assess the applicability of the hiPSCs for future use. For example, hiPSCs that 
are only partially reprogrammed might not differentiate into the desired cell type sufficiently 
(Koyanagi-Aoi  et  al.,  2013;  Takahashi  and  Yamanaka,  2016).  The  cell  lines,  which  were 
generated in this work, showed a typical hiPSC morphology (Figure 10). They grew in flat 
colonies with high cell density and distinct edges and were positive for alkaline phosphatase. 
Furthermore, an upregulation of the pluripotency-related genes NANOG, OCT4, LIN28, SOX2 
and GDF3 was observed compared to the dermal fibroblasts used for reprogramming (Figure
11).  Analyses  on  the  protein  level  of  LIN28,  OCT4,  NANOG,  SOX2,  SSEA4  and  TRA-1-60 
validated these results (Figure 12). This gene expression data suggests successful activation 
of the endogenous pluripotency network, since NANOG, LIN28, GDF3, SSEA4 and TRA-1-60 
encoding  genes  are  not  part  of  the  reprogramming  vectors.  Further  indication  of 
pluripotency  was  obtained  by  spontaneously  differentiating  the  iPSC  lines  in  vitro  and 
analyzing the expression of tissue-specific markers from each germ layer. In all cell lines, the 
expression  of  endodermal  AFP,  mesodermal  cTNT and  ectodermal  TH was  found  after 
prolonged differentiation, whereas NANOG expression was usually downregulated (Figure
13). Few cell lines showed germ layer-specific gene expression even at differentiation start. 
This is  most likely caused by iPSCs spontaneously differentiating under culture conditions 
where they should remain undifferentiated. This may occur during cocultivation with MEFs 
because  the  feeder  cell-dependent  cultivation  of  iPSCs  is  not  chemically  defined.  This 
unwanted  spontaneous  differentiation  of  iPSCs  is  influenced  by  the  quality  and  passage 
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number of MEF. In immunofluorescence analyses, endodermal AFP, mesodermal αSMA and 
ectodermal β-III-Tub were detected (Figure 14). Together, these results are a strong evidence 
for  pluripotency.  The  teratoma formation assay  is  widely  considered as  the pluripotency 
assay with the highest strength (Zhang et al., 2008). When implanted into immunodeficient 
SCID mice, PSCs proliferate and differentiate into cells of all germ layers supported by factors 
of the local milieu and circulating factors to form mostly benign teratomas. In this work, the  
teratoma formation assay  was  applied  to  at  least  one  cell  line  per  donor  and  neuronal 
rosettes  (ectoderm),  muscle  (mesoderm)  and  intestinal  tissue  (endoderm)  was  detected 
(Figure 15).  This further underlines the pluripotency stage of  the generated iPSCs in this 
work.
To  determine  the  cardiac  differentiation  efficiency  of  the  iPSCs,  EBs  containing  beating 
clusters were counted and the cardiac differentiation efficiency was shown to be 8-21 % 
(Table 3). This is consistent with a study in which fibroblast-derived hiPSCs at early passages 
differentiated into cardiac cells with an efficiency of 10.6 – 21.7% (Streckfuss-Bömeke et al., 
2013). hESCs have been reported to differentiate with an efficiency of about 10 – 25% into 
cardiac cells (He et al., 2003). In this work, a spontaneous in vitro differentiation protocol was 
used  to  determine  the  cardiac  differentiation  efficiency.  The  quantification  may  be 
problematic due to several  steps of the protocol using EBs. Since cardiac progenitor cells 
develop at around day 2-8 in  in vitro differentiation experiments with hiPSCs  (Cao et al., 
2012), the selection of EBs seems to be a critical step. It is not clear how the EB size and cell  
number is associated with the development of CMs. Furthermore, the differentiation might 
be influenced by the size and density of the used hiPSC colonies. 
Taken together, the characterization of 10 cell lines suggests that the analyzed Ctrl- and ACT-
iPSCs were pluripotent without differences between both groups. Furthermore, they contain 
a sufficient cardiac differentiation potential. Hence, the generated iPSCs were suitable for 
cardiac differentiation and to model ACT.  
5.1.2  Generation of hiPSC-CMs from ACT patients and controls
To derive large quantities of CMs from iPSCs with high purity, a direct cardiac differentiation 
protocol was used, which combines previously reported approaches  (Burridge et al., 2014; 
Lian et al., 2012, 2013; Tohyama et al., 2013). The differentiation of iPSCs into CMs took place 
under  chemically  defined  conditions  with  minimal  lot-dependent  influences,  thereby 
ensuring a high comparability between differentiation experiments. In a recent report, iPSC-
CMs  were  cultured  in  medium  supplemented  only  with  ascorbic  acid  and  human 
recombinant albumin for over 200 days  (Burridge et al.,  2014). In contrast to this, in our 
experiments this medium was suitable only for the initial differentiation steps. Prolonged 
cultivation of iPSC-CMs in this medium often caused cell detachment and death. In our work,  
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supplementation  with  B27  attenuated  these  problems.  iPSC-CMs  were  cultured  for  2-3 
month to enable maturation, which was previously suggested  (Lundy et al.,  2013). In our 
work, iPSC-CMs cultured for 2-3 month, expressed CM-specific genes, had a high sarcomeric 
organization and were often multinucleated. Furthermore, their beating frequency could be 
dynamically paced and they depicted Ca2+ transients, which reacted to β-adrenergic signaling 
by isoproterenol application (Figure 24). Taken together, these findings show that the iPSC-
CMs  generated  in  this  work  were  functional  and  reached  a  certain  level  of  maturity. 
However, all currently described iPSC-CMs have embryonic to neonatal features and do not 
resemble adult CMs (Kolanowski et al., 2017; Yoshida and Yamanaka, 2017). In our work, the 
focus was not on the analysis of the level of iPSC-CM maturity. Hence, no direct comparisons 
were performed between iPSC-CMs and adult human CMs. The same differentiation protocol 
was used to successfully model takotsubo cardiomyopathy, which develops in adult humans 
underlining a certain maturity of the cells  (Borchert et al., 2017). Several parameters were 
observed  in  our  work  that  show  immaturity  of  generated  iPSC-CMs  compared  to  adult 
human  CMs  (see  appendix,  Table  5).  iPSC-CMs  were  proliferating,  which  is  a  typical 
characteristic of embryonic CMs. In the postnatal heart, the size is increased by hypertrophic 
growth of CMs (Yang et al., 2014b). The morphology of iPSC-CMs resembled embryonic CMs 
(Figure 16), which is multi-angled. Adult CMs depict a rod shape with a length to width ratio 
of about 7 and a lengths of about 130-140 µm (Kolanowski et al., 2017; Tracy and Sander, 
2011). In adult CMs, sarcomeres are organized uniformly lengthwise. In the generated iPSC-
CMs, sarcomeres were often distributed multi-directionally or circularly (Figure 16). It is likely 
that  the  low  expression  of  NADPH  oxidase  subunits,  detected  in  this  work,  was  also  a 
consequence of immaturity of iPSC-CMs. To achieve higher degrees of maturation, various 
approaches have been suggested,  including biochemical  and physical  stimulation and 3D 
culture  techniques  (Kolanowski  et  al.,  2017).  It  is  reasonable  to  suggest,  that  significant 
increase of overall iPSC-CM maturity requires combination of those approaches to simulate 
in vivo development.
5.2 Modeling ACT with hiPSC-CMs from ACT patients and 
controls
The human ACT model generated in this work consists of ps-hiPSC-CMs which were treated 
with DOX to trigger ACT-associated phenotypes.  Accordingly,  finding an appropriate DOX-
application protocol was crucial for the entire study. The patients of the RICOVER-60 trials 
were treated with six or eight cycles of DOX, as part of the CHOP regiment, with 14 days  
intervals  (Pfreundschuh et al., 2008). The pharmacokinetics of DOX in human serum after 
intravenous injection is triphasic with successive half-lifes reached at about five minutes, one 
hour and 30 hours (Benjamin et al., 1977; Blaes et al., 2015; Robert and Gianni, 1993). Peak 
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plasma concentrations of about 5 µM and steady-state plasma concentrations of 25-250 nM 
have been reported  (Greene et al.,  1983; Minotti et al.,  2004) . However, there is a great 
variance between individual DOX dosage and schedule. The different ACT pathomechanisms 
seem to be highly intertwined and it  is  hard to distinguish between phenotypes directly 
induced by DOX and secondary phenotypes, resulting from accumulating damage. For this 
reasons, it was important to use comparable conditions of DOX treatment for all analyses.
Ultimately,  we  decided to  culture  the  ps-hiPSC-CMs in  medium supplemented with DOX 
ranging from 0.1 to 5 µM for 24 hours, thereby simulating the low serum elimination time 
and high range of concentration variety. We considered further treatment cycles and wash-
out intervals to be unfeasible, since even more variables would be added. When especially 
time  consuming  or  expensive  assays  where  performed,  only  low  and  high  DOX 
concentrations of about 0.25 and 5 µM were included, representing steady-state and peak 
plasma  concentrations,  respectively.  Interestingly,  several  independent  research  groups 
reported  similar  DOX-application  protocols  for  hiPSC-CMs,  thereby  strengthening  our 
rationale (Burridge et al., 2016; Chaudhari et al., 2016; Eldridge et al., 2014).
5.2.1 NADPH oxidase
To determine putative effects of ACT-associated SNPs and patient-specific phenotypes, the 
gene expression of NADPH oxidase subunits was determined on the mRNA and protein level.  
The overall expression of NADPH oxidase subunits on the mRNA level in iPSC-CMs of both 
groups was low, which was indicated by high CT values of qRT-PCR (see appendix, Table 5). 
Only  RAC1 expression was comparable to the analyzed cardiac genes.  NCF1,  NCF2,  NCF4 
were not detectable,  suggesting extremely low expression or inactivity of these genes in 
iPSC-CMs.  To still  ensure  validity  of  results,  qRT-PCR was  performed with  a  high  sample 
number (up to n=17). Similar to the concentration of mRNA, the amount of NADPH oxidase 
subunits NOX2, NOX4, p67phox, RAC2 and p22phox on the protein level was low and quality 
of  western blots  for  p22phox and RAC2 were not  sufficient  for  quantification.  For  these 
reasons, the results of NADPH oxidase subunit expression in our work have to be interpreted 
with caution and need to be validated by additional experiments.
The expression of NOX2, NOX4, CYBA and RAC1 on the mRNA level was comparable between 
iPSC-CMs from both groups without DOX treatment (Figure 17). The expression of  RAC2 in 
ACT-iPSC-CMs  was  higher  compared  to  the  control  group.  However,  this  trend  was  not 
statistically significant. In parts, these findings are in line with a study in human whole blood 
leukocytes. The authors reported significantly higher expression of RAC2 and NCF4 in donors 
with the ACT-associated allele of RAC2 SNP rs13058338 (Schirmer et al., 2007). In our work, 
NOX2,  NOX4 and  CYBA expression was downregulated after DOX application in iPSC-CMs 
from both groups, whereas RAC1 was downregulated only in ACT-patients (Figure 17). This is 
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contrary to a previous report where NOX2 and NOX4 are upregulated upon DOX application 
in  mice  heart  tissue  detected  by  qRT-PCR  (Zhao  et  al.,  2010).  On  the  other  hand,  DOX 
application did not change mRNA levels of NCF1, NCF2 or CYBA in ventricular tissue of mice 
(Yoshizawa et al., 2016). Furthermore, NADPH oxidase expression in heart tissue is described 
to be upregulated in mice models of heart disease, such as heart failure, cardiac hypertrophy 
and myocardial  infarction  (Kuroda and Sadoshima,  2010;  Looi  et  al.,  2008;  Zhang et  al., 
2013). Therefore, our findings on the mRNA level were surprising and the reasons for these 
discrepancies  remain  to  be  determined.  Since  we  detected  a  downregulation  of  mRNA 
expression  in  most  of  our  analyzed  genes,  we  could  not  rule  out  an  overall  defect  in 
transcription after DOX treatment in our cells.
Consistent with the findings on the mRNA level, the protein amount of NOX2, NOX4 and 
RAC1  were  comparable  in  Ctrl-  and  ACT-iPSC-CMs  without  DOX  treatment  (Figure  18). 
Although  p40phox  encoding  NCF4 expression  was  not  detectable  on  the  mRNA  level, 
p40phox was observed on the protein level. In future experiments, the efficiency of NCF4 
detection in iPSC-CMs via qRT-PCR should be optimized. Interestingly, p40hox amount was 
significantly higher in untreated ACT-iPSC-CMs than in Ctrl-iPSC-CMs. These findings are in 
line with the aforementioned study by Schirmer et al.  (Schirmer et al., 2007). The authors 
suggested  that  the  ACT-associated  allele  of  RAC2 SNP  rs13058338  may  contribute  to 
increased expression of NCF4, which encodes for p40phox. The DOX-induced downregulation 
of  NOX2,  NOX4, CYBA and RAC1 on the mRNA level was not observed on the protein level 
(Figure 18). Instead, p40phox and RAC1 were upregulated in the control and ACT patient 
group, respectively. To account for a possible delay between changes on the mRNA level and 
changes on the protein level, the amount of protein was determined 48 hours after single 
DOX  application.  The  changes  that  were  observed  on  the  mRNA  level  were  also  not 
represented  on  the  protein  level  after  the  48  hour  delay.  Interestingly,  the  amount  of 
p40phox was significantly reduced upon DOX treatment in Ctrl-iPSC-CMs but not in ACT-iPSC-
CMs  (Figure  18).  These  findings  suggest  that  p40phox  expression  may  be  regulated 
differently between iPSC-CMs of both groups under basal conditions as well as upon DOX 
application.  The  function  of  p40phox  as  part  of  the  NADPH  oxidase  is  somewhat 
controversial in the literature, since it has been described as both stimulating and inhibiting 
regulator of NADPH oxidase 2 (Bouin et al., 1998; Lopes et al., 2004; Sathyamoorthy et al., 
1997; Someya et al., 1999). Strong evidence support the common assumption that binding of 
p67phox (encoded by NCF2) to NOX2 and active RAC1/2 is required for activation of NADPH 
oxidase 2. Upon phosphorylation, p47phox (encoded by  NCF1) acts as an adapter protein 
and supports  the binding of  p67phox to NOX2  (Brandes et  al.,  2014).  In  the absence of 
p47phox, p40phox activates NADPH oxidase 2 expression  (Fan et al.,  2009; Tamura et al., 
2007). However, it was also reported that phosphorylated p40phox inhibits p47phox-bound 
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NADPH oxidase (Lopes et al., 2004). On the basis of their findings, Fan et al. hypothesize that 
dynamic phosphorylation of p40phox determines NADPH oxidase 2 activity on the basal level 
and upon stimulation. At basal conditions, p40phox is phosphorylated, contributes to basal 
NADPH oxidase 2 activity and inhibits p47phox phosphorylation. Upon agonist stimulation, 
p40phox gets rapidly dephosphorylated, enabling p47phox phosphorylation and increase in 
NADPH oxidase 2 activity. Rephosphorylation of p40phox finally contributes to full NADPH 
oxidase 2 activity (Fan et al., 2009). On the basis of the study of Fan et al., NADPH oxidase 2 
in  ACT-iPSC-CMs  may  be  more  active  on  the  basal  level  due  to  the  higher  amount  of 
p40phox.  The phosphorylation status  of  p40phox in  Ctrl-  and ACT-iPSC-CMs needs to be 
elucidated in future experiments.
In conclusion, ACT-iPSC-CMs showed a higher amount of NADPH oxidase subunit p40phox 
compared to Ctrl-iPSC-CMs under basal conditions. This may be an effect of the  RAC2 SNP 
rs13058338, as it has been previously suggested (Schirmer et al., 2007) and it may have an 
impact on NADPH oxidase 2 activity. Furthermore, p40phox regulation in response to DOX 
application differs between both groups, suggesting an important role of p40phox in ACT. 
However, the exact role of p40phox in the context of NADPH oxidase 2 activity is still unclear 
and needs to be analyzed in the future. To our knowledge, this is the first report of NADPH 
oxidase expression analyses in a patient-specific iPSC-CM ACT model.
5.2.2 ROS generation
In this work, a main focus was on the analysis of ROS generation in iPSC-CMs as part of  
modeling the ACT. Since the increase of oxidative stress is a key pathomechanism of ACT, we 
were interested in general DOX-induced changes on ROS levels. On the other hand, we also 
aimed to determine ACT patient- and control-specific ROS phenotypes in iPSC-CMs without 
and upon DOX treatment. The reason for this was that the recruited ACT patients contained 
ACT-associated SNPs in NADPH oxidase subunits. Therefore, a hypothesis of this work was 
that  NADPH oxidase activity  and subsequently  the amount of  ROS differs  between both 
groups  as  a  functional  consequence  of  the  ACT-associated  SNPs.  However,  the  accurate 
measurement and analysis of ROS can be a complex task due to their reactivity, ephemeral 
nature and similarities between different oxidative species. To measure and analyze ROS, the 
experimenter  may  choose  from  a  wide  variety  of  methodology,  each  having  certain 
advantages and disadvantages (Dikalov et al., 2007; Griendling et al., 2016). ·O2- and H2O2 are 
the most relevant ROS for the iPSC-CM ACT model, since they influence major pathways, are 
progenitors for further ROS and are generated by NADPH oxidase 2 and 4, respectively. For 
this purpose, assays were chosen that specifically detect ·O2- and H2O2. 
The Amplex Red assay is commercially available and developed by Molecular Probes. It is 
considered a first grade method by the American Heart Association as it specifically detects 
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H2O2 with a high sensitivity and allows for quantification (Griendling et al., 2016). In principle, 
the non-fluorescent Amplex Red is oxidized by horseradish peroxidase upon H2O2 binding to 
form the fluorescent molecule resorufin. Since horseradish peroxidase does not pass the cell  
membrane, only extracellular H2O2 is  detected.  However, it  has also been suggested that 
H2O2 is diffusible and an equilibrium between cytoplasm and the cell’s surrounding buffer 
may be reached (Dikalov et al., 2007). Using the Amplex Red assay, we found that ACT-iPSC-
CMs produce more H2O2 at every tested condition than Ctrl-iPSC-CMs, which was significant 
upon treatment  with 0.5  µM DOX (Figure  19 A).  Application of  low DOX concentrations 
induced a significant increase of H2O2 in iPSC-CMs of both groups. No differences between 
Ctrl- and ACT-iPSC-CMs were found when the relative DOX-induced increase in H2O2 amount 
was compared (Figure 19 B). Interestingly, application of high DOX concentrations did not 
change the H2O2 amount. A possible explanation for this phenomenon is based on the nature 
of the Amplex Red assay, which is dependent on the number of cells. Since iPSC-CMs of both 
groups were significantly apoptotic upon application of high DOX concentrations (Figure 29), 
the unchanged amount of detected H2O2 is likely due to a decrease of viable cells rather than 
actual  production of H2O2 per cell.  Importantly,  the amount of H2O2 was still  significantly 
increased seven days after single treatment with a low concentration of DOX in iPSC-CMs of 
both groups (Figure 19 C). Even 21 days later, iPSC-CMs of both groups depicted an H2O2 
increase of about two-fold. These findings indicate that single DOX treatment for 24 hours 
induces chronic pathological changes in the ACT iPSC-CM model.
We focused on  analyses  using genetically-encoded,  roGFP2-based biosensors.  The redox-
sensitive roGFP2 was originally generated by substituting surface facing residues of GFP2 
with cysteins that form disulfide bridges after oxidation  (Dooley et al.,  2004). As a result, 
roGFP2  possesses  two  excitation  maxima  at  about  400  and  490  nm  when  fluorescence 
emission is detected at 510 nm. The amplitude of both excitation maxima depends on the 
oxidation state. Upon oxidation of the roGFP2 cystein residues, the intensity of the excitation 
maximum at 400 nm increases, whereas the one at 490 nm decreases. Reduction causes the 
opposite effect. As a result, the oxidation state of roGFP2 can be analyzed ratiometrically, by 
detecting fluorescence emission at 510 nm upon excitation at both 400 and 490 nm with 
short  time intervals.  Ratiometric  analyses  offer  great  advantages  over  usual  photometric 
methods,  because  artificial  effects  caused  by  photobleaching  or  differences  in  detector 
expression level can be neglected. roGFP2 offers dynamic and fast detection of oxidation. It is 
not  affected by  pH changes in  the physiological  range of  5.5  –  8.0.  RoGPF2 detects  the 
oxidation state  of  the glutathione redox couple  (reduced:  GSH;  oxidized:  GSSG) which is 
mediated by glutaredoxins (Grx) but may also be oxidized by other mechanisms (Dooley et 
al.,  2004; Meyer et al., 2007). In this work, the constructs roGFP2-Orp1 and Grx1-roGFP2 
were used, which contain roGFP2 fused to oxidant receptor protein-1 (Orp1) or glutaredoxin-
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1 (Grx1), respectively, thereby influencing the specificity of the construct. Both constructs 
locate  to  the  cytoplasm  and  thereby  detect  intracellularly.  However,  the  signals  are  not 
exclusively cytosolic, since a nuclear localization was also observed (Figure 20). 
Orp1  is  a  peroxidase,  which  is  highly  selective  for  H2O2.  Upon  activation,  it  transmits 
oxidation to the transcription factor Yap1 (Delaunay et al., 2002). Interestingly, fusion of Orp1 
to roGFP2 causes Orp1 to transmit the H2O2 specific oxidation to roGFP2 instead of Yap1. 
Thereby, roGFP2 is converted into a highly specific H2O2 detector. roGPF2-Orp1 only allows 
for relative comparisons and no absolute H2O2 concentrations can be determined. OxD of 
roGFP2-Orp1  represents  the  amount  of  H2O2.  Although  roGFP2-fusion  proteins  are  not 
included in the official  statement by the American Heart Association, roGPF2-Orp1 offers 
similar advantages as HyPer, is  equally sensitive and additionally is not influenced by pH 
changes in the physiological range. Therefore, the value of analyses with roGPF2-Orp1 should 
be comparable to the first grade HyPer analyses  (Griendling et al.,  2016; Gutscher et al., 
2009).  Using  roGFP2-Orp1  in  iPSC-CMs,  we  found  the  intracellular  H2O2 amount  to  be 
comparable between ACT patients and controls at basal conditions (Figure 22). Upon DOX 
application, a dose-dependent increase of H2O2 was observed in both groups, which was 
significant at  0.75,  1 and 5 µM DOX. Upon DOX treatment with 0.5 µM, the increase of 
intracellular H2O2 was about 60 % in both groups (Figure 22). The increase of extracellular 
H2O2 at the same DOX concentration was about 60% in controls and 90 % in ACT patients, 
detected  with  Amplex  Red  (Figure  19).  These  data  indicate  comparability  between both 
assays  at  low DOX concentrations.  Since  roGFP2-based measurements  are  ratiometric,  a 
decrease in cell number, caused by DOX-induced apoptosis, does not influence the detection 
of H2O2. For this reason, no artificial decrease in intracellular H2O2 amount was observed, as 
it was likely the case for the Amplex Red assay (Figure 19 and Figure 22). This would explain 
the discrepancies between both assays upon application of higher DOX concentrations.
By  fusing  roGFP2  to  Grx1,  the  construct’s  specificity  towards  GSSG  is  greatly  enhanced 
(Gutscher et al., 2008). GSH is a tripeptide and belongs to the most important antioxidants in 
animals. Because of its high abundance, the oxidation state of the redox pair GSH/GSSG is  
traditionally used to reflect the overall  redox state of the cell  or the amount of oxidative 
stress, although these terms are poorly defined (Schafer and Buettner, 2001). Grx1-roGFP2 
detects the GSH redox potential (EGSH), which is determined by the OxD of GSH/GSSG and the 
total amount of GSH. In this work, EGSH and OxD of Grx1-roGFP2 were oxidized more in ACT-
iPSC-CMs than in  Ctrl-iPSC-CMs.  The  same was  found upon application of  DOX at  every 
tested concentration, which was significant at 0.5 µM (Figure 22 C). No differences between 
Ctrl- and ACT-iPSC-CMs were found when the relative DOX-induced increase in H2O2 amount 
was  compared  (Figure  22 D).  No  clear  dose-dependency  was  observed  in  both  groups, 
although the DOX-induced change of EGSH at 5 µM was about +6 mV (Table 4). This amounts 
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for about 40% increase of OxD (Figure 22 D). In untreated iPSC-CMs of controls and ACT 
patients the mean EGSH was -308.15 and -301.46 mV, respectively (Table 4). Although there is 
no clear consensus in the literature about cytosolic EGSH due to varying methodology, this 
data is consistent with other studies. For example, a cytosolic EGSH of -289 mV was found in 
hESC-CMs using Grx1-roGFP2 (Heta, 2017). Further studies were employed with genetically 
encoded fluorescent probes in different organisms. A cytosolic EGSH of -320 to -310 mV and 
-289 mV was reported in the yeast  S.  cerevisiae (Morgan et al.,  2011;  Østergaard et  al., 
2004),  and  -320  mV  in  the  tobacco  plant  (Brach  et  al.,  2009).  Additionally,  a  general 
estimation for the cytosolic EGSH of -320 to -300 mV in unstressed cells has been suggested 
(Meyer and Dick, 2010). However, a more oxidized cytosolic EGSH of about -256.5 mV (mean 
of two mouse lines) was reported in isolated mouse CMs (Swain et al., 2016).
Taken together, in this work the extracellular H2O2 amount (Amplex Red), the intracellular 
H2O2 amount (roGFP2-Orp1) and the cytosolic EGSH (Grx1-roGFP2) was analyzed. DOX caused 
a dose-dependent increase in intra- and extracellular H2O2 in iPSC-CMs. These results show 
that  a  key  pathomechanism  of  ACT,  namely  the  DOX-induced  increase  in  ROS,  can  be 
modeled using iPSC-CMs. Our findings are in line with the study of Burridge et al. who show 
that ROS increases dose-dependently in iPSC-CMs from ACT patients and controls upon DOX 
application  (Burridge et  al.,  2016).  Since the ACT-associated variants  of  SNPs  in  the ACT 
patients are linked to NADPH oxidases, a hypothesis of this work was that ROS production 
would  differ  between  ACT  patients  and  controls.  On  basal  level,  we  found  a  higher 
extracellular H2O2 amount and a more oxidized EGSH in ACT-iPSC-CMs compared to Ctrl-iPSC-
CMs. Furthermore, the extracellular H2O2 amount and EGSH was significantly higher in ACT-
iPSC-CMs than in Ctrl-iPSC-CMs upon treatment with 0.5 µM DOX. These findings support 
the hypothesis that NADPH oxidase activity is higher in ACT patients with ACT-associated 
SNPs than in controls. Burridge et al. reported that the amount of ROS in iPSC-CMs under 
basal conditions is comparable between ACT patients and controls (Burridge et al., 2016). To 
analyze ROS, the authors used a commercially available general ROS detector called CellROX 
(Thermo Fisher Scientific), whose molecular formula is not published. Furthermore, in the 
study of Burridge et al. the commercially available H2O2 detector ROS-Glo H2O2 (Promega) 
was used, which has not yet been critically assessed in the literature.
In our work, the DOX-induced relative change of ROS in iPSC-CMs was comparable between 
controls and ACT patients using Ampex Red, roGFP2-Orp1 and Grx1-roGFP2 (Figure 19 B and 
Figure 22 B, D). These findings are contradicting the work of Burridge et al. who reported a 
stronger DOX-induced increase of ROS production in iPSC-CMs from ACT patients, compared 
to controls (Burridge et al., 2016). Because the relative increase of ROS was the same in Ctrl- 
and  ACT-iPSC-CMs,  our  findings  favor  the  hypothesis  of  Zhang  et  al.,  which  states  that 
generation of ROS is not a direct cause of ACT and may not be directly induced by DOX 
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(Zhang et al., 2012). Zhang et al. show that TOP2β mediates DOX-induced downregulation of 
genes  involved  in  regulation  of  mitochondrial  biogenesis  and  function.  Subsequently, 
impairment of mitochondria results in the generation of ROS which was reduced by 70% in 
TOP2β depleted mice.
As discussed in detail in chapter 5.2.2.1, several other methodologies have been attempted 
in our work to detect ROS that are directly generated by the NADPH oxidase. Thereby, we 
aimed to assess the activity of the NADPH oxidase. Unfortunately, these approaches were 
not successful. As a result, the NADPH oxidase activity could not be directly determined in 
iPSC-CMs in our work. This is because the ROS that was detected in our work could have 
been generated by additional  sources  besides  the NADPH oxidase.  Hence,  we could not 
determine the functional consequences of the ACT-associated SNPs on the activity of the 
NADPH oxidase.
The  results  of  this  work  show  that  roGFP2  based  biosensors  were  functional  in  our 
experimental setup and responded to reduction and oxidation in a dynamic way. However, 
both biosensors located in the entire cytoplasm and nucleus. The Amplex Red assay detects 
extracellular H2O2. For this reasons, it is possible that ACT patient-specific phenotypes were 
not detected that are restricted to certain compartments, such as mitochondria or the SR, or 
microdomains as the NADPH oxidase environment. Therefore, DOX-induced ROS production 
in  iPSC-CMs  should  be  analyzed  in  organelles  and  microdomains  to  determine  patient-
specific patterns. For this purpose, genetically encoded ROS detectors may be used, which 
are fused to proteins with a  distinct  localization.  For  example,  roGFP has  been fused to 
p47phox, which is part of the NADPH oxidase 2 activating complex, thereby locating roGFP in  
close proximity to the NADPH oxidase (Pal et al., 2013). Using this fusion protein p47-roGFP, 
the NADPH oxidase activity was detected in macrophages. However, it was also shown that 
p47phox activity was still mediated by p47-roGFP. Hence, p47-roGFP expression likely causes 
an artificial activation of NADPH oxidase. Consequently, p47-roGFP is not suitable to analyze 
the  activity  of  NADPH  oxidase  in  the  iPSC-CM  ACT  model.  Nevertheless,  similar  sensor 
constructs  may be  generated  to  measure  ROS in  NADPH  oxidase  microdomains  without 
artifacts.  Furthermore,  genetically  encoded  ROS  biosensors  have  been  described,  which 
locate to specific organelles such as mitochondria, the ER or the nucleus (Bilan and Belousov, 
2017). 
An  alternative  approach  to  analyze  the  patient-specific  NADPH  oxidase  activity  and 
functional  effects  of  ACT-associated  SNPs  may  be  the  stimulation  of  NADPH  oxidase. 
Angiotensin II was shown to activate NADPH oxidase 2  (Wagner et al., 2014). Alternatively, 
the  use  of  recently  described  inhibitors,  which  are  specific  against  NADPH oxidase  may 
contribute to the determination of NADPH oxidase generated ROS (Altenhöfer et al., 2015). 
In this work it was not feasible to perform additional experiments with further conditions 
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such  as  application  of  angiotensin  II  or  NADPH  oxidase  inhibitors.  However,  additional 
specific activation or inhibition of the NADPH oxidase may reveal patient-specific phenotypes 
which are otherwise concealed.
In conclusion, the amount of extracellular H2O2 at basal conditions was higher and cytosolic 
EGSH was more oxidized in ACT-iPSC-CMs than in Ctrl-iPSC-CMs. Our findings show, that ROS 
production is increased in iPSC-CMs upon DOX treatment, which is a key pathomechanism of 
ACT and thereby highlight the applicability of iPSC-CMs for modeling ACT. Significantly higher 
amounts of ROS were observed in ACT-iPSC-CMs compared to Ctrl-iPSC-CMs upon treatment 
with 0.5 µM DOX.
5.2.2.1 Alternative approaches for ROS analysis
First trials of the 2',7'-dichlorodihydrofluorescein diacetate (H2DCF-DA) assay in iPSC-CMs in 
this work showed increased amounts of ROS after treatment with 0.1 µM DOX for 24 hours 
(see appendix, Figure 38). H2DCF-DA is a commonly used dye to measure intracellular ROS in 
living cells. In theory, the cell permeable H2DCF-DA is cleaved by intracellular esterases to 
2',7'-dichlorodihydrofluorescein, which is not cell permeable and thereby trapped within the 
cell.  Oxidation by  ROS produces  the fluorescent  molecule  2',7'-dichlorofluorescein  (DCF), 
which can be analyzed. However, the H2DCF-DA assay is often criticized and accumulating 
evidence suggest that it should not be used for accurate analyses. H2DCF is not a specific 
indicator for a certain ROS but is oxidized by H2O2, peroxynitrite, lipid hydroperoxide and ·O2- 
(Dikalov  et  al.,  2007).  Furthermore,  H2DCF  itself  may  cause  the  generation  of  ·O2- by 
photoreduction and redox cycling. It may be oxidized by peroxidases and its oxidation by ROS 
is indirect, requiring transition metals and heme enzymes  (Bonini et al., 2006; Rota et al., 
1999a, 1999b).
The  lucigenin-enhanced  chemiluminescence  assay  is  the  most  commonly  used 
chemiluminescence-based methodology to detect ·O2-, among others such as luminol, L-012 
or coelenterazine.  In principle,  lucigenin reacts with ·O2- to form an energy-rich product, 
which emits a photon. In this work, we aimed to determine the NADPH oxidase activity in 
iPSC-CMs by detecting generated ·O2- using lucigenin in cell homogenates after stimulation 
with  NADPH.  In  first  trials,  the  luminescence  signal  significantly  increased  upon  NADPH 
application but not upon additional treatment with the ·O2- scavenger tiron (see appendix, 
Figure 39). Additionally, specific enzyme inhibitors were applied, to determine the source of 
·O2-. Diphenyleneiodonium (flavoprotein inhibitor), VAS2870 (NADPH oxidase inhibitor), NG-
nitro-L-arginine methyl ester (nitric oxide synthase inhibitor),  oxipurinol (xanthine oxidase 
inhibitor) and rotenone (mitochondrial electron chain inhibitor) were used. The application 
of  these inhibitors suggested that  the source of  the signal  was the NADPH oxidase (see 
appendix,  Figure 39). Unfortunately, a poor reproducibility was observed between different 
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experiments. Furthermore, no feasible means of normalization could be established, which is 
necessary to compare results of different conditions and donor groups. As a consequence of 
the poor reproducibility and comparability of the assay, further analyses were canceled. The 
validity of  this  assay has  been questioned,  since potential  redox cycling of  lucigenin and 
oxygen may produce ·O2-  (Vásquez-Vivar et al.,  1997). However, in studies that report this 
redox cycling, the assay was often performed under artificial conditions (Dikalov et al., 2007). 
It is now mostly accepted, that redox cycling does not contribute significantly to the detected 
signal if the assay is set up correctly  (Dikalov et al., 2007; Griendling et al., 2016; Li et al., 
1998;  Skatchkov  et  al.,  1999).  Much  insight  into  the  involvement  of  ·O2- production  in 
diseases such as atherosclerosis, hypertension, diabetes and heart failure was gained using 
the lucigenin-enhanced chemiluminescence assay which was validated by the use of other 
methodologies  (Dikalov et  al.,  2007).  On the other  hand,  the validity  of  NADPH oxidase 
activity determination using the lucigenin-enhanced chemiluminescence assay upon NADPH 
stimulation has recently been questioned (Rezende et al., 2016).
Whereas the lucigenin-enhanced chemiluminescence assay is considered a third grade assay 
by the American Heart Association, detection of ·O2- by electron paramagnetic resonance 
(EPR) is classified as first grade and is the most accepted method (Griendling et al., 2016). 
EPR detects the absorption of microwave energy on the transition of unpaired electrons in an 
applied magnetic field  (Dikalov et al., 2007). By using molecules called spin traps, specific 
radicals such as ·O2- can be identified and quantified in a biological sample like iPSC-CMs. 
Apart from being the most accurate way to detect ·O2-, EPR analyses of iPSC-CMs are also 
expensive,  since  a  large  amount  of  cells  are  necessary  (1.5  x  106 cells  per  condition). 
Additionally, advanced training is needed to operate the space consuming EPR devices and to 
analyze the data. In this work, we aimed to detect ·O2- generated in iPSC-CMs upon DOX 
application using EPR as part of a collaboration with Dr. med. Andreas Petry and Prof. Agnes 
Görlach from the German Heart Centre, Munich (data not shown). In the first trial, ·O2- was 
detected in iPSC-CMs and reduced by superoxide dismutase. However, these results were not 
reproducible  in  subsequent  experiments.  Unfortunately,  further  analyses  were  made 
impossible, due to technical failure of the EPR device at the partner site in Munich.
An alternative approach to detect ·O2- is the use of dihydroethidium (DHE) which specifically 
reacts with ·O2- to form the fluorescent 2-hydroxyethidium. However, other ROS and enzymes 
react with DHE to form ethidium which is also fluorescent and not distinguishable from 2-
hydroxyethidium. Furthermore, the reaction products of DHE only exhibit fluorescence upon 
binding of DNA. Since DOX has similar fluorescent properties as 2-hydroxyethidium and also 
intercalates into DNA, this assay could not be used in the iPSC-CM ACT model. However, 
subsequent  separation  and  detection  of  DHE,  2-hydroxyethidium  and  ethidium  by  high-
performance  liquid  chromatography  (HPLC)  provides  a  promising  means  to  specifically 
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analyze ·O2- in iPSC-CMs upon DOX treatment (Griendling et al., 2016). Applying the correct 
conditions such as inhibition of further ·O2- producing enzymes would make it possible to 
analyze  the activity  of  NADPH oxidase.  The probe MitoSOX is  designed to  detect  ·O2- in 
mitochondria. Since it is chemically similar to DHE the aforementioned restrictions also apply 
for MitoSOX, rendering it impractical  for quantitative analyses in the ACT iPSC-CM model 
without further combination with HPLC (Zielonka and Kalyanaraman, 2010).
Genetically encoded biosensors such as HyPer are the best means to analyze intracellular 
H2O2 since they offer distinct advantages (Griendling et al., 2016). Hyper is a hybrid between 
the  bacterial  H2O2 sensor  OxyR  and  the  circularly  permuted  yellow  fluorescent  protein 
(Belousov et al., 2006). It is highly sensitive and specifically detects H2O2 without artificial 
ROS  production.  Contrary  to  means  to  detect  ROS  already  mentioned,  HyPer  reacts 
dynamically. As a result, fast changes in both directions in the H2O2 amount can be observed. 
In this work, iPSC-CMs were transfected with HyPer3 (Bilan et al., 2013), an improved version 
of  HyPer,  using  common transfection reagents  at  different  conditions  (data  not  shown). 
Unfortunately,  the  transfection  efficiency  was  very  poor  with  only  few  cells  showing 
fluorescence. The fluorescence could not be detected with a microplate reader. In future 
work,  HyPer3 analyses of  single DOX-treated iPSC-CMs should be performed using a fast 
switching monochromator and fluorescence microscopy. 
5.2.3 Calcium Signaling
Dysregulation  of  Ca2+ signaling  is  connected  to  a  plethora  of  heart  conditions,  including 
arrhythmia, systolic and diastolic dysfunction, hypertrophy and heart failure  (Eisner et al., 
2017; Røe et al.,  2015). Importantly, DOX has been shown to interact with key players of 
calcium signaling  and also  to  alter  their  gene  expression,  thereby  causing  impaired  Ca2+ 
homeostasis. This is suggested to be a pathomechanism of ACT. In this work, Ca2+ transients 
were analyzed using the fluorescent dye Fluo-4. The transient kinetics are a direct indicator  
of Ca2+ channel activity. ISO was used as a positive control  and additional activator of  β-
adrenergic signaling. As expected, no differences were found between untreated Ctrl- and 
ACT-iPSC-CMs in transient rise time and amplitude. The transient decay time was significantly 
faster  in  ACT-iPSC-CMs.  ISO caused a  fastening  of  transient  rise  and decay  time in  both 
groups, indicating a good functionality of the system (Figure 24).
Previous  in  vitro studies  in  cardiac  and  skeletal  muscle  suggest  that  anthracyclines  may 
stimulate as well as inhibit Ca2+ release from the SR  (Abramson et al.,  1988; Olson et al., 
2000; Pessah et al., 1990). Interestingly, in our work a biphasic effect of DOX on the transient 
rise time and amplitude was found in iPSC-CMs of both groups. A low DOX concentration 
caused  a  significant  decrease  in  rise  time  and  increase  of  amplitude,  whereas  a  high 
concentration caused no changes in rise time and a significant decrease of amplitude  (Figure
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24). Both parameters are mainly determined by RYR2 activity. These data suggest that DOX 
activates RYR2 at low concentrations, whereas it inhibits RYR2 at high concentrations in iPSC-
CMs. Recent findings from Hanna et al.  support this data  (Hanna et al.,  2014). Here, the 
authors examined the channel open probability of single RYR2 channels in a planar bilayer 
system upon treatment with different DOX concentrations. They found a RYR2 activation by 
DOX  concentrations  of  up  to  0.5  µM  which  was  maintained  for  the  lifetime  of  the 
experiment. However, following an initial activation, a sustained RYR2 inhibition was found 
upon  application  of  1  and  2.5  µM  DOX  and  the  activity  was  reduced  to  81  and  48%,  
respectively. The activation upon low DOX concentrations was reversible after drug wash-out, 
whereas the inhibition upon high concentrations was not reversible but preventable by pre-
incubation with the reducing agent DTT. The authors concluded that DOX may activate RYR2 
by ligand binding and inhibit it  by oxidation of thiol  residues. Similar effects of the DOX-
related anthracycline daunorubicin have been reported  (Hanna et al.,  2011). In our work, 
Ctrl-iPSC-CMs depicted a significantly stronger activation than ACT-iPSC-CMs upon treatment 
with a low amount of DOX, whereas no differences between both groups were observed at a 
high DOX concentration (Figure 24). Presupposing that our data and those of Hanna et al. are 
based on the same mechanisms,  these findings suggest that RYR2 from controls may be 
more prone to DOX binding than those from ACT patients but that both are equally modified 
at  thiol  groups.  This  would  be  a  novel  hypothesis  that  requires  further  validation  and 
explanation. 
DOX induced a significant decrease in transient decay time at low and high concentrations in 
both Ctrl- and ACT-iPSC-CMs (Figure 24). This parameter of Ca2+ signaling is determined by 
SERCA  and  NCX  activity.  Hwang  et  al.  compared  hiPSC-CMs  generated  by  different 
laboratories and showed that SERCA contributes 61% and NCX 31% to the decay of  Ca2+ 
transients in iPSC-CMs. This is comparable to human and rabbit CMs  (Hwang et al., 2015; 
Piacentino et al., 2003). Our findings therefore suggest an increase in activity of one or both 
channels. Unlike transient rise time and amplitude, the transient decay times were decreased 
to a comparable level in both groups. Since the decay times in untreated ACT-iPSC-CMs were 
significantly lower, the relative DOX-induced changes were significantly stronger in Ctrl-iPSC-
CMs compared to ACT-iPSC-CMs (Figure 24 C, D). In contrast to our data, other studies report 
anthracyclines  and  their  metabolites  to  compromise  SERCA  function  by  direct  binding 
(Cusack et al., 1993; Hanna et al., 2014).  
Accumulating evidence suggests that influences of anthracyclines on Ca2+ channels ultimately 
result in a decrease of SR content and increase in cytosolic Ca2+ concentration  (Kim et al., 
2006; Sag et al., 2011). Unfortunately, diastolic Ca2+ concentration could not be analyzed in 
this  work  due to limited time and work  capacity.  Quantitative Ca2+ analyses  would have 
required the use of a different Ca2+ sensitive dye, a different experimental setup and complex 
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standardization for every measurement. For the future, analyses of diastolic calcium with this 
ACT model seem promising.
As discussed above, the observed DOX-induced changes in Ca2+ transient properties might 
result from direct interactions of key proteins with DOX or from their oxidation by increased 
amount of ROS. However, changes in their gene expressions upon DOX treatment have also 
been reported and may contribute to impaired Ca2+ handling. Furthermore, phosphorylation 
by PKA and CamKII regulates the activity of RYR2 and PLN (and thereby SERCA). For these 
reasons, the expression of key proteins was analyzed on the mRNA and protein level. The 
amount of  SERCA,  PLN,  NCX and  CamKII mRNA was comparable in Ctrl- and ACT-iPSC-CMs 
under  basal  conditions  (Figure  25).  RYR2 was  expressed  about  twice  as  high  in  control 
patients. Upon treatment with a low DOX concentration, significant downregulation of RYR2 
and SERCA was found. This is in agreement with previous studies in rat CMs (Gambliel et al., 
2002; Zhang et al., 2014). Our findings on the protein level validate the mRNA data to some 
extent, since the amount of RYR2, CamKII, SERCA, PLN and NCX was comparable between 
groups  (Figure  26 and  Figure  27).  However,  no  significant  changes  were  observed upon 
treatment with low DOX concentrations. Phosphorylation of PLN at S16 and Thr17 was about 
twice as high in the ACT-iPSC-CMs, although it did not reach statistical significance (Figure
27).  This  might  contribute  to  the  faster  transient  decay  time  in  ACT-iPSC-CMs  at  basal 
conditions (Figure 24), since phosphorylated PLN is inactive resulting in a stronger activity of 
SERCA. Upon treatment with high DOX concentrations, the amount of RYR2 was reduced in 
ACT-iPSC-CMs to about 50 % and RYR2 is hyperphosphorylated at S2814 (Figure 26). This 
means  that  ACT-iPSC-CMs  possess  less  amounts  of  RYR2,  which  is  more  active  upon 
treatment with high DOX concentrations. In Ctrl-iPSC-CMs, on the other hand, no significant 
changes  in  RYR2  amount or  phosphorylation were found.  Both  findings  may explain  the 
unchanged Ca2+ transient rise time upon high DOX treatment, but not the reduced transient 
amplitude (Figure 24). Additionally, the significant decrease of Ca2+ transient rise time and 
increase  of  amplitude  at  low  DOX  concentration  do  not  seem  to  be  based  on  RYR2 
expression or phosphorylation.
High DOX concentrations induced a significant increase in the amount of SERCA in Ctrl-iPSC-
CMs  but  not  in  ACT-iPSC-CMs  (Figure  27).  The  amount  of  SERCA-regulating  PLN  was 
unchanged in both groups. However, a significant hyperphosphorylation of PLN at S16 was 
observed  in  both  groups  induced  by  high  DOX  concentrations.  ACT-iPSC-CM  PLN  was 
hyperphosphorylated at Thr17 upon application of high DOX concentrations. These findings 
suggest  that  the  reduction of  transient  decay  time induced by  high  DOX concentrations 
(Figure  24)  is  caused  by  an  upregulation  of  SERCA  expression  and  PLN-S16 
hyperphosphorylation in  the control  group and by hyperphosphorylation of  PLN-S16 and 
PLN-Thr17  in  the  ACT  patient  group.  These  distinct  mechanisms  may  explain  why  the 
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transient decay time decrease is significantly stronger in the control group. The significant 
decrease of Ca2+ transient decay time upon low DOX concentrations does not seem to be 
based on SERCA and PLN expression.
The  amount  of  CamKII  is  not  changed by  DOX in  both  groups,  which is  consistent  with 
previous  findings  (Sag et al.,  2011).  However,  the hyperphosphorylation of  CamKII  target 
sites S2814 of RYR2 and Thr17 of PLN suggests increased activity of CamKII in ACT-iPSC-CMs 
but not in Ctrl-iPSC-CMs upon application of high concentrations of DOX. CamKII activity has 
been shown to be regulated by oxidation (Erickson et al., 2008). Importantly, recent studies 
conclude  that  CamKII  is  a  target  of  NADPH  oxidase  2  generated  ROS  (He  et  al.,  2011; 
Swaminathan et al., 2011; Zhao et al., 2011). It is tempting to conclude that the observed 
hyperphosphorylation of  CamKII  targets in ACT patient iPSC-CMs may be connected to a 
higher activity of NADPH oxidase 2 upon DOX treatment, which in turn may be caused by 
SNPs in NADPH oxidase subunit encoding genes. However, more validation is necessary to 
support such a hypothesis. Especially the NADPH oxidase 2 activity needs to be assessed 
specifically and a causal relation with the SNPs has to be shown. Furthermore, the oxidation 
status of CamKII should be analyzed in future experiments in the iPSC-CM ACT model.
In conclusion, we found severe disturbances of Ca2+ homeostasis in both Ctrl- and ACT-iPSC-
CMs upon DOX treatment. The basis of these may be direct interactions of DOX with key 
proteins or their oxidation by increased amounts of ROS and DOX-induced changes in gene 
expression.  Furthermore,  the  DOX-induced  mechanisms  causing  disturbances  in  Ca2+ 
transients seem to be different between both groups. 
5.2.4 Apoptosis and cell death
There is wide acceptance that a common result of different discussed ACT pathomechanisms 
is cell death of CMs by apoptosis (Carvalho et al., 2014; Zhang et al., 2009). Accordingly, high 
concentrations of DOX induced a significant amount of apoptosis and cell death in both Ctrl- 
and  ACT-iPSC-CMs  (Figure  29).  Unexpectedly,  about  twice  as  many  Ctrl-iPSC-CMs  were 
apoptotic at culture conditions without DOX treatment compared to the ACT-iPSC-CMs. Upon 
24  hours  of  treatment  with  low  concentrations,  the  relative  DOX-induced  increase  of 
apoptotic cells was about twice as high in ACT-iPSC-CMs as in Ctrl-iPSC-CMs. After treatment 
for 72 hours, the relative increase was higher at all tested DOX concentrations in ACT-iPSC-
CMs, which was significant at 1 µM (Figure 29). These data indicate that ACT-iPSC-CMs are 
more  sensitive  to  DOX treatment  with  regard  to  the  development  of  apoptosis.  Similar 
findings were reported by Burridge et al. who showed that ACT patient iPSC-CMs are more 
prone to DOX-induced apoptosis than control iPSC-CMs (Burridge et al., 2016). The authors 
show that iPSC-CMs from ACT patients are significantly more apoptotic upon application of 
0.1 – 10 µM DOX for 72 hours using the annexin V / PI assay.
113
5 Discussion
Several distinct DOX-induced pathways have been described that cause both intrinsic and 
extrinsic  apoptosis  of  CMs.  For  example,  CMs  are  more  prone  to  Fas/FasL  dependent 
apoptosis upon DOX application (Yamaoka et al., 2000). Also, pro-survival pathways such as 
NRG1/ErbB are impaired by DOX, leading to increased rates of cell death (Horie et al., 2010). 
However, iPSC-CMs were cultured with high purity and no further signaling molecules were 
tested, which would induce extrinsic apoptosis. Hence, the observed DOX-induced apoptosis 
is  most  likely  caused by  intrinsic  signaling.  For  one,  transcription factors  or  coactivators 
involved in induction or inhibition of apoptosis are dysregulated by DOX such as GATA-4, 
CARP, NF-κB, NFAT and p300 (Aihara et al., 2000; Aries et al., 2004; Jeyaseelan et al., 1997; 
Kalivendi et al., 2005; Kim et al., 2007; Wang et al., 2002). Since DOX-induced ROS generation 
is often implicated in these dysregulations, the observed increase of ROS in iPSC-CMs upon 
DOX application (Figure 19 and 22) may be a reason for induction of apoptosis (Aihara et al., 
2000; Kalivendi et al., 2005; Kim et al., 2007; Wang et al., 2002). Additionally to transcription 
factors, other important apoptosis-related proteins are also dysregulated by DOX, such as 
p53,  Akt,  MAPKs  and  Bcl-2  family  members  (Zhang  et  al.,  2009).  p53  signaling  and 
subsequent activation of intrinsic apoptosis is also induced by DNA damage which may be 
directly caused by DOX or indirectly via TOP2 poisoning and oxidation. Furthermore, DOX-
induced organelle damage has been reported to result in apoptosis. For example, elevated 
cytosolic Ca2+ levels cause increased Ca2+ influx into the mitochondria,  which in turn may 
cause an overload and the disruption of the outer membrane. Thereby, cytochrome c and 
apoptosis  inducing  factor  (AIF)  could be released into  the cytoplasm,  inducing apoptosis 
(Childs et al., 2002; Deniaud et al., 2008; Kim et al., 2006). The high number of apoptosis 
pathways that have been linked to ACT shows the complexity of DOX toxicity. Good evidence 
has been reported for all of the pathways, which were mentioned above. Therefore, they 
should all be investigated in the iPSC-CM ACT model in future experiments. Thereby, it may  
be elucidated whether increased levels of ROS, DNA damage or disturbed Ca2+ handling is the 
main reason for the DOX-induced apoptosis in iPSC-CMs, which was found in our work.
In  conclusion,  DOX  induces  apoptosis  and  cell  death  dose-dependently  in  iPSC-CMs. 
Furthermore, our findings suggest that ACT-iPSC-CMs more prone to DOX-induced apoptosis 
than Ctrl-iPSC-CMs. However, until now it is unclear, which apoptosis-related pathways are 
involved in apoptosis of ACT-iPSC-CMs. This has to be answered in the future. It is plausible 
to conclude that the DOX-induced ROS generation and dysregulation of Ca2+ signaling, which 
were observed in this work, may contribute to apoptosis in iPSC-CMs.
5.2.5 Sarcomeric integrity
Sarcomeric disarray is a feature of ACT, which can be found in heart biopsies. α-actinin is part 
of the Z-discs, structures that make up the borders of one sarcomere (Minotti et al., 2004). 
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Because of its distinct localization within the sarcomeric cytoskeleton, immunofluorescence 
stainings of α-actinin can be used to assess the regularity of sarcomeres. As expected, the 
regularity of sarcomeres in iPSC-CMs was comparable between ACT patients and controls 
under  basal  conditions  (Figure  30).  Upon  treatment  with  high  DOX  concentrations,  a 
significant reduction of sarcomeric regularity of about 20% was found in both groups (Figure
30).  Importantly,  treatment  with  low  DOX  concentrations  induced  a  significantly  greater 
decrease of  regularity  in  ACT-iPSC-CMs than in  Ctrl-iPSC-CMs (Figure  30).  These findings 
suggest that ACT-iPSC-CMs react significantly more sensitive towards DOX with regard to the 
sarcomeric cytoskeleton. Our findings are in line with a previous study by Burridge et al. who 
claim  that  iPSC-CMs  from  ACT  patients  lose  sarcomeric  organization  at  lower  DOX 
concentrations compared to iPSC-CMs from healthy donors  (Burridge et al.,  2016). In our 
work, α-actinin regularity was quantified with minimal bias by the experimenter using the 
FFT  algorithm  and  radial  integration  of  the  frequency  domain,  whereas  Burridge  et  al. 
assessed the sarcomeric organization only visually. 
The loss of sarcomeric integrity in our iPSC-CM ACT model may be a result of several DOX-
induced  mechanisms.  For  one,  the  Ca2+-dependent  cysteine  protease  calpain  has  been 
implicated in ACT. Independent studies suggest an increase of  calpain activity  upon DOX 
treatment and subsequent degradation of  essential  sarcomeric proteins such as titin and 
dystrophin (Campos et al., 2011; Chen et al., 2012; Jang et al., 2004; Lim et al., 2004; Min et  
al.,  2015),  although  another  report  claims  reduced  calpain  activity  (Wang  et  al.,  2013). 
Increased  calpain  activity  is  also  connected  to  other  heart  conditions  such  as 
ischemia/reperfusion-induced myocardial injury and diabetic cardiomyopathy, which favors 
the role of calpain in ACT (Khalil et al., 2005; Li et al., 2011; Perrin et al., 2003). Additionally, 
stress-conditions may increase calpain activity and thereby involve it in CM apoptosis and 
inflammatory response  (Li  et al.,  2009a, 2009b). Degradation of titin and dystrophin may 
explain the DOX-induced reduction of sarcomeric regularity in Ctrl- and ACT-iPSC-CMs. This is 
because the loss of α-actinin localization regularity does not seem to be connected to the 
amount of α-actinin. The amount of α-actinin is not significantly changed by DOX treatment 
(Figure  31).  Furthermore,  previous  experiments  performed  by  Andrey  Fomin  from  the 
research group of Prof. Dr. W. A. Linke from the University Hospital of Münster showed titin 
degradation  in  iPSC-CMs  from  healthy  control  donors  upon  treatment  with  high  DOX 
concentrations  (see  appendix,  Figure  40).  Since  calpain  activity  depends  on  Ca2+ binding 
(Moldoveanu et al., 2002), the reduction of sarcomeric integrity in iPSC-CMs may be caused 
by DOX-induced changes in calcium homeostasis. As discussed in chapter  5.2.3, we found 
significant DOX-induced changes of Ca2+ transient properties in both groups. However, the 
experiments  performed  in  this  work  are  not  suitable  to  assess  quantitative  amounts  of 
diastolic cytosolic Ca2+, making comparisons between groups impossible. In the future, the 
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diastolic  cytosolic  Ca2+ amount  should  be  determined  to  analyze  a  possible  connection 
between DOX-induced dysregulation of Ca2+ handling and sarcomeric integrity.
Interestingly, several reports suggest that calpain activity is positively regulated by NADPH 
oxidase 2 in CMs and other cell types such as mesangial cells and neurons (Guemez-Gamboa 
et al., 2011; Li et al., 2009a, 2009c, 2009b; Sheu et al., 2017). Inactivation of NADPH oxidase 
2 by depletion of RAC1, on the other hand, results in inhibition of calpain activity in CMs 
(Shan et al., 2010). In the context of these reports the significantly stronger disturbance of 
sarcomeric integrity in ACT-iPSC-CMs upon application of low DOX concentrations may be 
explained by a higher activity of NADPH oxidase 2. The result would be a higher amount of  
ROS  and thereby  an  increased calpain  induced degradation  of  titin and dystrophin.  The 
reason for this may be the alleles of SNPs in RAC2 and CYBA contained by ACT patients but 
not  controls.  However,  as  mentioned in  the previous  chapters,  such a  hypothesis  needs 
further validation, especially regarding the influence of SNPs on NADPH oxidase activity and 
calpain activity status. Also, titin degradation may be analyzed directly on the protein level by 
gel  electrophoresis,  although  the  size  of  about  3,6  MDa  makes  the  methodology  more 
complex. First trials were already performed by Andrey Fomin (see appendix, Figure 40).
Another explanation of DOX-induced reduction of sarcomeric integrity in iPSC-CMs may be 
altered  expression  of  genes  encoding  for  sarcomeric  proteins.  We found  a  DOX-induced 
reduction of expression of  α-actinin, α-MHC, β-MHC and cTNT in iPSC-CMs of both groups. 
Respective changes on the protein level  may contribute to the disturbance of sarcomere 
regularity upon DOX application. However, since α-actinin is not significantly influenced by 
DOX on the protein level, the amount of α-MHC, β-MHC and cTNT needs to be assessed in 
DOX-treated iPSC-CMs in future experiments. Our findings are supported by reports of DOX-
induced decrease of cardiac sarcomeric gene expression on the mRNA level  in vitro and  in  
vivo in mice (Chen et al., 2012; Ito et al., 1990). Since no significant differences between ACT 
patients  and  controls  were  found  in  our  work,  it  is  unlikely  that  altered  cardiac  gene 
expression  on  the  mRNA  level  contributes  to  the  increased  sensitivity  of  ACT  patients 
regarding DOX-induced disruption of sarcomeric integrity.
5.2.6 Mechanical functionality
ACT is characterized by decreased heart function, which is often accompanied by reduced 
LVEF  (Minotti et al., 2004; Nousiainen et al., 2002). This reduction of heart function is the 
result of accumulating damage on the subcellular level. In this work we generated an iPSC-
CM  model  of  ACT  and  analyzed  underlying  damage-causing  pathomechanisms  such  as 
increase  of  ROS  production  and  involvement  of  NADPH  oxidases,  impairment  of  Ca2+ 
handling,  induction of  apoptosis  and reduction of  sarcomeric  integrity.  To determine the 
ultimate  effects  of  these  pathomechanisms,  we  aimed  to  assess  the  overall  mechanical 
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functionality of Ctrl- and ACT-iPSC-CMs upon DOX application. For this purpose, analyses of 
the mechanical beating behavior of iPSC-CMs  in vitro were necessary. However, these are 
challenging and often require advanced equipment and training.  As a  result,  few studies 
describing iPSC-CM disease models assess the mechanical functionality but rather rely on 
electrophysiological analyses (Laurila et al., 2016). The force of contraction of a single iPSC-
CM may be determined by traction force microscopy in which iPSC-CMs are cultured on a 
substrate containing fluorescent  beats.  By observing the displacement of  beats,  which is 
caused by beating iPSC-CMs, the force of contraction can be calculated (Wang and Lin, 2007). 
Furthermore,  atomic  force microscopy may be used to analyze  beating characteristics  of 
iPSC-CMs.  By  applying  a  small  cantilever  to  the cell  surface,  the  CM contraction can  be 
observed  (Domke  et  al.,  1999).  Impedance  assays  and  video  microscopy  are  additional 
computational approaches to determine iPSC-CM beating characteristics (Laurila et al., 2016; 
Peters et al.,  2015). Unfortunately, approaches that assess single iPSC-CMs or monolayers 
may not reproduce phenotypes that develop in a tissue context.
3D-cultures such as EHMs offer the opportunity to analyze the functionality of iPSC-CMs in a  
model  of  the  human  myocardium.  This  state-of-the-art  approach  furthermore  facilitates 
iPSC-CM  maturation  as  indicated  by  structural  and  functional  properties  (Tiburcy  et  al., 
2017). In our work, we generated EHMs from iPSC-CM of ACT patients and controls. EHMs 
from both groups showed an increase in beating frequency and irregular beating upon DOX 
application. These findings suggest that EHMs generated from iPSC-CMs recapitulate DOX-
induced symptoms of ACT and are therefore a suitable tool to model functional phenotypes 
of ACT (Bristow et al., 1978; Ewer et al., 2003; Octavia et al., 2012; Rudzinski et al., 2007). 
Interestingly,  the  increase  of  beating  frequency  of  ACT-EHMs  was  significantly  greater 
compared to  Ctrl-EHMs,  suggesting a  higher  susceptibility  to  DOX (Figure  32).  The DOX-
induced changes in beating properties of EHMs likely result from the observed impairment of 
Ca2+ handling (Figure 24). The decrease of Ca2+ transient rise time and decay time, which was 
observed in iPSC-CMs upon DOX treatment, favors fastening of beating but also arrhythmia. 
However, our findings regarding Ca2+ handling do not explain, why the DOX-induced increase 
of beating frequency is higher in the ACT-EHMs, because changes in Ca2+ transient properties 
were greater in Ctrl-iPSC-CMs. 
The  most  important  finding  of  this  work  was  that  DOX  application  caused  a  significant 
reduction of force of contraction of ACT-EHMs but not of Ctrl-EHMs (Figure 33). This effect 
was even stronger, when the force of contraction was normalized to the CSA (Figure 33). To 
rule out that the differences in DOX-dependent force of contraction between Ctrl- and ACT-
EHMs are based on different CM content in the EHMs, immunhistochemical stainings of EHM 
should be performed in the future. In this way, it would be possible to analyze the CMs and 
the percentage of matrix in each EHM ring. Our data suggests that iPSC-CMs recapitulate ACT 
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patient-specific impairments on a functional level, highlighting the importance of the ACT 
model generated in this work. The DOX-induced reduction of contraction force in ACT-EHMs 
but not Ctrl-EHMs is likely a result of impaired sarcomeric integrity and increased apoptosis  
of iPSC-CMs. Both parameters were shown to be affected stronger in ACT-iPSC-CMs upon 
treatment with clinically relevant DOX concentrations compared to Ctrl-iPSC-CMs (Figure 29 
and Figure 30). The sarcomeric integrity governs the generated force of an iPSC-CM, whereas 
the number of vital iPSC-CMs influence the maximal force generated by EHMs. DOX-induced 
changes  in  Ca2+ handling  may  also  contribute  to  reduction  of  EHM  force.  For  example, 
increased diastolic Ca2+ concentrations would cause an incomplete relaxation of sarcomeres 
and thereby a reduction of force. However, the parameters of Ca2+ handling observed in this 
work  are  not  sufficient  to  determine  the  influence  on  EHM  maximal  force.  More  work 
regarding SR Ca2+ content  and diastolic  Ca2+ concentrations have to be performed in the 
future.   To  our  knowledge,  this  is  the  first  report  of  ACT  patient-specific  iPSC-CMs 
recapitulating DOX-induced phenotypes regarding the contractile force.  
5.2.7 Screening for protectants against ACT using the iPSC-CM 
model
A main advantage of disease modeling using iPSC-CMs is the possibility to screen for drugs.  
In  this  work,  first  trials  were performed to use the iPSC-CM ACT model  for  screening of 
cardioprotectants against ACT, which may be used during chemotherapy. In clinical trials, DEX 
had cardioprotective effects during chemotherapy and is approved for adult patients who 
already  received  over  300  mg/m2 DOX  (FDA,  2011).  Since  iron  chelating  by  DEX  and 
subsequent attenuation of DOX-induced oxidative stress may be a way of action, we analyzed 
the effects of DEX on the production of H2O2 in iPSC-CMs using the Amplex Red assay (Figure
19). Application of 100 µM DEX did not alter H2O2 production in untreated ACT-iPSC-CMs or 
upon treatment with 0.5 µM DOX. A mild decrease of H2O2 production was observed in Ctrl-
iPSC-CMs. This is in good agreement with the hypothesis that DEX cardioprotection is not a 
result of iron chelating or reduction of ROS but is rather caused by TOP2 inhibition (Martin et 
al., 2009). Hence, the effects of DEX on parameters such as DOX-induced apoptosis should 
further be investigated in the iPSC-CM ACT model. Interestingly, it was reported that DEX 
application aggravates DOX-induced reduction of iPSC-CM viability  (Burridge et al.,  2016). 
However, the authors treated the iPSC-CMs with 100 mM DEX, which is considerably higher 
than the clinically  relevant concentration of about 100 µM, which was used in our work 
(Deng et al., 2015; Hochster et al., 1992; Sparano et al., 1999). 
The selective late sodium current blocker RAN was the second drug that was tested in this 
work for its protective effects against DOX. Recently, accumulating evidence shows that RAN 
attenuates  DOX-induced symptoms such as  diastolic  dysfunction and increased mortality, 
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which is accompanied by reduced oxidative stress (Cappetta et al., 2017; Maurea et al., 2016; 
Tocchetti et al., 2014). In our work, first experiments of RAN-treated iPSC-CMs resulted in 
reduction of late sodium current as proof of principle (data not shown). But, RAN application 
did not alter DOX-induced H2O2 production in ACT-iPSC-CMs (Figure 19). Surprisingly, RAN 
application  significantly  increased  H2O2 production  in  DOX-treated  Ctrl-iPSC-CMs.  Since 
sodium currents  are  strongly  connected  to  Ca2+ handling  in  CMs,  these  findings  may be 
related  to  the  differences  in  Ca2+ handling  properties  between  Ctrl-  and  ACT-iPSC-CMs. 
Therefore, it will be interesting to analyze the effects of RAN on Ca2+ transient in the iPSC-CM 
ACT-model.
Due to limited time, we could not expand the analyses of cardioprotectants in this work. 
However, application of additional DEX and RAN concentrations may reveal further effects. 
Similarly,  the  variation  of  application  time  seems  promising.  Several  candidates  for 
prophylactic  treatment  against  ACT  have  been  reported,  among  those  are  plant-derived 
small  molecules, metallothionein, visnagin, diphenylurea and resveratrol  (Gu et al.,  2015; 
Kimura et al., 2000; Liu et al., 2014; Ojha et al., 2016).
5.2.8 Limitations of this work
The present work was limited by several  factors.  As discussed above (see chapter  5.1.2), 
iPSC-CMs generated with current protocols do not resemble adult human CMs. Hence, it is 
possible that ACT patient-specific phenotypes that develop in the context of an adult CM are 
not present in our iPSC-CM model. Accordingly, the phenotypes that were identified in our 
work might not develop in more mature CMs. While it is beneficial to model a disease in a 
single cell type, the pathophysiology of the heart is influenced by other cell types despite 
CMs. In our model, the effect of additional cell types, such as cardiac fibroblasts, cells of the 
immune system or endothelial cells is not represented. 
The  hiPSC  technology  offers  great  advantages  over  animal  models.  On  the  other  hand, 
several disadvantages are implied. Animal models are usually breed to achieve isogenicity. 
Thereby, the effects of the genetic background are reduced in animal disease modeling. The 
genetic variability between human individuals is much greater. Therefore, it is possible that 
phenotypes that were identified in our iPSC-CM model are influenced by differences in the 
genetic background. An additional disadvantage of the hiPSC model is the high effort, which 
is needed to recruit an individual donor and generate and maintain iPSCs. As a result, studies  
of  hiPSC-based  disease  models  are  often  performed  with  considerably  fewer  biological 
samples than studies with animal models. Accordingly, the sample number of our study was 
small with 2 controls and 3 ACT patients.
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The  definition of  ACT is  not  consistent  between studies.  The  recruitment  of  actual  ACT 
patients is therefore complicated. Similarly, recruitment of controls is hampered by the fact 
that ACT can develop years after chemotherapy. As a result, it is possible that ACT patients in 
this work did not actually develop ACT and that controls were really ACT patients. This is 
because heart conditions that were diagnosed in ACT patients during chemotherapy may 
also have been unrelated to DOX and rather have been caused by high age, for example. 
Controls  could  have  developed  chemotherapy-induced  heart  conditions  after  they  were 
recruited for our work. Furthermore, milder ACT-associated symptoms may not have been 
detected  in  a  chemotherapy  patient.  Subsequently,  the  patient  would  have  been falsely 
classified as control.
5.2.9 Conclusions and proposed model
Figure 34 summarizes the findings of this work. We show that ACT-iPSC-CMs recapitulate the 
DOX-induced  reduction  of  mechanical  functionality.  We  postulate  that  DOX-induced 
impairment of sarcomeric integrity and increase of apoptosis are the basis of attenuated 
contractile  force  in  ACT-iPSC-CMs.  Furthermore,  Ctrl-  and  ACT-iPSC-CMs  showed 
disturbances  in  Ca2+ handling  upon  DOX  application,  which  may  be  caused  by  distinct 
pathways. These findings likely explain the DOX-induced increase in beating frequency and 
irregular  beating,  which  was  observed  in  both  groups.  ACT-iPSC-CMs  showed  a  higher 
production of ROS at basal conditions compared to Ctrl-iPSC-CMs. Furthermore, the amount 
of  ROS  was  increased  in  both  groups  upon  DOX  application,  which  likely  influences 
aforementioned parameters. Unfortunately, we could not determine the direct influence of 
NADPH oxidases or ACT-associated SNPs in the established iPSC-CM ACT model.
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5.2.10 Outlook
In this work, an iPSC-CM based model of ACT was established and the focus was mainly on 
the analysis of phenotypes that occurred after a single DOX application for 24 hours with 
varying concentrations. Thereby, we found 0.25 and 5 µM DOX to be concentrations that 
induce  changes  in  iPSC-CM  functionality  and  may  reflect  steady-state  and  peak 
concentrations in the serum of  patients during chemotherapy.  In the future, it  would be 
interesting to investigate these phenotypes with different time intervals between single DOX 
applications and analyses. The aim of such an experimental design would be to determine 
whether DOX-induced phenotypes in iPSC-CMs attenuate, aggravate or remain unchanged 
over time. Thereby, a possible reversibility of ACT could be investigated. In this work, first 
analyses of ROS production using such an experimental design suggest recovery to a certain 
degree  (Figure  19).  However,  increased ROS production was  still  observed 21 days  after 
single DOX treatment, which indicates chronic, non-reversible alterations. In this work, the 
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Figure 34: Schematic summary of the iPSC-CM ACT model. The boxes depict the parameters that 
were  analyzed  in  this  work  in  Ctrl-iPSC-CMs  (yellow  background)  and  ACT-iPSC-CMs  (green 
background). The described changes refer to DOX-induced changes. Bold text represents stronger 
effects in the respective group. Arrows indicate proposed connections between findings, based on 
current literature. Bold arrows represent a strong influence.  
5 Discussion
DOX-induced disruption  of  sarcomeric  integrity  is  suggested  to  be  a  main  cause  for  the 
reduction of maximal force of EHMs. Therefore, it would be especially interesting to observe 
the  dynamics  of  sarcomeric  integrity  after  single  DOX  application.  Additionally  to  the 
extension of follow-up time after DOX application, the effects of cumulative DOX treatment 
should also be investigated. Thereby,  application schedules during chemotherapy may be 
mimicked more closely  and phenotypes  may be observed that  result  from accumulating 
damage. 
We used the iPSC-CM ACT model to test the cardioprotective effects of DEX and RAN on the 
production of ROS upon DOX application. In the future, the screening for protectants against 
ACT  should  be  expanded.  As  discussed  in  chapter  5.2.7,  plant-derived  small  molecules, 
metallothionein, visnagin, diphenylurea and resveratrol are promising candidates. It will be 
interesting to analyze cardioprotective effects of drugs on additional ACT pathomechanisms 
investigated in this work.  Especially  analyses of DOX-induced apoptosis and disruption of 
sarcomeric integrity seem promising, since they are suggested to be the cause of reduced 
force of contraction of EHMs.
Unfortunately, the activity of NADPH oxidases and the functional influence of ACT-associated 
SNPs in  RAC2 and  CYBA could not be determined in this work. In the future, assessing the 
activity of NADPH oxidases in living iPSC-CMs will be crucial to assess the influence of SNPs 
for  the  development  of  ACT.  Recently  developed  gene  editing  technology  such  as 
CRISPR/Cas9 should be applied in Ctrl- and ACT-iPSCs (Chaterji et al., 2017). In this way, iPSC 
cell  lines  can  be  generated  that  only  differ  in  the  allele  of  the  respective  SNP  and  are 
otherwise isogenic. Such isogenic iPSCs would be a powerful means to analyze functional 
consequences  of  ACT-associated  SPNs  in  human  CMs.  Furthermore,  recently  described 
inhibitors,  which are  more  specific  against  NADPH oxidases,  may help to determine  the 
source of observed ROS production. It will also be interesting to determine the effects of 
such inhibitors on the remaining pathomechanisms of ACT investigated in this work, to reveal 
the influence of NADPH oxidase based redox cycling. 
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Table 5: Mean CT-Values of qRT-PCR analyses.
Gene CT-value
CamKII 24
cTNT 17.94
CYBA 30.41
GAPDH 18.89
HPRT 27.35
NCX 21.33
NOX2 31.37
NOX4 29.85
PLN 20.42
RAC1 22.77
RAC2 32.85
RYR2 25.32
SERCA 21.9
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Figure  35: Verification of primers for amplification of NCF1, NCF2 and NCF4. Expression of NCF1, 
NCF2 and NCF4 was detected in a heart biopsy of a dilated cardiomyopathy patient but not in iPSC-
CMs.
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Gene CT-value
α-actinin 17.9
α-MHC 23.95
β-MHC 19.22
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Figure 36: Original western blots of NADPH oxidase subunits. Bands used for quantification are 
marked with a red arrowhead. GAPDH was stained additionally on every membrane. 
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Figure 37: Original western blots of Ca2+ handling proteins, α-actinin and reference proteins. Bands 
used for quantification are marked with an arrowhead.
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Figure  38:  H2DCF-DA assay trial  in  iPSC-CMs. H2DCF-loaded iPSC-CM from a  healthy donor were 
observed with confocal laser scanning microscopy in the frames can mode. The mean fluorescence 
intensity was normalized to the base value. Sample number: 2.
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Figure  39: Lucigenin-enhanced chemiluminescence assay trial in iPSC-CMs.  Homogenates of iPSC-
CM  were  treated  with  respective  ·O2- scavengers  or  enzyme  inhibitors  and 5  µM  lucigenin. 
Luminescence  intensity  was  observed  10  min  after  addition  of  300  µM  NADPH.  Tiron  is  a  ·O2- 
scavenger. Diphenyleneiodonium (DPI) is a flavoprotein inhibitor. VAS2870 (VAS) is a NADPH oxidase 
inhibitor.  NG-nitro-L-arginine methyl ester (L-NAME) is a nitric oxide synthase inhibitor. Oxipurinol 
(OXY) is a xanthine oxidase inhibitor. Rotenone (ROT) is a mitochondrial electron chain inhibitor.
Figure  40: DOX-dependent titin degradation in iPSC-CMs. Western blot of a human heart biopsy 
sample (hH) and DOX-treated iPSC-CMs from a healthy control donor. Titin was visualized with an 
antibody that is specific for the C-terminus of titin. N2BA and N2B:  Titin isoforms. Data generated by 
Andrey Fomin.
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